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Abstract 
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by amyloid 
plaques that are comprised of aggregated amyloid- peptides. These toxic proteins 
promote mitochondrial dysfunction and neuronal cell death. A shift in metabolism away 
from oxidative phosphorylation and toward aerobic glycolysis, with the concomitant 
production of lactate, affords neurons a survival advantage against amyloid- toxicity. 
Recent evidence now suggests that aerobic glycolysis in the brain plays a critical role in 
supporting synaptic plasticity, learning, and memory. However, the role of aerobic 
glycolysis and lactate metabolism in AD-mediated cognitive decline is unknown. My 
objective was to test the hypotheses that aerobic glycolysis is upregulated in neurons to 
mediate amyloid- resistance and promote memory processes in vivo using the APP/PS1 
mouse model of AD. Cerebral lactate levels within the frontal cortex of control mice 
were found to decline with age, whereas lactate levels remained unaltered in APP/PS1 
mice. An age-dependent decline in levels of key aerobic glycolysis enzymes and an 
increase in lactate transporter expression were detected in control mice. Increased 
expression of lactate-producing enzymes correlated with improved memory performance 
in control mice, yet the opposite effect was detected in APP/PS1 mice. To determine if 
aerobic glycolysis plays a role in mediating spatial memory processes, mice were injected 
with dichloroacetate, an inhibitor of pyruvate dehydrogenase kinase. Dichloroacetate 
caused a reduction in conversion of pyruvate to lactate in the brain and a decline in 
phosphorylation of pyruvate dehydrogenase, the target of dichloroacetate, yet there was 
no significant effect on memory.  In agreement with previous observations, a correlation 
analysis of cortical extracts revealed that increased phosphorylation of pyruvate 
dehydrogenase correlated with better spatial memory in control mice. These observations 
indicate that production of lactate, via aerobic glycolysis, is beneficial for memory 
function during normal aging, yet is not explicitly required for spatial memory tasks. In 
addition, elevated lactate levels in APP/PS1 mice indicate perturbed lactate processing, a 
factor that may contribute to memory impairment in AD. Collectively, this research 
demonstrates several novel observations that will lead to a better understanding of 
cerebral lactate metabolism in the AD brain and aid in the development of metabolic 
strategies to treat this devastating disease.  
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Chapter 1  
1 Literature review 
The motivation for this work comes primarily from two research questions that I aim to 
answer: does lactate metabolism in the brain mediate resistance to amyloid- plaques, 
and does lactate metabolism in the brain contribute to memory? This literature review 
will provide background information on three main areas of research that all converge in 
this thesis: (1) Alzheimer’s disease, (2) the link between cerebral metabolism and 
Alzheimer’s disease, and (3) the link between cerebral metabolism and memory. First, I 
provide a background of the underlying causes of Alzheimer’s disease and the current 
state of Alzheimer’s disease research, which is shifting toward early diagnosis and 
prevention. Second, I introduce the link between Alzheimer’s disease and glucose 
metabolism, as well as the metabolic phenotype of aerobic glycolysis and associated 
lactate metabolism that is central to this work. I also introduce relevant components of 
the metabolic pathways involved in aerobic glycolysis because they are integral to several 
experiments performed. Third, I review neuron and astrocyte metabolic coupling and the 
role of lactate in memory. Finally, I provide the rationale for the questions driving this 
research, as well as the specific aims of this work, and the central hypotheses.  
1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is a progressive and irreversible neurodegenerative disease that 
affects the elderly and is the most common form of dementia worldwide. AD represents a 
considerable challenge to the Canadian health care system due to its high prevalence in 
the population (564,000 Canadians in 2016, or 1.5% of the population), rising incidence 
(projected 937,000 Canadians in 2032, or 2.8% of the population), and high cost of care 
for individuals with dementia ($10.4 billion in annual cost to Canadians in 2016)
1
. There 
are two different types of AD: early-onset (familial) and late-onset (sporadic). Familial 
AD affects less than 1% of all cases of AD and is directly caused by a genetic mutation 
resulting in the development of AD before the age of 65, sometimes as early as 30
2,3
. The 
vast majority of AD patients have the sporadic version, in which the exact cause is 
unknown although several risk factors have been identified including age, genetics, diet, 
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and lifestyle
4
. Diagnosis of dementia is based on a physician’s evaluation of cognitive 
tests and criteria given in the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM-IV), yet an individual with AD will progress through different 
stages of the disease as cognitive and functional abilities decline. Symptoms of AD 
commonly begin with mild cognitive impairment (MCI) characterized by confusion or 
loss of memory that disrupts daily life and eventually leads to loss of executive functions 
including speaking, swallowing, and walking. As the disease progresses, more 
pronounced dementia arises leading to physical complications, such as immobility and 
malnutrition, which can increase the risk of other serious complications, including 
pneumonia, ultimately leading to death of the individual
5
. The median survival time of 
individuals with AD depends on age and is approximately 8 years from diagnosis to death 
for individuals over 65 years of age, and less than 4 years for individuals aged over 90 
years
6
.   
1.1.1 Causes of Alzheimer’s disease 
AD was first characterized in 1906 by Alois Alzheimer after post-mortem analysis of a 
55 year old woman with pre-senile dementia revealed the presence of dense protein 
deposits in both the intracellular and extracellular regions of the brain
7
. The intracellular 
deposits, commonly known as neurofibrillary tangles (NFTs), are composed of 
aggregates of the microtubule-associating protein tau (tubulin-associated unit), that arise 
from abnormal hyperphosphorylation
8–10
. The extracellular deposits are known as 
amyloid plaques and are primarily comprised of an aggregated peptide called the 
amyloid- peptide (A) derived from the proteolytic cleavage of the amyloid precursor 
protein (APP)
11,12
. These two distinct pathologies, amyloid plaques and neurofibrillary 
tangles, have formed the neuropathological criteria for post-mortem diagnosis of AD
13
. 
The etiology of AD has evolved over the past 100 years and has now been attributed to 
the accumulation of several different pathological features in the brain that collectively 
lead to neurodegeneration and dementia. Researchers have attempted to understand the 
causes of AD by focusing on the specific mechanisms that lead to AD pathology in order 
to design effective interventions for the prevention, attenuation, or reversal of disease 
progression.  
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Tau Protein 
In 1986, a link between tau and neurodegenerative diseases was established with the 
extraction and subsequent identification of hyperphosphorylated tau as the primary 
component of NFTs in the AD brain
8–10,14
. The tau protein, also known as the 
microtubule-associating protein tau (MAPT), is one member of a family of microtubule-
associating proteins, including MAP1(A/B) and MAP2, that are functionally redundant 
and widely expressed, especially in the central nervous system
15
. The tau protein 
functions to promote assembly and organization of microtubules, which are important for 
growth of axons and dendrites in neurons
16
. Tau is regulated by  phosphorylation; the 
degree of which can lead to a conformational change that impairs its ability to promote 
microtubule assembly
17,18
. Mutations in the tau gene MAPT cause Frontotemporal 
dementia and Parkinsonism linked to chromosome 17 (FTDP-17), a neurogenerative 
disease known as a “taupathy”19–21. While hyperphosphorylation of tau and accumulation 
of NFTs are common in taupathies, they lack the characteristic amyloid plaques of AD, 
suggesting that NFTs alone cannot cause AD. In addition, no mutations in MAPT have 
been found associated with familial AD, suggesting that A is the initiator of AD 
pathogenesis
22
. Human genetic and biomarker studies have suggested A deposition 
precedes tau hyperphosphorylation and that neurofibrillary tangles are a late-stage 
pathology correlating more closely with symptom severity in AD patients than amyloid 
plaques
23–26
. A recent study using transgenic mice expressing a human tau repeat domain 
demonstrated that amyloid plaques are necessary but not sufficient for the conversion of 
wild-type to pathological tau, suggesting that a second risk determinant (risk 
alleles/factors) is required to drive the pathological conversion of tau
27
.    
Amyloid precursor protein processing to generate amyloid- peptides 
The most prevalent theory for the root cause of AD is the amyloid cascade hypothesis, 
which posits that AD arises from the abnormal deposition, or improper clearance, of A 
in the brain
28
. This was largely supported by the discovery that all of the familial versions 
of AD are caused by mutations within the APP gene itself or within genes that directly 
affect APP processing in favor of A production29. In contrast, a mutation in APP that 
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results in a reduction of A was found to be protective against AD and age-related 
cognitive decline
30
. The discovery of the APP gene was made possible by the 
identification of the amino acid sequence of the A peptide isolated from the AD 
brain
11,31
 and was subsequently used to clone the APP gene and map the location to 
chromosome 21
32
. Consistent with this discovery, individuals with trisomy 21 (Down 
syndrome) develop dementia at an early age and display plaques and tangles consistent 
with AD pathology
33
.  
APP is one member of a family of single-pass transmembrane proteins that includes the 
amyloid precursor-like proteins (APLP1 and APLP2) in mammals, all of which are 
highly homologous and functionally redundant
34
. APP and APLP2 are ubiquitously 
expressed but APLP1 expression is restricted to the nervous system
35
. The biological 
function of the APP is still unclear although several studies have suggested that APP 
participates in cell adhesion, neurite outgrowth, synaptogenesis, and neuron survival
36–39
. 
Knockout mice individually lacking APP, APLP1, or APLP2 are viable and fertile with a 
small growth deficit, minor behavioural phenotypes, and a reduced number of synaptic 
vesicles at presynaptic terminals
40–42
. Mice lacking both APP and APLP2, or APLP1 and 
APLP2, display perinatal lethality
41
. Yet mice lacking APP and APLP1 are viable and 
fertile, indicating a key physiological role for APLP2
41
. Despite the functional 
redundancy of the APP family, APP itself is the only member that generates the 
amyloidogenic peptide, due to sequence differences at the internal A cleavage site43. 
APP is highly expressed in neurons and is processed in the Golgi apparatus and 
transported in vesicles down the axon where it collects at the cell surface of the 
synapse
44
. APP undergoes proteolytic processing in two distinct pathways: 
amyloidogenic and non-amyloidogenic
45
 (Figure 1).  
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Figure 1. Schematic of amyloid precursor protein processing 
APP is a transmembrane protein that is cleaved in two distinct 
pathways: non-amyloidogenic (left) or amyloidogenic (right). Cleavage 
by the -secretase followed by the -secretase generates the non-
amyloidogenic P3 fragment. In contrast, cleavage by the -secretase 
followed by the -secretase results in the generation of the 
amyloidogenic A peptide, which can subsequently form oligomers and 
fibrils that are neurotoxic. 
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In the non-amyloidogenic pathway, APP is first cleaved by the -secretase to release the 
extracellular secreted -APP (sAPP) ectodomain. APP is then cleaved by the -
secretase, which generates the non-amyloidogenic extracellular P3 fragment and the APP 
intracellular domain (AICD) C-terminal fragment . In the amyloidogenic pathway, APP 
is first cleaved by the -site APP-cleaving enzyme 1 (BACE1), which produces the 
extracellular secreted -APP cleavage product (sAPP). Subsequent cleavage of APP by 
the -secretase then generates the intracellular AICD fragment and releases the 
extracellular A (pathogenic) fragment. The -secretase cuts at one of several different 
sites to produce A peptides of varying sizes with A(1-40) and A(1-42) being most 
common. Presenilin 1 (PSEN1) and presenilin 2 (PSEN2) are homologous proteins that 
form the active site of the -secretase complex. Autosomal  dominant mutations have 
been identified in both PSEN1 and PSEN2 that favor the cleavage of A(1-42) in familial 
AD
46–48
. The A1-42) peptide in particular is hydrophobic and highly prone to undergo 
self-aggregation forming insoluble fibers leading to the development of amyloid 
plaques
49,50
. Until recently there was no known biological function of the A peptides, 
but a recent study reported that injection of Salmonella typhimurium in a mouse model of 
severe amyloid pathology accelerated amyloid plaque deposition which co-localized to 
invading bacteria and prevented their attachment to host cells, suggesting that A might 
play a role in antimicrobial defense
51
. A is actively metabolized and cleared in the 
normal brain, however individuals with AD have increased production or reduced 
clearance which leads to an age-dependent accumulation of A and deposition of plaque 
in the brain
52,53
.  
Apolipoprotein E 
Aside from the characteristic plaques and tangles of AD pathology, several genetic and 
environmental risk-factors have been shown to be directly associated with AD onset. The 
most prominent genetic risk factor for sporadic AD is the 4 polymorphism in the 
apolipoprotein E (APOE) gene, which increases the risk of AD 5- to 15-fold depending 
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on the allelic dosage
54–56
. The prevalence of the 4 allele in AD patients is greater than 
50%, while individuals homozygous for 4 have a 95% chance of developing AD by the 
age of 80 years old
57
. Although the epidemiological link between APOE-4 and AD is 
well established, the mechanism by which 4 is a risk factor for AD remains largely 
unclear. APOE is a 34 kDa lipid binding protein that transports cholesterol and 
triglycerides throughout the body by binding to cell surface lipoprotein receptors
58
. In 
humans, there are three different APOE isoforms (2, 3, and 4), which differ from each 
other by a single amino acid affecting lipid association and receptor binding
59,60
. The 4 
allele is the only variant that increases risk of AD, while the 2 allele is associated with 
protection against AD and the 3 allele has no correlation with AD55,61. The link between 
APOE and AD is likely through clearance mechanisms of A. APOE is a chaperone 
molecule that binds directly with amyloid plaques
54
. The 3 isoform binds to A with 
higher affinity and clears more efficiently than 462. Accordingly, APOE-3 mice 
displayed fewer amyloid plaques than 4 mice63,64. AD patients with APOE-4 display 
increased plaque load in both sporadic and familial variants, as well as in subjects with 
amyloid load but are cognitively normal 
65–67
. Interestingly, the 4 iosoform has also been 
implicated as a transcription factor that promotes the activation of genes associated with 
programmed cell death, microtubule disassembly, synaptic function, and insulin 
resistance
68
. It is also a known risk factor for other neurodegenerative diseases including 
cerebral amyloid angiopathy (CAA), taupathies, Parkinson’s disease, and multiple 
sclerosis, suggesting it plays a general role in susceptibility to neurodegeneration
69–72
. 
Age 
The single greatest risk factor for AD is age. Epidemiological evidence suggests that 
beyond the age of 60 the incidence of sporadic AD rises exponentially with the risk 
doubling every 5 years after 65
73–75
. Even in individuals afflicted with familial AD, the 
disease rarely develops before the age of 45, suggesting significant A accumulation or 
age-associated brain changes are necessary before the onset of cognitive decline
2,3
. The 
aging process itself carries an inherent risk of cognitive dysfunction. Normal aging is 
associated with reductions in gross brain volume
76–79
, accelerated atrophy in the 
8 
 
hippocampus and cortex
76,80–82
, and disruption of episodic memory
83,84
. In fact, 
significant A accumulation also occurs in cognitively normal elderly individuals and 
may simply be a part of normal aging
85–87
. These features of the aging brain make it 
difficult to tease apart the relative contributions of aging and AD-pathology to cognitive 
decline
88
, which has led to a new proposed diagnostic criteria for AD that incorporates 
the use of biomarkers showing underlying pathogenesis
89–92
. The link between aging and 
AD likely involves the progressive accumulation of A either through over production in 
familial AD or through reduced ability to clear A in sporadic AD52,93,94. Evidence in 
support of this model comes from preclinical investigation using multi-modal imaging 
strategies to demonstrate that abnormal A biomarkers are the earliest indicators of AD95. 
Yet at some point a pathological threshold of A accumulation is reached which triggers 
a cascade of downstream processes that mediates neurodegeneration
96,97
.       
1.1.2 Toward Alzheimer’s disease prevention 
Since 2002, there have been over 400 clinical trials for AD therapeutics with an overall 
failure rate of 99.6%
98
. Current FDA-approved treatment options for AD patients are 
limited to acetylcholinesterase inhibitors for mild-to-moderate dementia and the N-
methyl-D-aspartate (NMDA)-receptor antagonist Memantine for moderate to severe 
dementia
99–103
. These therapies reduce the severity of symptoms for AD patients but do 
not alter the course of the disease progression. In fact, there are currently no FDA-
approved therapies that prevent or reverse cognitive decline in AD
104
. A growing 
consensus has emerged that the problem with failed clinical trials may not be related to 
the strategy of targeting AD pathology, or even the animal models for testing pre-clinical 
candidate drugs, but that the therapies are applied to human patients too late to alter the 
course of sustained brain damage
105,106
. In recent years a large initiative toward 
prevention of AD has been undertaken, in which the goal is to discover the earliest 
reliable biomarker for probable AD in order to implement therapeutic or lifestyle 
interventions for at-risk individuals before the onset of neurodegeneration and 
dementia
107
. In 2005, the Alzheimer’s Disease Neuroimaging Initiative (ADNI) was 
launched with the goal of tracking the progression of AD and establishing criteria for 
early diagnosis
108,109
. In 2008 an international partnership called the Dominantly 
9 
 
Inherited Alzheimer’s Network (DIAN) was initiated to develop a database of AD 
individuals carrying familial mutations while their non-carrier siblings act as genetically 
similar controls
110
. The goal is to determine a temporal sequencing of preclinical AD 
biomarkers in order to identify the most ideal therapeutic window for treatment of at-risk 
AD patients. More recently an initiative called the Alzheimer’s Prevention Initiative 
(API) was started with the goal of evaluating the extent to which AD-modifying 
treatments predict clinical benefit in at-risk individuals
111,112
. Despite the fact that all 
individuals registered with the DIAN carry autosomal dominant mutations for AD, the 
pathological phenotype of familial AD is largely similar to sporadic AD, which has 
prompted some to suggest that they are the same disease just with an age delay in 
sporadic individuals
113,114
. Another reason why subjects with autosomal dominant AD 
mutations are recruited for these clinical trials is because defining preclinical AD in 
sporadic individuals is difficult even when significant A is detected in the brain by 
positron emission tomography (PET) and in the cerebrospinal fluid (CSF) by ELISA 
analysis
115–117
. 
These neuroimaging initiatives use a variety of techniques to measure pathological 
changes in the brain, of which the two most reliable biomarkers of AD pathophysiology 
are measurements of the CSF and PET imaging. The CSF can be used to detect 
alterations in A and tau as a reflection of physiological changes to amyloid plaques and 
neurofibrillary tangles occurring in the brain. Reductions in A(1-42) and increased 
phosphorylated-tau or total tau in the CSF correlate well with late-stage 
neurodegeneration and cognitive decline
115,118–121
. PET scans are a useful imaging 
technique to measure a wide variety of parameters depending on the radio-labelled tracer 
used in the analysis. The two most commonly used tracers are the 
11
C-labeled Pittsburgh 
compound B (PiB) that binds with high specificity and high affinity to fibrillar-A found 
predominantly in amyloid plaques
122
, and the 
18
F-fluorodeoxyglucose (FDG) compound 
that is an analog of glucose used to measure glucose metabolism in the brain
123,124
. 
Biomarker research from the ADNI and DIAN programs provided a clear picture of 
preclinical AD progression that begins with A accumulation in the brain and follows in 
a sequence of cerebral inflammation, oxidative stress, synaptic loss, regional 
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hypometabolism, tau pathology accumulation, and finally atrophy, neurodegeneration, 
and dementia
125–132
. These studies also identified an interesting phenomenon in AD 
pathogenesis: A accumulation begins decades before clinical diagnosis of AD-dementia. 
PiB-PET scans suggest that deposition of amyloid plaque can begin 20 to 30 years before 
the onset of cognitive decline, while reductions of A(1-42) in CSF are present up to 25 
years before symptom onset
25,131,133,134
. Pathological changes in CSF tau were detected up 
to 15 years before the onset of clinical symptoms, while individuals with both abnormal 
A and tau CSF biomarkers were associated with a more rapid progression to a clinical 
state
25,133,135–137
. Cerebral hypometabolism and impaired episodic memory also occurred 
10 years before expected symptom onset, suggesting that neurodegeneration precedes 
clinical diagnosis by up to a decade
25
.    
Non-demented individuals with Alzheimer’s disease neuropathology 
Although A accumulation and tau hyperphosphorylation have been consistent 
pathological features of AD, the presence of these biomarkers is also observed in 
cognitively normal elderly people
138
. This group of individuals, which have been called 
non-demented individuals with AD neuropathology (NDANs), were first discovered in 
1968 after autopsy of cognitively normal individuals found 8 of 28 brains to have 
amyloid plaque deposition and neurofibrillary tangles similar to AD patients
139
. Since 
then it has been established that approximately 30-50% of the elderly (aged 57 to 102) 
are cognitively normal yet have A and tau pathology indistinguishable from AD patients 
of the same age
140–143,85,144–148
. In fact, the distribution of amyloid plaques and NFTs 
matches the pattern in AD patients and the sequence of pathological events is the same as 
AD irrespective of cognitive status
149–151
. However, it is currently unclear if all 
cognitively normal individuals with AD biomarkers will eventually develop AD-related 
dementia. Some have argued that NDAN individuals are in the preclinical stages of AD 
and will eventually progress to AD with increased age
152–156
, while others suggest that 
AD pathology may be a normal part of the aging process
157
. Several studies have shown 
that CSF A(1-42) and tau can predict cognitive decline in healthy individuals with a mean 
follow up of at least 3 years
158–160
. One study demonstrated that NDAN individuals 
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meeting criteria for intermediate likelihood or high likelihood of AD displayed subtle 
deficits in episodic memory after adjusting for age, sex, and education
161
. Yet, another 
study found that measures of cognition did not correlate with any of the measured AD 
biomarkers within cognitively normal individuals
162
. In addition, some longitudinal 
studies showed only about 20% of individuals positive for AD biomarkers will progress 
from cognitively normal to MCI or AD-related dementia with a mean follow-up of 2.8 
years
25,131
. Due to an estimated lag time of 15 to 20 years between the appearance of AD 
biomarkers and onset of cognitive impairment, it is still unknown if all individuals 
positive for AD biomarkers will progress to AD. However, it is clear that certain 
environmental and lifestyle factors can either increase or reduce the risk of developing 
AD-related dementia in cognitively normal individuals.  
Epidemiological evidence suggests that several different environmental factors can 
reduce or increase the risk of developing dementia
163
. The dementia risk reducing factors 
include: higher education, aerobic exercise, cognitive training, social engagement, and 
healthy diet; while the dementia risk increasing factors include: smoking, diabetes, 
obesity, hypertension, traumatic brain injury, depression, and sleep disturbances
163
. 
Collectively these findings suggest that certain adjustable lifestyle choices can impact the 
healthy aging of the brain despite the presence of neuropathology and has led to the 
argument that a greater emphasis should be placed on preventative measures to treat AD 
in at-risk individuals
164
. While it is clear that environmental factors can alter the risk of 
developing dementia, the biological mechanisms underlying this effect are still unknown. 
The association between lifestyle effects and progression of AD pathology has been 
inconsistent. It has been shown that physical activity and cognitive engagement can 
reduce A and tau pathology in middle-aged at-risk individuals165–167, yet this finding 
was not replicated in a follow up study
168
. In addition, these observations do not explain 
how some individuals can tolerate AD neuropathology and remain cognitively normal. 
One prevalent theory that explains the discrepancy between neuropathological changes 
and their clinical expression is called “cognitive reserve”, which refers to the capacity of 
the brain to tolerate pathological insult
169
. The proposed mechanism involves both 
passive and active models
170
. The passive model simply refers to an anatomical 
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difference in brain size with increased neuron count and a higher threshold for AD 
pathology or neurodegeneration. The active model refers to the adaptive use of 
underlying neurological networks to compensate for neuropathology and localized insult. 
Taken together, individuals with higher cognitive reserve will tolerate an overall higher 
burden of AD pathology before succumbing to cognitive impairment
171,172
. In fact, 
cognitive decline is delayed in individuals with higher reserve
173–175
, yet progresses more 
rapidly than lower reserve individuals once a pathological threshold is reached
173,176–179
. 
Several studies have shown associations between higher cognitive reserve and structural 
changes in the brain, including neurogenesis, synaptic density, synaptic protein 
expression, neuronal density, dendritic complexity, and neuronal hypertrophy
180–186
. Yet, 
a causal mechanism underlying cognitive reserve and maintenance of brain function in 
the presence of AD pathology has yet to be demonstrated.  
1.2 Glucose metabolism and Alzheimer’s disease 
A progressive decline in brain glucose metabolism, called cerebral hypometabolism, is a 
common feature of AD that correlates temporally with symptom severity and has high 
predictive value for onset of dementia
153,187–191
. Current estimates suggest that cerebral 
glucose metabolism is 20-25% lower in the AD brain
192
. Cerebral hypometabolism has 
been traditionally perceived as a result of decreased energy demand due to synaptic 
dysfunction and neuronal loss at later stages of the disease
193
. However, there is a 
growing consensus that impaired glucose metabolism precedes clinical symptoms in AD 
and may serve as a preclinical biomarker
153,188,190,191,194–196
. Impaired glucose metabolism 
is likely due to mitochondrial dysfunction, which is directly caused by A interference 
with mitochondrial enzymes. The A peptide has been shown to progressively 
accumulate in the mitochondria of CNS neurons in both AD patients and AD transgenic 
mice prior to amyloid plaque deposition and cognitive deficits
197–200
. In addition, 
embryonic neurons derived from the hippocampus of triple-transgenic AD female mice 
displayed reduced mitochondrial respiration and increased glycolysis, suggesting that 
mitochondrial dysfunction occurs early in AD pathogenesis
199
. Defects in mitochondrial 
metabolism are also well documented in the human AD brain
201
.  
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Amyloid- and the mitochondrion 
The mitochondrion is a vital organelle responsible for producing the majority of cellular 
ATP and regulating cell survival. Several in vitro and in vivo studies have directly linked 
A exposure to mitochondrial dysfunction including the  inhibition of respiratory chain 
complexes, reduced membrane potential and ATP levels, and increased reactive oxygen 
species (ROS) production, as well as mitochondrial swelling and depolarization leading 
to the induction of apoptosis
202–211
. Consistent with the targeted production of A in 
synaptic terminals, A preferentially accumulates in synaptic mitochondria and likely 
contributes to early synaptic dysfunction in AD
212
. Certain soluble species of oligomeric 
A are amphipathic in nature and have the ability to permeabilize lipid bilayers thereby 
passively entering the mitochondria
213–216
. APP also contains a mitochondrial targeting 
signal and can be actively imported into the mitochondria by the translocase of the outer 
membrane (TOM) machinery
217,218
. Once inside the mitochondria, A directly binds to 
and impairs the activity of the pyruvate dehydrogenase (PDH) complex, which is 
responsible for converting pyruvate to acetyl-coenzyme A (acetyl-CoA) and is the first 
committed step for pyruvate to oxidative phosphorylation in the mitochondria
204
. Aalso 
impairs activity of proteins in the tricarboxylic acid (TCA) cycle and the electron 
transport chain (ETC), including the -ketoglutarate dehydrogenase complex (-
KGDHC) and cytochrome oxidase (COX)
204,219
. Reduced activity and expression of these 
enzymes in the AD brain has been well documented
220–222
. This diminished enzyme 
activity leads to a reduction in oxygen consumption rate and ATP production, suggesting 
a direct link between defective mitochondrial and preclinical hypometabolism in AD
209
.  
Defective mitochondria can produce high levels of ROS, which can lead to a state of 
oxidative stress and is a common feature of AD. Under normal circumstances, 
physiological levels of ROS function as important redox-dependent signaling molecules 
that regulate cellular growth and homeostasis
223
. The ETC of the mitochondria is the 
main source of cellular ROS via the reduction of oxygen to the superoxide free radical 
anion and subsequent conversion to hydrogen peroxide by superoxide dismutase
224
.  An 
overproduction of ROS or a decline in antioxidant response can lead to oxidative damage 
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and ultimately cell death. The AD brain displays several markers of oxidative damage to 
biomacromolecules including proteins, nucleic acids and lipids
225,226
.  In vitro work has 
demonstrated a dose-dependent effect between A and mitochondrial-derived oxidative 
stress and neuronal toxicity
227,228
. Synergistic effects between A and tau have been 
observed in the mitochondria of triple-transgenic AD mice leading to reduced ATP 
production and an increase in oxidative stress
229
. Moreover, mitochondrial-derived 
oxidative stress has been shown to potentiate A formation and suggests a feed-forward 
mechanism in AD pathogenesis
230
.  This has led to the oxidative stress hypothesis of AD, 
which posits that the generation of oxygen free radicals from the mitochondria participate 
in the cascade of events that lead to neuronal death in AD
231
. 
Cerebral hypermetabolism in Alzheimer’s disease 
In contrast to cerebral hypometabolism in AD, the exact opposite effect (cerebral 
hypermetabolism) has also been observed in the AD brain at very early stages of the 
disease. This may represent an early compensatory mechanism in response to A 
accumulation and mitochondrial dysfunction. A recent PET study of autosomal dominant 
AD mutation carriers revealed regionally higher glucose uptake ~25 years before the 
estimated age of onset
232
.  PET imaging of cognitively normal people at risk for AD 
revealed area-specific increases in both Aβ deposition and glucose metabolism in 
individuals before MCI
233
. Although reduced glucose metabolism was observed 5 to 10 
years before the estimated age of onset in many cortical areas with Aβ deposition, a 
divergent pattern was observed subcortically; the caudate and pallidum did not show 
either metabolic decline or atrophy, despite markedly elevated PiB uptake
232
.  APP/PS1 
transgenic-AD mice display an age-dependent increase in glucose uptake in the 
hippocampus and cortex that precedes cognitive impairment and correlates spatially with 
amyloid plaque deposition
234
. In addition to these observations, the same enzymes that 
were shown to be inhibited by A at later stages of the disease, COX and -KGDHC, can 
also be up-regulated before the appearance of amyloid plaques in the APP(Tg2576) mouse 
model of AD
235
.  
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Cerebral hypermetabolism in the preclinical AD brain may be accounted for by the 
compensatory up-regulation of glycolytic machinery in response to mitochondrial 
damage. Glycolysis is the metabolic pathway in the cytosol that breaks down glucose to 
pyruvate with the concomitant production of ATP and NADH. The specific activity of 
the glycolytic rate-limiting enzymes phosphofructokinase-1 (PFK), hexokinase (HK), and 
pyruvate kinase (PK) were found to be increased in the frontal and temporal cortex of AD 
patients
236–238
. Increased activity was also found for lactate dehydrogenase (LDH), the 
enzyme responsible for the production of lactate as the end-product of glycolysis
238
. 
Embryonic neurons derived from the triple-transgenic AD mouse hippocampus displayed 
reduced mitochondrial respiration but increased rates of glycolysis
199
. In addition, recent 
evidence has revealed that nerve cells can be made to be resistant to A toxicity by 
undergoing a metabolic shift toward enhanced glycolysis and reduced oxidative 
phosphorylation in the mitochondria
239,240
. Thus, glycolytic metabolism may be elevated 
in certain regions of the brain as a compensatory mechanism in response to A 
accumulation and mitochondrial dysfunction.  Loss of this protective mechanism may 
render certain areas of the brain susceptible to A-induced neurotoxicity.   
1.2.1 Aerobic glycolysis and amyloid- resistance 
Under normal conditions, the majority of glucose consumed by the cell is oxidized to 
carbon dioxide and water in the mitochondria to yield large amounts of ATP to support 
cellular functions. Glycolysis can be up-regulated in a state of low oxygen (hypoxia) or 
mitochondrial dysfunction in order to compensate for energy demand with the production 
of lactic acid (lactate) as an end-product
241,242
. However, a characteristic feature of 
rapidly proliferating cells is the extensive reliance on glycolysis for energy needs, even 
under normoxic conditions. In cancer cells, this type of metabolism is known as the 
Warburg effect in recognition of its discovery by Otto Warburg
243
. The reliance on 
glycolysis in the presence of oxygen is commonly referred to as “aerobic glycolysis” and 
is a characteristic feature of cancer cells and stem cells
244
. It is now understood that 
aerobic glycolysis occurs in many different cell types including: endothelial cells, skeletal 
muscle, vascular smooth muscle, monocytes and leukocytes of the immune system, as 
well as astrocytes and neurons of the brain
245–252
. The relative contribution of glycolysis 
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to ATP production highly depends on the cell type, growth environment, and phase of 
cell cycle. Through precise measurements of oxygen consumption and lactate production 
rates, it has been estimated that glycolysis can account for between 0.94% to 65% of total 
ATP produced in the cell with an average of approximately 17% in most tissues
253
. 
Interestingly, aerobic glycolysis has been estimated to account for up to 85% of ATP 
produced in endothelial cells despite their direct contact with oxygenated blood
251
.  
A high glycolytic rate has several advantages for energy-demanding cells. First, despite 
its low efficiency at producing energy (2 ATP per glucose) compared to oxidative 
phosphorylation in the mitochondria (34 ATP per glucose), glycolysis can generate ATP 
at a faster rate when the supply of glucose is abundant
254
. This feature has obvious 
benefits for cellular processes that have a rapid energy demand, such as in maintaining 
resting membrane potential via the ATP-dependent Na
+
/K
+
-ATPase pump. For neurons, 
the Na
+
/K
+
-ATPase pump can account for up to 50% of total expended energy
255
. 
Second, proliferating cells require metabolites to support the biosynthetic requirements of 
mitosis and glycolytic intermediates can provide the carbon building blocks for the de 
novo synthesis of nucleotides, lipids, and non-essential amino acids
256,257
. In addition to 
glycolysis in the cytosol, the supply of acetyl-CoA and glutamine to the TCA cycle 
within mitochondria drives the production of metabolites that can be siphoned off to the 
cytosol and participate in the anabolic metabolism of amino acids and lipids
257
.  Finally, 
the conversion of pyruvate to lactate produces NAD
+
, which is an important cofactor for 
continued glycolytic flux and biosynthesis of nucleotides and amino acids, in addition to 
maintaining the NAD
+
/NADH redox balance of the cytosol
258,259
. These metabolic 
pathways will be described in greater detail in later sections. Thus, when glucose is not 
rate-limiting, aerobic glycolysis provides several advantages to the cell and may persist 
as the predominant metabolic phenotype despite the presence of oxygen.  
Our lab has previously demonstrated that nerve cells selected for resistance to A toxicity 
undergo metabolic reprogramming and shift toward aerobic glycolysis through the 
stabilization of the transcription factor hypoxia-inducible factor 1 (HIF-1) and up-
regulation of pyruvate dehydrogenase kinase-1 (PDK1) and lactate dehydrogenase-A 
(LDHA)
260
. Over-expression of either PDK1 or LDHA enzymes in nerve cell lines 
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represses mitochondrial respiration and confers resistance to A and other neurotoxins, 
whereas chemical or genetic inhibition of these enzymes results in re-sensitization of 
resistant lines to A toxicity239,240.  Moreover, mitochondrial-derived ROS, which are 
closely associated with A toxicity, are markedly diminished in resistant relative to 
sensitive cells. By repressing mitochondrial respiration, A-resistant cells are less likely 
to produce ROS and are more resistant to mitochondrial depolarization; two events 
tightly linked to induction of apoptosis
261
. In support of this discovery, a recent 
multimodal PET imaging study has revealed a strong correlation between the spatial 
distribution of elevated aerobic glycolysis in healthy resting individuals and A 
deposition in the brains of both healthy individuals and AD patients
262
. In contrast, brain 
regions that rely primarily on oxidative phosphorylation for energy needs displayed little 
amyloid burden. The observation that A deposition in the AD brain closely matches the 
spatial pattern of elevated aerobic glycolysis in both the healthy and AD brain suggests 
that aerobic glycolysis may arise as a mechanism to counter the toxic effects of A in the 
AD brain.  
1.2.2 Cerebral glucose metabolism 
Glucose is nearly the sole fuel source of the human brain
263
. The metabolism of glucose 
in the brain is a complex process integrating several different cell types and competing 
biochemical pathways in order to sustain the energy needs of neuronal activation. Here I 
describe each step of glucose metabolism as it relates to aerobic glycolysis, the shuttling 
of metabolites between astrocytes and neurons, as well as any connections to AD 
pathophysiology. Considering the tight connection between aerobic glycolysis and 
proliferation, many of the properties of glycolytic enzymes and regulators were 
characterized in cancer cells. The first rate-limiting step in cerebral glucose metabolism is 
the facilitated transport of glucose across the blood brain barrier. This is mediated by the 
glucose transporter (GLUT)-family of integral membrane proteins of which there are 14 
members in humans, each with different affinities for glucose and related sugars
264
. 
GLUT-1 is primarily expressed in astrocytes and the capillary endothelium that form the 
blood-brain barrier
265
. Astrocytes are generally believed to act as an intermediary cell 
between glucose uptake from the blood and delivery to neurons, yet current models 
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suggest that glucose can also diffuse from endothelial cells through the basal lamina and 
interstitial fluid (ISF) to neurons where it is directly imported via GLUT-3
266–268
. GLUT-
1 and GLUT-3 expression is decreased in the AD brain which correlates spatially with 
cerebral hypometabolism
269–272
. GLUT-1 expression can also be up-regulated by HIF-1 
in response to hypoxia
273–275
. Once glucose is taken into the cell it is irreversibly 
phosphorylated by HK1 to form glucose-6-phosphate (glucose-6P), which traps it in the 
cell by adding a negative charge to prevent it from diffusing back through the 
membrane
276
. Glucose-6P is the precursor to three main metabolic pathways: glycolysis, 
the pentose phosphate pathway (PPP), and glycogenesis (Figure 2).  
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Figure 2. Schematic representation of cerebral glucose metabolism 
Glucose enters cells via glucose transporters and is phosphorylated by 
hexokinase to produce glucose-6-phosphate (Glucose-6P). In 
astrocytes, glucose-6P can be reversibly converted to glycogen by 
glycogen phosphorylase. Glucose-6P can also enter the pentose 
phosphate pathway (PPP) to generate two molecules of NADPH and 
Ribose-5-phosphate for the biosynthesis of nucleotides, fatty acids, and 
amino acids. Glucose-6P is further metabolized in the cytosol through 
glycolysis giving rise to two molecules of pyruvate, ATP, and NADH. 
Pyruvate is further processed in the mitochondria through the 
tricarboxylic acid (TCA) cycle to produce NADH which fuels oxidative 
phosphorylation thereby generating ATP and CO2 while consuming 
oxygen. The complete oxidation of glucose produces far larger amounts 
of energy in the form of ATP in the mitochondria (34 ATP) compared 
to glycolysis (2 ATP). During aerobic glycolysis pyruvate is reduced to 
lactate by lactate dehydrogenase which is subsequently released in the 
extracellular space.  
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The pentose phosphate pathway 
The main fate of glucose-6P is to continue through the glycolytic pathway to generate 
pyruvate, NADH, and ATP, but it can also be funnelled into the PPP depending on the 
redox and energy status of the cell. The PPP is a metabolic branch that runs parallel to 
glycolysis and is primarily responsible for generating reducing equivalents in NADPH 
and biosynthetic precursors for growing or dividing cells. The first committed step to the 
PPP is catalyzed by the enzyme glucose 6-phosphate dehydrogenase (G6PDH), which 
oxidizes glucose-6P to 6-phosphogluconolactone while reducing NADP
+
 to NADPH
277
. 
G6PDH is strongly inhibited by NADPH, while NADP
+
 is a cofactor for its proper 
conformation, thus the cytosolic ratio of NADP
+
/NADPH is the main modulator of 
G6PDH and entry to the PPP
278,279
. The NADP
+
/NADPH ratio is also a redox sensor. 
NADPH is a necessary cofactor for the reduction of glutathione (GSH) molecules, which 
are the primary reducing agents for the cell. Consequently, the PPP is upregulated in 
response to oxidative stress in order to replenish depleted glutathione levels
280,281
. The 
PPP is also important for the synthesis of nucleotides and fatty acids. Ribose-5-phosphate 
(R5P), an intermediate metabolite of the PPP, is the requisite building block for 
nucleotides, while NADPH is a necessary reducing agent for the synthesis of nucleotides, 
fatty acids, and amino acids
257
. Therefore, the PPP is also up-regulated in highly 
proliferating cells, including cancer cells, in order to meet the increased demands for 
synthesis of biological building blocks
282
. 
Glycogenesis 
In astrocytes, glucose-6P can also be converted to glycogen, a polymer composed of 
glucose residues that serves as a fuel reserve of the brain
283
. The prominent role of 
glycogen storage in astrocytes is to act as an energy buffer in times of glucose 
deprivation or high glucose consumption
284–287
. Yet, in recent years it has been 
hypothesized that the storage and mobilization of astrocytic glycogen serves to enhance 
the availability of glucose for neuronal metabolism
286,288–291
. Neuronal activation can 
trigger glycogen breakdown in astrocytes by as much as 20%
292
, while decreased 
neuronal activity during anesthesia is accompanied by an increase in glycogen storage by 
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up to 85%
293
. Recent evidence also points to a direct association between glycogen 
mobilization and functional memory through synthesis of glutamate in astrocytes
294,295
. In 
addition, glycogen-derived lactate has also been shown to contribute to memory 
processing via shuttling between astrocytes and neurons
296
. However, the role of lactate 
in brain energy metabolism is still unresolved. Another study has suggested that glycogen 
mobilization in astrocytes functions primarily to preserve glucose supply for neurons, 
rather than provide neurons with glycogen-derived lactate
297
. Thus, glycogen storage and 
metabolic coupling between astrocytes and neurons are important for proper metabolic 
homeostasis during neuronal activity or in cases of severe energy crisis. 
Glycolysis 
The final rate-limiting step in glycolysis is the conversion of phosphoenolpyruvate (PEP) 
and ADP into pyruvate and ATP. This is catalyzed by the enzyme pyruvate kinase (PK), 
of which there are four isoforms (M1, M2, L, and R).  The L and R isoforms of PK are 
exclusively expressed in liver and red blood cells, respectively, while PKM1 and PKM2 
are expressed in most adult tissues and arise from alternative splicing of the same M-gene 
under regulation of the oncogene C-MYC
298,299
. The PKM1 isoform assembles as a 
constitutively active tetramer for rapid substrate turnover
300
.  In contrast, PKM2 is among 
the most tightly regulated enzymes of the glycolytic pathway and is important for 
controlling levels of ATP and glycolytic intermediates in the cell.  PKM2 can exist as a 
tetramer (high activity), or as a dimer (low activity). The dimeric form of PKM2 is 
characterized by low affinity for PEP which results in accumulation of glycolytic 
intermediates and increased flux through the PPP
301
. The ratio of PKM2/PKM1 is an 
indication of the metabolic phenotype of the cell, whereby high levels of PKM2 promote 
aerobic glycolysis and high levels of PKM1 promote oxidative phosphorylation
299
. 
Consistent with this observation, cancer cells preferentially splice the M2 isoform over 
M1 through the action of C-MYC in order to promote aerobic glycolysis and 
proliferation
302
. Replacing PKM2 expression with PKM1 effectively inhibited the growth 
of xenograft tumors by impairing nucleotide production and promoting cell cycle 
arrest
303,304
. PKM2 is also sensitive to oxidative stress as it can be inhibited by cysteine 
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oxidation to divert more glucose-6P toward the PPP to generate NADPH as an 
antioxidant response
305
.  
As the end product of glycolysis, pyruvate has two major fates: conversion to acetyl-CoA 
in order to fuel oxidative phosphorylation in the mitochondria, or conversion to lactate to 
regenerate NAD
+
 in the cytosol. The breakdown of pyruvate in the mitochondria occurs 
over a series of successive reactions in the citric acid cycle that ultimately produces 
NADH and FADH2 as reducing equivalents to drive the proton gradient necessary for 
oxidative phosphorylation and ATP production. The first committed step in this process 
is the irreversible decarboxylation and acetylation of pyruvate to acetyl-CoA with the 
concomitant reduction of NAD
+
 to NADH. This is catalyzed by PDH, which is a 
ubiquitously expressed protein complex composed of four sub-complex proteins (E1, E2, 
E3, and the E3 binding protein)
306
. The PDH complex serves as a critical link between 
glycolysis and the citric acid cycle, and thus its activity is highly regulated at the 
transcriptional and post-translational levels. For example, during starvation, the genes of 
the PDH complex are repressed in the liver in order to reduce pyruvate metabolism and 
maintain glucose levels in the blood stream
307
. In addition, the products of the PDH 
reaction, acetyl-CoA, NADH, and ATP, can exhibit direct feedback inhibition when their 
concentrations are sufficiently elevated in the mitochondria
308,309
. Yet, the principal mode 
of PDH regulation is reversible phosphorylation. The E1 subunit of the PDH complex 
forms the active site for the oxidative decarboxylation of pyruvate and contains three 
target serine residues (at positions Serine-232, -293, and -300) that are susceptible for 
post-translational modification by phosphorylation
310
. Phosphorylation of any serine is 
sufficient to completely inhibit the activity of the PDH complex, which allows for the 
rapid and reversible regulation of pyruvate metabolism or to maintain energy 
homeostasis
311
.  
Pyruvate dehydrogenase kinase 
Pyruvate dehydrogenase kinase (PDK) phosphorylates the regulatory serine residues of 
PDH, while the pyruvate dehydrogenase phosphatase (PDP) removes the phosphate 
groups. There are four isoforms of PDK (PDK1-4), each with unique and overlapping 
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tissue expression. PDK1 and PDK2 are expressed ubiquitously while predominantly in 
the heart and nervous system, respectively. PDK3 is found only in heart and skeletal 
muscle, and PDK4 is expressed in the kidneys, brain, liver, heart and skeletal muscle
312
. 
The PDK isoforms also have different specificity to the PDH-E1 serine residues. All 
PDK isoforms are able to phosphorylate Serine-232 and Serine-293, while only PDK1 
can phosphorylate all three sites
313
. The PDK enzymes are themselves tightly regulated at 
the transcriptional and post-translational levels. All PDK isoforms are allosterically 
activated by high levels of acetyl-CoA, NADH, and ATP (the opposite effect occurs with 
the PDH complex), and are inhibited by the mitochondrial accumulation of pyruvate, 
NAD
+
, and ADP
314
. The expression of PDK2 and PDK4 are upregulated in the heart, 
liver, and kidneys during starvation, yet this trend is not observed in the brain
315,316
. More 
recently a growing body of evidence links the expression of PDK1 to cancer cells through 
transcriptional activation by HIF-1 as a means of reducing mitochondrial metabolism 
and preventing ROS production
317–319
. Less is known about the role of pyruvate 
metabolism in aging or AD. One study has shown that aged rats display a reduction in the 
expression of PDK1 and PDK2 in the brain
320. Alzheimer’s patients also typically show a 
reduction in PDH activity, and increased pyruvate levels in the cerebrospinal fluid may 
be a potential biomarker of AD
321,322
. 
Lactate dehydrogenase 
Pyruvate that is not imported into the mitochondria can be converted to lactate in the 
cytosol. Lactate dehydrogenase (LDH) is the enzyme complex that catalyzes the 
reversible conversion of pyruvate to lactate with the concomitant oxidation of NADH to 
NAD
+
. LDH is a ubiquitously expressed tetramer composed of two different subunits, 
LDHA and LDHB, which can assemble into five different combinations (LDH-1 through 
LDH-5) depending on the relative expression levels of each subunit in the cytosol
323,324
. 
LDH-1 is comprised entirely of LDHB subunits while LDH-5 is comprised entirely of 
LDHA subunits. LDHA favors the forward reaction of pyruvate and NADH to lactate and 
NAD
+
, while LDHB favors the reverse reaction of lactate and NAD
+
 back to pyruvate 
and NADH. The LDHA gene promoter contains two hypoxia response elements, the 
essential binding sites of HIF-1, which implicates a role of LDHA in cellular response to 
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hypoxia and oxidative stress
325
. LDHA is also commonly over-expressed in many 
tumours and is a promising target for cancer therapy
326,327
. Previous evidence has 
suggested that neurons exclusively express LDHB, while astrocytes can express both 
LDHA and LDHB
328
. However, a more recent report has demonstrated that primary 
cultures of rat neurons and astrocytes both preferentially express LDHA, yet are capable 
of expressing all isofoms of LDH
329
. In addition, LDHB expression was higher in freshly 
isolated synaptic terminals, which implicates that lactate conversion to pyruvate in 
neurons is specific to synapses
329
. A recent study using a mouse model of advanced aging 
demonstrated a progressive shift toward higher LDHA/LDHB ratio resulting in higher 
cortical lactate levels with age
330
. Yet, it has been suggested that the observed elevation 
in lactate is unlikely to be caused by a shift in the isoform ratio of LDH due to the near 
steady-state conditions of the reaction
331
. The age-dependent change in LDH expression 
and its effect on cerebral lactate metabolism and AD remains to be elucidated. 
Hypoxia-inducible factor 
Cellular metabolism is a complex process regulated by many intrinsic and extrinsic 
factors. Shifts in metabolic states occur naturally in order to meet the energy demands of 
active cellular processes while responding to a dynamic environment and changing 
nutrient availability. Hypoxia inducible factor-1 (HIF-1) is the master transcriptional 
regulator of anaerobic respiration and also plays a key role in promoting aerobic 
glycolysis. HIF-1 is a heterodimeric transcription factor comprised of two subunits that 
are constitutively expressed: a stable  subunit, and an  subunit that is highly regulated 
by changing oxygen levels
332
.  Under normal oxygen conditions, HIF-1 is hydroxylated 
by prolyl hydroxylases and targeted for ubiquitin-mediated degradation
333
.  Under 
hypoxic conditions, HIF-1 is stabilized and translocates to the nucleus where it 
dimerizes with HIF-1 and induces expression of genes regulated by hypoxic response 
elements
334
. These genes include glucose transporters GLUT-1 and GLUT-3, as well as 
glycolytic enzymes and regulators LDHA, and PDK1
335
.  HIF-1 activation represents a 
well-characterized mechanism by which the cell can quickly respond to hypoxic 
environments by up-regulating glycolysis and inhibiting mitochondrial respiration in 
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order to meet cellular energy demands.  However, even when oxygen is abundant, HIF-1 
can be stabilized and transcriptionally active during periods of rapid proliferation and 
increased metabolic demand. HIF-1 expression can be elevated under normoxic 
conditions through the PI3K/Akt/mTOR pathway, which results in transcriptional up-
regulation of PKM2 and promotes cell proliferation
336
.  Expression of HIF-1 is induced 
by the glycolytic intermediates pyruvate, lactate and NAD
+
, in addition to other TCA 
cycle metabolites
319,335
. This feed-forward mechanism perpetuates HIF-1 activity and 
contributes to prolonged aerobic glycolysis commonly associated with proliferating cells. 
HIF-1 is over-expressed in many human cancers and loss of HIF-1 dramatically slows 
tumor growth in nude mice
337–340
.  HIF-1α activation promotes several cellular responses 
that are beneficial for a growing tumor, including vascular remodelling, increased 
glucose uptake, oxidative stress response, and cell survival.  As such, it also directly 
opposes known deleterious effects of AD pathophysiology, including reduced cerebral 
blood flow, impaired glucose uptake and metabolism, increased oxidative stress, and 
uncontrolled cell death
341
. A has also been shown to decrease HIF-1 expression in 
activated astrocytes resulting in a reduced rate of glycolysis
342
. In addition, nerve cell 
lines and primary cortical neurons can be made resistant to A toxicity by activating HIF-
1 resulting in enhanced glycolysis260.   
1.3 Cerebral metabolism and memory 
The brain is a very energetically demanding organ. Despite being 2% of the total body 
weight, the human brain accounts for approximately 20% of basal metabolism in healthy 
adults
343,344
. An updated account of ATP consumed in the cerebral cortex predicts that 
most of the energy is directed at the maintenance of post-synaptic receptors, which 
includes the energy used to reverse glutamate-evoked Na
+
 and Ca
2+
 fluxes
255
.  The 
remaining energy is directed at pumping Na
+
 ions out of neurons for the maintenance of 
resting membrane potentials and the generation of action potentials, while only a small 
fraction of total energy consumed is used for neurotransmitter recycling
255,345
. Current 
estimates suggest that approximately 10-12% of the total glucose consumed by the 
resting brain is in excess of oxygen consumption, suggesting a role for non-oxidative 
(glycolytic) metabolism
346–351
. Different regions of the resting brain also display different 
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levels of glycolytic metabolism. Aerobic glycolysis accounts for nearly 25% of glucose 
consumed in two distinct cortical systems: the default mode network (DMN) and areas of 
the frontal and parietal cortex
351
. The DMN is defined as the region of the brain that 
shows high levels of activity when no explicit task is performed, while the frontal and 
parietal cortex are associated with task control processes
352–355
. In contrast to these brain 
regions displaying higher levels of aerobic glycolysis, the cerebellum relies almost 
entirely on oxidative phosphorylation for energy needs. These observations could be 
explained by the ratio of neurons to astrocytes in each brain region. The cerebral cortex 
contains only about 19% of the brains’ total neurons and 72% of non-neuronal cells, 
while the cerebellum contains approximately 80% of the brains’ neurons and only 19% of 
non-neuronal cells, which supports the hypothesis that neurons preferentially exhibit a 
phenotype of oxidative metabolism
356
.  
Cerebral activation and aerobic glycolysis 
The brain must also rapidly respond to changing energy demand and supply, as reflected 
by task-dependent cerebral activation, changes in localized blood flow, and glucose 
utilization
357
. It was traditionally perceived that most of the energy needed for brain 
function is derived by the complete oxidation of glucose to carbon dioxide and water. 
Therefore, it was postulated that blood-flow increases accompanied by cerebral activation 
must be related to an increased demand for oxygen
358
. However, several early 
observations during cerebral activation suggested regional cerebral blood flow (rCBF) 
and cerebral metabolic rate of glucose (CMRglc) increase in excess oxygen 
consumption
346,359,360
. In fact, there is a very close correlation between rCBF and 
CMRglc, but not between rCBF and oxygen consumption
346,361,362
.  It is now known that 
during cerebral activation, aerobic glycolysis is quickly up-regulated and can account for 
up to 40% of the glucose consumed by activated regions
361,363
. A recent multimodal PET 
analysis identified high rates of aerobic glycolysis in cortical regions of the adult brain 
known to participate in cognitive control networks
351
. Local aerobic glycolysis can also 
persist for up to 40 minutes following activation despite the return of physiological 
conditions back to baseline
349
. Correspondingly, it is well documented that there is an 
increase in local brain lactate efflux during cerebral activation
363–368
. Yet, this lactate 
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efflux accounts for only about 50% of the excess glucose consumed by glycolysis and 
suggests that some of the lactate is also recycled as a fuel source.  
Recent work has provided a potential mechanism between rCBF and glycolytic 
metabolism through changes to the lactate/pyruvate ratio and the cytosolic NADH/NAD
+
 
ratio. Experiments in support of this hypothesis are based on lactate and pyruvate 
injections, whereby the intravenous injection of lactate augmented rCBF in response to 
visual stimulus, while the injection of pyruvate attenuated this response
369–371
. The 
NADH/NAD
+
 ratio is a sensor of the redox state of the cell that increases when NADH is 
produced by glycolysis and the citric acid cycle at a faster rate than can be used by the 
mitochondria to synthesize ATP. The excess electrons from NADH can be transferred to 
oxygen by NADPH oxidase (NOX) to generate superoxide, which elevates cytosolic Ca
2+
 
levels and activates nitric oxide production by nitric oxide synthase (NOS)
372,373
.  Nitric 
oxide is a signaling molecule in endothelial cells that causes cerebral vasodilation and 
increases local blood flow
374
. Lactate has also been shown to directly promote the ability 
of astrocytes to induce vasodilation through accumulation of  prostaglandin E2 (PGE2), a 
well characterized vasodilating agent
375
. The induction of rCBF serves to remove excess 
lactate and promotes the delivery of glucose and oxygen to activated tissues. Taken 
altogether, under resting conditions, glucose is almost entirely oxidized to carbon dioxide 
to generate large amounts of ATP. Cerebral activation triggers the up-regulation of 
aerobic glycolysis to rapidly synthesize ATP with the concomitant production of lactate 
as an end product. The rapid increase in glycolysis raises the NADH/NAD
+
 ratio and 
promotes an increase in rCBF. The increased blood flow serves to remove the excess 
lactate and promotes the delivery of glucose and oxygen to activated tissues in order to 
sustain metabolic flux. 
1.3.1 Neuron-astrocyte metabolic coupling 
The question of how glucose is utilized by the different cell types of the brain, namely 
neurons and astrocytes, has been extensively investigated yet remains to be fully 
characterized. Astrocytes are the most common non-neuronal cell in the brain and play a 
key role in cerebral homeostasis, including neurotransmitter recycling, ion and water 
regulation, defense against oxidative stress, and synapse formation and remodeling
376
. 
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Despite the general assumption that the human brain contains about 100 billion neurons 
and ten-times as many astrocytes, it was recently calculated that the human brain contains 
approximately equal numbers of neurons and astrocytes with a total of 86.1 ± 8.1 billion 
neurons and 84.6 ± 9.8 billion astrocytes
356
. While neurons traditionally account for the 
majority of energy consumed in the brain, astrocytes are thought to regulate the energy 
supply from the blood stream to neurons in a process called “metabolic coupling”.  
The astrocyte-neuron lactate shuttle hypothesis 
In 1994, a seminal discovery by Pellerin and Magistretti identified glutamate as the 
molecular trigger for glucose uptake and up-regulation of aerobic glycolysis in response 
to brain activation
377
. Glutamate is the principal excitatory neurotransmitter of the central 
nervous system, accounting for well over 80% of all synaptic activity in the human 
brain
378
. In response to axon depolarization, glutamate is released into the synapse from 
the pre-synaptic terminal and propagates the action potential in the post-synaptic neuron 
by binding to specific ionotropic and metabotropic receptors
379
. Glutamate is then quickly 
removed by glutamate transport 1 (GLT-1), located on astrocytes and neurons, in order to 
terminate signal propagation and prevent excitotoxicity. Glutamate transport is coupled 
with the import of three Na
+
 ions into the cell, which leads to the activation of the Na
+
/K
+
 
-ATPase to restore the osmotic balance
380
. This is an energetically demanding process 
that increases ATP consumption and triggers an increase in glucose uptake to compensate 
for energy demand. Pellerin and Magistretti observed an increase in glucose uptake and 
lactate released by primary mouse cortical astrocytes in response to glutamate 
stimulation
377
. It is proposed that the increased lactate production implicates aerobic 
glycolysis in astrocytes as the key mechanism coupling neuronal activity to glucose 
utilization. The discovery led to the long-standing hypothesis called the astrocyte-neuron 
lactate shuttle hypothesis (ANLSH). The ANLSH posits that astrocytes can rapidly 
mobilize glucose from either glycogen stores, or directly from cerebral blood vessels, and 
process it through glycolysis to generate lactate which is exported and subsequently used 
as a fuel source for oxidative phosphorylation in the mitochondria of neurons (Figure 
3)
377,381–383
.  
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Figure 3. The astrocyte-neuron lactate shuttle model 
The astrocyte-neuron lactate shuttle model proposes that astrocytes 
readily take up glucose from cerebral blood vessels, via glucose 
transporters (GLUT-1) and process it at a high capacity, by aerobic 
glycolysis, to produce lactate by lactate dehydrogenase A (LDHA) 
which is released into the extracellular space via monocarboxylate 
transporters 1 or 4 (MCT1/4). Extracellular lactate is then taken up by 
neurons (via MCT2) and converted to pyruvate by LDHB, which enters 
the TCA cycle followed by oxidative phosphorylation in the 
mitochondria. Lactate may also be transported and oxidized in the 
mitochondria through an unknown process. Recent studies suggest that 
extracellular lactate may also bind GPR81 (a G-protein coupled 
receptor) on neurons and trigger a phosphorylation of ERK and possibly 
activate downstream signaling events, including phosphorylation of the 
cAMP-binding protein (CREB), that may affect memory. In addition, 
astrocytes remove the excitatory neurotransmitter glutamate from 
synapses via glutamate transporters (GLT-1) and convert it to glutamine 
as part of a recycling of the neurotransmitter. In doing so, glutamate 
triggers a cascade of molecular events leading to an enhancement of 
glucose utilization by astrocytes. Astrocytes can also breakdown 
glycogen for entry into glycolysis. Neurons also have the capacity to 
fully oxidize glucose following uptake by the neuron-specific glucose 
transporter (GLUT-3).  
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Monocarboxylate transporters 
The shuttling of lactate and other monocarboxylates, including pyruvate and ketone 
bodies, is dependent on the proton-linked monocarboxylate transporter (MCT) family of 
transmembrane proteins
384
. There are a total of 14 members of MCT, yet only four 
isoforms are well-characterized (MCT1 to MCT4), each with different tissue-specific 
expression patterns and substrate specificity. Among the three MCTs that are known to 
be expressed in the brain, MCT2 is almost exclusively expressed in neurons, while 
MCT4 is almost exclusively expressed in astrocytes, and MCT1 is expressed in 
astrocytes, oligodendrocytes, and endothelial cells of cerebral blood vessels
385–390
. In 
addition to neurons, MCT2 has also been observed specifically in the foot processes of 
astrocytes and has a ten-fold higher affinity for substrates than MCT1 and MCT4, 
suggesting it is particularly suited to lactate import
391,392
. The transport of lactate via 
MCTs is dependent on H
+
 co-transport and thus movement of lactate is pH-sensitive, 
whereby lactate transport is enhanced at low pH on the H
+
 binding side or high pH on the 
opposite side
393
. In this manner, the export of lactate out of the cell is regulated by the 
redox potential and is enhanced by a high glycolytic rate
394
. The transport of lactate is 
also freely reversible with a trans-acceleration effect, which means that shuttling is 
accelerated if the lactate concentration is increased on the opposite side
395
. Given the 
tissue-specific expression and the kinetic characteristics of each, the distribution of MCTs 
in the brain supports the ANLSH whereby astrocytes are a lactate ‘source’ and neurons 
are a lactate ‘sink’396,397. The low lactate-affinity of MCT1 and MCT4 in astrocytes 
would ensure that lactate is exported to continue a high glycolytic rate and prevent lactate 
accumulation inside the cell. In contrast, the high lactate-affinity of MCT2 in neurons 
would ensure a high degree of lactate import and consumption.  
Support for the astrocyte-neuron lactate shuttle hypothesis 
Several lines of evidence support the ANLSH. First, from an anatomical standpoint, 
astrocytes are positioned in such a manner to support the coupling between glucose 
supply from blood vessels and energetic demand in neurons. Astrocytes project 
specialized processes called perivascular end-feet to surround cerebral blood vessels in 
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order to form the blood-brain-barrier and express GLUT-1 at the surface to promote 
glucose import into the brain
398,399
. In parallel, astrocytes have perisynaptic end-feet that 
enclose synaptic clefts in order to recycle glutamate released from neurons
400–402
. 
Therefore, astrocytes are positioned to respond to synaptic activity and supply glucose to 
neurons from the blood stream. Astrocytes and neurons also display markedly different 
metabolic phenotypes. Astrocytes typically present a high glycolytic rate and release 
lactate in the extracellular space
403–408
. The glycolytic phenotype of astrocytes may be 
maintained through either the low expression of PDH, or a high degree of the 
phosphorylation-mediated inactivation of PDH, in order to promote the conversion of 
pyruvate to lactate
409,410
. In contrast to astrocytes, neurons sustain a high rate of oxidative 
metabolism and even prefer lactate as a fuel source over glucose when both are 
present
403,405,411–416
. Further, neurons have a reduced capacity to perform glycolysis due 
to the constant proteasomal degradation of the enzyme 6-phosphofructose-2-
kinase/fructose-2,6-bisphosphatase-3 (PFKFB3), which is an activator of the rate-limiting 
glycolytic enzyme PFK
407
. In contrast, astrocytes express high levels of PFKFB3
407
. In 
addition, the LDH isoforms display differential cell-type specific expression in the 
hippocampus and occipital cortex of post-mortem tissues: neurons exclusively express 
with LDHB, while astrocytes express both LDHA and LDHB isoforms
328
. Thus the 
enrichment of LDHB in neurons favors lactate metabolism as a fuel source, while 
astrocytes are capable of both lactate metabolism and production. Perhaps the most 
convincing evidence in support of the ANLSH comes from in vivo studies using 
13
C-
labeling of lactate and nuclear magnetic resonance (NMR) spectroscopy. These 
experiments demonstrated that lactate is almost exclusively metabolized by neurons and 
that lactate produced by glycolysis in astrocytes serves as a substrate for neurons
413,417–
419
.  In addition to these observations, it has been demonstrated that a decline in neuronal 
synaptic transmission arising from glucose deprivation could be rescued by exogenous 
delivery of glucose or lactate specifically to astrocytes
267
. This effect was abolished in the 
presence of an MCT inhibitor, which indicates a role in metabolic trafficking of pyruvate 
or lactate in astrocytic networks to sustain neuronal activity
267
.   
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Controversy regarding astrocytic versus neuronal aerobic glycolysis 
The role of lactate as an intermediate metabolite shuttled between astrocytes and neurons 
to meet active energy requirements of the brain is still highly debated
266,420–425
. The 
ANLSH posits that neurons preferentially consume lactate over glucose as a fuel source, 
which is provided by astrocytes following activation-induced glycolytic metabolism. Yet, 
both cell types are capable of consuming glucose as a fuel source and producing lactate in 
vitro under various conditions
425–427
. Astrocytes also have a considerable capacity to 
perform oxidative metabolism and rely on their mitochondria for approximately 75% of 
total ATP produced
428
. In fact, it was estimated that astrocytes exhibit no preferential 
utilization of either glycolysis or oxidative phosphorylation to support the Na
+
/K
+
 
ATPase pump
428,429
. Neurons also have a high capacity for glycolysis and it has been 
suggested from several studies using isolated synaptosomes from the adult brain that 
neuronal glycolysis increases in response to cerebral activation
430–433
. Several lines of 
evidence also suggest that lactate is not a major fuel source during normal brain 
activation, yet can be used as peripheral supply from the blood when glucose availability 
is inadequate such as during physical exercise
434–438
. Some researchers have argued that 
glycogen mobilization in astrocytes may simply help to offset the energy requirements of 
neurons, thereby reducing astrocytic utilization of blood-borne glucose and increasing 
glucose availability for activated neurons
297,439
. Interestingly, alternative theories have 
been proposed counter to the ANLSH called the neuron-to-astrocyte lactate shuttle. The 
authors used concentration and kinetic parameters of GLUT-1 and MCTs in endothelial 
cells, astrocytes, and neurons, to simulate neuronal uptake of glucose during activation 
and release of lactate to be taken up by astrocytes
266,440
. This model was further supported 
by in vivo functional magnetic resonance spectroscopy (fMRS) to demonstrate that 
neurons, not astrocytes, are the primary source of glucose uptake and lactate 
production
424
. Yet, regardless of the direction of lactate flow during cerebral activation, 
these authors suggested that the overall contribution of lactate to glucose metabolism is 
so small that it should be considered negligible
441
. Taken altogether, cerebral activation 
triggers an up-regulation of aerobic glycolysis in affected brain regions with the 
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associated production of lactate, yet the role of lactate as an intermediate metabolite 
shuttled between astrocytes and neurons remains a contentious issue. 
1.3.2 The role of lactate in memory 
Memory is a complex cognitive process regulated by several different cellular and 
molecular signaling cascades in the brain working together to encode and retrieve 
information. Memory is often described as a process that can divided into three distinct 
stages: acquisition, consolidation, and retrieval. Memory acquisition (encoding) is the 
process by which an animal learns the association between a cause and effect in a given 
context, while memory consolidation (storage) involves the stabilization of the 
association into a long-term memory trace, and retrieval (recall) is the process by which a 
memory trace is accessed to modulate future behaviour
442
. A large body of literature 
implicates the role of different brain regions in these sequential processes: in general, 
memory acquisition involves synaptic changes in the hippocampus, while memory 
consolidation involves the transfer of information from the hippocampus to the frontal 
and temporal cortex where it is stored for long-term retention, and memory retrieval links 
neural connections between the hippocampus and cortex to elicit a recall of 
information
443–447
. The specific transfer of information between two neurons was 
originally proposed to involve cellular changes such that the repeated and persistent 
activity of one neuron induces a lasting increase in efficiency of firing the other 
neuron
448
. This mechanism is now commonly referred to as synaptic plasticity, which 
describes the ability of synapses to change their strength over time in response to changes 
in their activity
449
. The molecular changes occurring at the synapse that strengthen or 
weaken the connection are referred to as long-term potentiation (LTP) and long-term 
depression (LTD), respectively. While short-term changes at the synapse involve post-
translational modifications, changes associated with consolidation or stabilization of 
long-term memory requires changes in gene expression and new protein synthesis
450
. The 
role of LTP in the hippocampus associated with memory formation has been examined 
extensively and reviewed in great detail
451–455
. On a molecular level, long-term LTP 
begins with the depolarization of the post-synaptic site through the -amino-3-hydroxy-
5-methyl-4-isoxazolepropionate (AMPA) receptor and the coincident binding of 
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glutamate to the NMDA receptor, which stimulates an influx of Ca
2+
 into the cell and 
triggers a signaling cascade that activates Ca
2+
-dependent protein kinases. This ultimately 
leads to activation of the transcription factor cAMP-response element binding protein 
(CREB), which promotes gene expression of proteins that remodel the actin cytoskeleton 
and are required for long-term LTP and memory consolidation
456–458
. Several studies 
have demonstrated that genetic loss of CREB impaired long-term memory formation
459–
461
.  
A growing body of evidence suggests that lactate participates in LTP and memory 
formation. Inhibitory avoidance training in rats caused an increase in activated CREB and 
its downstream targets, ARC and COFILIN. This effect was completely blocked with 
administration of 1,4-dideoxy-1,4-imino-D-arabinitol (DAB), which blocks glycogen 
breakdown, and led to impaired memory formation
462
. Exogenous lactate can rescue 
CREB activation back to a level comparable to vehicle-injected rats, although glucose 
was not tested.  A recent meta-analysis of whole-genome microarray data revealed a 
strong correlation between aerobic glycolysis and changes in gene expression associated 
with synapse formation and neurite growth in the adult brain
463
. This observation may be 
explained by results from a recent study showing that lactate can potentiate NMDA 
signaling and promote the expression of synaptic plasticity-related genes downstream of 
CREB by raising the cytosolic NADH/NAD
+
 ratio in cultured neurons and in vivo in the 
mouse sensory-motor cortex
464
. This is in agreement with previous studies showing 
redox-dependent regulation of the NMDA receptor
465,466
. Lactate has also been 
implicated as a receptor-mediated signaling molecule independent of metabolic 
coupling
467
. Lactate was identified as a natural ligand of a G protein-coupled receptor 81 
(GPR81), also known as hydroxycarboxylic receptor 1 (HCA1)
468
. This receptor is 
expressed on post-synaptic terminals of excitatory synapses as well as the perivascular 
astrocytic processes and endothelial cells that comprise the blood-brain barrier, although 
it is expressed at 100-fold levels in adipose tissues where it plays a prominent role 
inhibiting lipolysis
468–471
. Activation of GPR81 causes an inhibition in adenylyl cyclase 
activity resulting in a decline in cAMP levels, which in turn reduces calcium-spiking 
activity in cortical neurons
471,472
. The ability of lactate to suppress neuronal activity has 
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been observed previously in hippocampal slices, yet a direct role for GPR81 in synaptic 
plasticity and memory has yet to be discovered
473
. 
Perhaps the most convincing evidence that implicates a role of lactate in memory 
processes is directly through metabolic coupling and fuel delivery. Given that aerobic 
glycolysis is quickly up-regulated in active regions of the brain and cognitive tasks are 
energetically demanding processes, lactate production and transport may simply comprise 
a system of energy delivery to brain regions participating in memory processes. The first 
evidence of this emerged from experiments demonstrating that glycogen is mobilized 
from astrocytes in neonatal chicks following training in a taste-aversion task
474,475
. 
Administration of DAB or 2-deoxyglucose (2DG), which impaired glycogen breakdown 
and glycolysis respectively, impaired memory performance
476,477
. Supplementation with 
lactate was sufficient to rescue memory in the presence of DAB or 2DG, while glucose 
was able to rescue memory from DAB but not 2DG. These observations suggested that 
mobilization of glycogen and glycolysis both play a key role in memory formation. A 
similar study demonstrated that IA training in rats caused an increase in extracellular 
lactate in the hippocampus that was completely blocked with DAB
462
. Administration of 
DAB had no effect on short-term memory (tested after an hour) but blocked long-term 
memory (tested after 24 hours) that was rescued with exogenous lactate
462
. The authors 
also demonstrated that knock down of MCT1, MCT2, or MCT4 expression impaired 
memory that was rescued with administration of lactate following disruption of MCT1 or 
MCT4 (astrocytic) but not MCT2 (neuronal) expression. Pharmacological blockage of 
MCT2 with -cyano-4-hydroxycinnamate (4-CIN) also caused an inhibition of spatial 
working memory formation in rats that could not be rescued with lactate or glucose 
administration
296
.These results have been confirmed by independent groups using a 
cocaine-induced model of conditioned responses
478
. Ultimately, these studies 
demonstrating lactate production through glycogen breakdown in astrocytes and 
subsequent transport to neurons plays a key role in memory formation
479
. However, it 
remains to be discovered how neuronal activation, aerobic glycolysis, and lactate 
shuttling varies during aging and in AD and contributes to cognitive decline under 
physiological conditions.  
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1.4 Research questions 
Aerobic glycolysis and glycogen breakdown both play a central role in long-term 
memory formation through the production of lactate in astrocytes and subsequent 
transport to neurons. Lactate may act as a redox-mediated signaling molecule to directly 
promote the expression of synaptic plasticity genes or bind directly to a receptor to elicit 
downstream signaling cascades that regulate neuronal activity. Aerobic glycolysis is up-
regulated in activated regions of the brain to quickly support the energy demands of firing 
neurons and promote the de novo synthesis of biosynthetic building blocks for synaptic 
remodeling. Aerobic glycolysis also shares a close spatial distribution to amyloid 
deposition in AD patients and confers a survival advantage to neurons in culture when 
exposed to A. However, the changes in aerobic glycolysis that occur with age and the 
role of lactate production and transport in memory decline associated with Alzheimer’s 
disease have yet to be investigated. Furthermore, the transgenic-AD mouse line used in 
this study, APPswe/PS1ΔE9, develops memory loss with age, yet does not exhibit extensive 
neuron loss consistent with atrophy in the human AD brain
480
. This has remained a 
contentious issue for decades and has given rise to several research questions that I aim to 
answer including:  
 
1. Does aerobic glycolysis mediate resistance to A in vivo? 
2. Does aerobic glycolysis play a role in memory performance during both normal 
aging and under the conditions of high A deposition? 
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1.5 Hypothesis 
I hypothesize that neurons upregulate aerobic glycolysis in response to A deposition to 
promote A resistance in vivo. Furthermore, I hypothesize that aerobic glycolysis 
contributes to memory processes in both normal aging and under conditions of high A 
deposition.   
1.6 Specific aims 
In order to test the hypothesis that neurons upregulate aerobic glycolysis in response to 
A deposition, a mouse model of cerebral amyloid pathology, APP/PS1, and control 
littermates will be treated with DCA (an inhibitor of PDK1) in the drinking water over 
the course of age. I predict that APP/PS1 mice treated with DCA will undergo 
neurodegeneration and succumb to memory decline at an earlier age than untreated 
APP/PS1 mice. In order to test the hypothesis that aerobic glycolysis contributes to 
memory, a standard memory test will be used to compare the spatial memory 
performance of control mice and APP/PS1 mice to the expression of aerobic glycolysis 
enzymes measured by Western blot analysis. This will determine if a correlation between 
aerobic glycolysis enzyme expression and memory exists during normal and pathological 
conditions. In addition, the effect of chemical inhibition of aerobic glycolysis on memory 
in control and APP/PS1 mice will be assessed. I predict that the expression of aerobic 
glycolysis enzymes in the brain will correlate with memory performance in both control 
and APP/PS1 mice. Moreover, inhibition of aerobic glycolysis will have a more adverse 
effect on memory in APP/PS1 mice due to the reliance of this metabolism to preserve 
neuronal function under pathological conditions. 
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Chapter 2  
2 Materials and Methods 
2.1 Animals 
Male APPswe/PS1ΔE9 mice
481
 were maintained on a C57BL/6J background (Charles River 
Laboratories International, Inc.) and will henceforth be referred to as APP/PS1 mice. 
Age-matched male C57BL/6J littermates were used as controls and will henceforth be 
referred to as control mice. All animals were housed in groups of up to 3 animals per 
cage under a 12 hour light/dark cycle with ad libitum access to water and the Mouse Diet 
5015 breeder chow base diet (LabDiet). A single red, transparent plastic house was 
placed in each cage with cotton nesting material and corn cob bedding and that was 
changed weekly. Animals were weaned at 3 weeks of age and ear punches were used for 
identification and PCR-based genotyping. All animal procedures were conducted in 
compliance with the Canadian Council of Animal Care (CCAC) guidelines with 
approved animal protocol from the Institutional Animal Care and Use Committees at the 
University of Western Ontario (protocol number 2011-079). 
2.2 
1
H-Magnetic resonance spectroscopy 
Animals were anesthetized starting with 3.5% isoflurane and then reduced to 2% 
combined with 30% oxygen. Mice were scanned using a 9.4 T small animal MRI scanner 
equipped with a 30 mm millipede volume radiofrequency coil (Agilent, Palo Alto, CA, 
USA). T2-weighted images were acquired using a 2-dimensional fast spin echo (FSE) 
pulse sequence with parameters: repetition time (TR)/echo time (TE) = 4000/10 ms, echo 
train length (ETL) = 4, effective TE = 40 ms, field of view (FOV) = 19.2 x 19.2 mm
2
, 
matrix size = 128 x 128, slice thickness= 0.5 mm, 25 slices, 4 averages. Based on the T2-
image, a voxel (2 x 4 x 3 mm
3
) was localized to the frontal cortex for magnetic resonance 
spectroscopy using a LASER pulse sequence with the following parameters:  
TR/TE = 4000/270 ms, 384 averages for the metabolite spectrum with water suppressed. 
An unsuppressed water spectrum (8 averages) was also acquired and a QUECC 
correction was applied. Metabolite levels were measured by fitting spectra using fitMAN 
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software incorporated into a graphical user interface written in the IDL (Version 5.4, 
Research Systems Inc.) programming language
482
.  
2.3 In vivo microdialysis and interstitial fluid lactate 
measurements 
In vivo microdialysis was performed as previously described
483
.  Briefly, guide cannulae 
(BR-style, Bioanalytical Systems, West Lafayette, IN, USA) were stereotaxically 
implanted into the hippocampus and secured into place with dental cement.  Twenty-four 
hours post-cannulation, mice were transferred to Raturn sampling cages (Bioanalytical 
Systems) and microdialysis probes (2 mm; 38 kDa molecular weight cut-off; BR-style, 
Bioanalytical Systems) were inserted into the guide cannula, connected to a syringe pump 
and infused with artificial cerebrospinal fluid (aCSF; 1.3 mM CaCl2, 1.2 mM MgSO4, 3 
mM KCl, 0.4 mM KH2PO4, 25 mM NaHCO3 and 122 mM NaCl; pH 7.35) at a flow rate 
of 1 µl/minute.  Following an 8-hour habituation period, hippocampal ISF was collected 
in hourly fractions and lactate measurements using a lactate oxidase method were 
quantified for each hour using the YSI 2900 analyzer (YSI Incorporated, Yellow Springs, 
OH, USA) per the manufacturer’s instructions.   
2.4 SDS-PAGE and Western blot analysis of brain extracts 
Mice were euthanized by cervical dislocation and then immediately perfused with PBS, 
pH 7.4 ± 0.1. The frontal cortex and hippocampus of the right hemisphere were removed 
and snap frozen in dry ice. Tissues were homogenized by hand using a pestle in an 
extraction buffer containing 50 mM Tris pH 7.5, 2% SDS, 100 mM EDTA, protease 
inhibitors: 2 mM leupeptin, 0.1 mM pepstatin A, and 1 mM PMSF, and the phosphatase 
inhibitor 0.5 mM sodium orthovanadate. Protein extracts were separated by 10% SDS-
PAGE, and electroblotted onto PVDF membrane (Bio-Rad, Hercules, CA, USA). 
Membranes were probed with the following antibodies: PDK1 (Enzo, Farmingdale, NY, 
USA), PDH-E1 (pSer232) (Millipore, Darmstadt, Germany), PDH-E1 (pSer293) 
(Millipore), PDH-E1 (AbCam, Cambridge, UK), LDHA (Cell Signaling, Danvers, MA, 
USA), LDHB (AbCam), PKM2 (Cell Signaling), PKM1 (Cell Signaling), MCT2 
(Millipore), MCT4 (Millipore) and -actin (Cell Signaling), followed by incubation with 
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an appropriate horseradish peroxidase-conjugated secondary antibody (Bio-Rad). The 
blots were developed using Pierce ECL western blotting substrate (Thermo Fisher 
Scientific, Waltham, MA, USA) and visualized with a Bio-Rad Molecular Imager 
(ChemiDoc XRS, Bio-Rad). Densitometric analysis was performed using Quantity One 
software (Bio-Rad).  
2.5 The Morris water maze 
Spatial learning and memory was assessed as previously described
484
 using the Morris 
water maze (MWM) with the following specifications: A white circular tank with 
diameter 48" and height 30" (San Diego Instruments, San Diego, CA, USA) was filled 
with water and maintained at a temperature of 26 ± 1 ºC using a 300 W submersible 
aquarium heater (Aqueon, Franklin, WI, USA) that was removed immediately before 
mice were brought into the testing room. Spatial visual cues in the form of different 
shaped cardboard pictures were placed on the walls surrounding the water tank, including 
a white diamond at the North position, a blue cross at the North-East, a yellow triangle at 
the South-East, a green circle at the South, a pink heart at the South-West, and a red 
square at the North-West (Figure 4). Visual data were collected using a HD Pro Webcam 
C920 (Logitech, Romanel-sur-Morges, Switzerland) and analyzed by the video tracking 
software ANY-maze v4.98 (Stoelting Company, Wood Dale, IL, USA). A circular, clear 
plastic platform (diameter 10.16 cm) was submerged 1 cm below the surface of the water. 
The platform was positioned in the correct quadrant according to virtual tracer lines 
generated by the ANY-maze software with a radial grid from the center spaced at 45 
degrees as well as a square grid spaced to the edge of the water line and a concentric grid 
spaced to the edge of the square. The platform was positioned in the tank in the correct 
quadrant with its center at the intersection of the radial and concentric lines.  
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Figure 4: Configuration of the Morris water maze.   
(Top) Virtual tracer lines in red outline the edge of the water level and 
the division of the tank into four quadrants, as well as the platform in 
the South-East quadrant. Virtual tracer lines in black outlining the 
positioning of the platform using a radial grid from the center spaced 
at 45 degrees as well as a square grid spaced to the edge of the water 
line and a concentric grid spaced to the edge of the square. 
Representative images are shown of cardboard pictures placed on the 
walls surrounding the water tank, including a white diamond at the 
North position, a blue cross at the North-East, a tallow triangle at the 
South-East, a green circle at the South, a pink heart at the South-West, 
and a red square at the North-West. Scale bar in the bottom right is 30 
cm. (Bottom) Photograph taken of the MWM with a mouse swimming 
and platform located in the South-East quadrant. 
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Before the first training day, mice were acclimatized to the experimental room and water 
tank. For mice naïve to the MWM, the acclimatization period lasted three consecutive 
days: on the first day, mice spent 30 minutes in the experimental room in their native 
cages; on the second day, mice spent 30 minutes in the experimental room in their native 
cages followed by 15 seconds on the platform located in the center of the tank and 
allowed 90 seconds to swim to the platform if they jumped off, or guided to the platform 
if they did not find it within 90 seconds; on the third day, mice spent 30 minutes in the 
experimental room in their native cages followed by 15 seconds on the platform located 
in the center of the tank, then followed by a release into the water at the North release 
point of the tank and allowed 90 seconds to find the platform, or guided to the platform if 
they did not find it in 90 seconds. For mice that were not naïve to the MWM, an 
acclimatization period of one day was performed consisting of 30 minutes spent in the 
experimental room in their native cages followed by 15 seconds spent on the platform 
located in the center of the tank, then followed by a release into the water at the North 
release point of the tank and allowed 90 seconds to find the platform, or guided to the 
platform if they did not find it in 90 seconds. For all subsequent training days mice were 
first acclimatized to the experimental room for 30 minutes before the beginning of the 
first trial. 
Mice were then trained for 4 consecutive days with 4 trials per day to find the location of 
the platform submerged in the correct quadrant. The release point of the first trial 
corresponded to the cardinal directions (North, East, South, and West) rotating with each 
training day (Table 1). For each of the 4 trials in one day, mice were released into the 
water with a clockwise rotation of release placements for each trial that day. A trial lasted 
until the mouse found the platform or until 90 seconds had elapsed, at which point the 
mouse was gently guided to the platform. The mouse was then placed for 15 seconds on 
the platform before it was removed and briefly dried in paper towel before placing it back 
in its cage. An inter-trial interval (ITI) of 10 minutes was used to ensure consistency of 
timing between trials for each mouse.  
45 
 
Table 1: Release point schedule for mice training in the Morris water maze 
Training Day 
Release Point (4 per day) 
Trial 1 Trial 2 Trial 3 Trial 4 
1 N E S W 
2 E S W N 
3 S W N E 
4 W N E S 
Probe Center 
 
On the fifth day, mice were exposed to a probe trial in which the platform was removed 
and the mouse was released in the center of the tank and given 60 seconds to attempt to 
find the missing platform. After swimming in the probe trial, the mouse was then 
removed from the tank and briefly dried in paper towel before placing it back into its 
cage. A flag trial was then performed in which the platform was placed back into the 
water in the opposite quadrant that originally held the platform and a small red plastic 
pole was inserted into the platform so it was sticking out of the water. The mouse was 
released in the center of the tank and given 90 seconds to find the location of the 
platform. A trial lasted until the mouse found the platform or until 90 seconds had 
elapsed, at which point it was gently guided to the platform. The mouse was then given 
15 seconds on the platform before it was removed and briefly dried in paper towel before 
placing it back into its cage.  
Mice were disqualified from the data analysis of the MWM according to criteria that they 
did not appear to be using visual spatial strategies to actively search for the platform, or 
they appeared  unable or unmotivated to escape
485
. This behavior could occur in the 
following ways: (1) the mouse frequently swims around the edge of the pool in an 
attempt to climb up the wall of the tank and does not make a clear attempt to find the 
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platform; (2) the mouse frequently stops swimming and floats on the surface of the water 
for long periods of time. If the mouse attempted to climb up the wall of the tank and 
continued to swim on the edge of the pool, the timer continued until the end of the trial. If 
at any point the mouse stopped swimming and floated in the water, the timer was paused 
until it started swimming again and continued until the end of the trial. A mouse was 
disqualified from analysis if it failed to demonstrate active searching behavior on 
consecutive training days or on the probe trial. If a mouse was disqualified from analysis 
it was removed from all training days as well as the probe and flag trials for that 
particular training phase. 
For acute exposure to chemical inhibitors of aerobic glycolysis, the location of the 
platform was moved to different quadrants between each set of chemical treatments 
(Table 2). The platform was located in the south-east quadrant for the 1
st
 training phase 
(Vehicle), the north-west quadrant for the 2
nd
 training phase (Isosafrol), the north-east 
quadrant for the 3
rd
 training phase (DCA), and the south-west quadrant for the 4
th
 training 
phase (Saline). During the probe trial, mice were injected intraperitoneally with the 
specified treatment (vehicle, Isosafrol, DCA, or saline) 30 minutes prior to the start of the 
probe trial. 
Table 2: Treatment schedule for mice in memory testing with Isosafrol and 
dichloroacetate 
Training Phase Age (months) Treatment Platform Location 
1 12-13 Vehicle SE 
2 13-14 Isosafrol NW 
3 14-16 DCA NE 
4 16-17 Saline SW 
Euthanization 17-18 Saline or DCA  
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2.6 Preparation of mouse brain soluble and insoluble 
amyloid--extracts and ELISA 
Mouse brain tissue from the frontal cortex was extracted in a 50 mM Tris pH 7.5, 2% 
SDS buffer with a protease inhibitor cocktail containing AEBSF (Millipore), then 
sonicated briefly and centrifuged at 100,000 × g for 1 hour at 4ºC. The supernatant was 
collected as the soluble A fraction and initially diluted in cold Reaction buffer BSAT-
DPBS (Dulbecco’s phosphate buffered saline at pH7.4 containing 5% BSA and 0.03% 
Tween-20), then diluted as necessary for ELISA analysis. To analyze the insoluble A 
fraction, the pellet was dissolved in 70% formic acid and sonicated briefly before 
centrifugation at 100,000 × g for 1 hour at 4 ºC. The supernatant was neutralized by 1 M 
Tris phosphate buffer, pH 11, and then initially diluted in cold BSAT-DPBS, followed by 
dilution as necessary for the ELISA. ELISAs for A40 and A42 (Thermo Fisher 
Scientific) were performed according to standard protocol and measured at 450 nm using 
an Infinite M1000 microplate reader (TECAN, Männedolf, Switzerland).  
2.7 Cryo-immunohistochemistry and confocal microscopy 
Left hemi-brains were fixed in 4% paraformaldehyde at 4 ºC overnight, then incubated in 
30% sucrose at 4 ºC for 48 hours, and snap frozen in freezing microtome cassettes 
containing Tissue-Tek
®
 O.C.T. compound (Sakura Finetek USA Inc., Torrance, CA, 
USA). Brain tissues were sectioned on a serial sagittal plane using a CM350 Cryostat 
(Leica, Wetzlar, Germany) at a thickness of 30 m and free-floating brain slices were 
stored in 25 % glycerol in PBS at 4 ºC for up to three weeks. Sections were washed in 
PBS, then permeabilized using PBST (PBS and 0.1 % Triton X-100), and blocked 
overnight at 4 ºC in 10% goat serum in PBST. Sections were incubated in primary 
antibody solutions at a 1:100 dilution in PBST + 1% BSA overnight at 4 ºC: PDK1 
(Enzo), LDHA (Cell Signaling), GFAP (AbCam), and TUJ1 (AbCam). Sections were 
washed in PBS and incubated in secondary antibodies: AlexaFluor
®
 488 and AlexaFluor
®
 
647 (Thermo Fisher Scientific) at a 1:1000 dilution in PBST + 1% BSA for 1 hour at 
room temperature then washed with PBS and mounted with ProLong
®
 Gold reagent with 
DAPI (Thermo Fisher Scientific) on Superfrost slides (Fisher Scientific, Waltham, MA, 
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USA). For staining of A plaques, sections were dehydrated with 80% ethanol then 
incubated in 0.01%Thioflavin S (Sigma, St. Louis, MO, USA) for 15 min at room 
temperature, followed by rehydration in PBS and mounting with ProLong
®
 Gold antifade 
reagent without DAPI (Thermo Fisher Scientific) on Superfrost slides (Fisher Scientific). 
2.8 Dichloroacetate 
Dichloroacetate (DCA) is an analog of acetic acid in which two of the hydrogens of the 
methyl group are replaced by chlorine atoms. Humans have a long history of exposure to 
DCA through chlorinated drinking water with an average daily consumption at 
approximately 4 mg/kg
486
. DCA has been used as a metabolic treatment in laboratory 
animals since 1973
487
 and in humans since 1980
488
. DCA is a selective inhibitor of PDK, 
thereby preventing the phosphorylation of PDH and promoting the active form
489
.  
2.9 Isosafrol 
Isosafrol is an analog of stiripentol, an inhibitor of cytochrome P450, which has been 
used for the treatment of severe myoclonic epilepsy in infancy (SMEI), a rare congenital 
form of epilepsy called Dravet syndrome
490
. Isosafrol lacks the hydroxyl group and 
tertiary-butyl group of stiripentol. It was recently discovered that isosafrol is a potent 
inhibitor of LDHA and strongly prevented pyruvate-to-lactate conversion in vitro
491
.   
2.10 Chronic exposure to dichloroacetate through oral 
administration in drinking water 
DCA (Sigma) was orally administered to mice at a daily dose of 200 mg/kg (pH 7.4 ± 
0.1) by changing the drinking immediately water after weaning (3 weeks of age), based 
on an average daily water consumption of 5mL per mouse. Mice were weighed twice 
weekly and the average weight of mice in each cage was used to calculate the amount of 
DCA to add to drinking water of each bottle per cage. Drinking water was replaced twice 
per week with freshly prepared DCA. 
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2.11 Acute exposure to Isosafrol and dichloroacetate 
through intraperitoneal injection 
The chemical inhibitor of LDH, Isosafrol (Sigma) was prepared fresh the day of injection 
at a concentration of 15mg/mL in a sterile solution of 1% Carboxymethylcellulose 
(CMC) (Sigma) in 0.9% NaCl (saline). Mice were weighed and then injected 
intraperitoneally with the correct volume of Isosafrol solution for a dosage of 300 mg/kg 
(1 mL for a 50 mg animal). The vehicle injection was a sterile solution of 1% CMC 
(Sigma) in saline. Mice were weighed and then injected intraperitoneally with the correct 
volume of vehicle assuming a dosage of 300 mg/kg of Isosafrol from a 15 mg/mL 
concentration. DCA (Sigma), was prepared fresh the day of injection at a concentration 
of 10 mg/mL in a sterile solution of saline and neutralized to pH 7.4 ± 0.1 with NaOH. 
Mice were weighed and then injected intraperitoneally with the correct volume of DCA 
solution for a dosage of 200 mg/kg (1 mL for a 50 mg animal). For saline injections, mice 
were weighed and injected intraperitoneally with the correct volume of sterile saline 
assuming a dosage of 200 mg/kg of DCA from a 10 mg/mL solution.  
2.12 Preparation of mouse brain extracts and LDHA/LDHB 
enzyme activity assay 
Mice were injected intraperitoneally with vehicle (1% CMC) or Isosafrol (300 mg/kg) 
and euthanized 30 minutes later by cervical dislocation. The hippocampus was dissected 
and snap frozen in dry ice. Tissues were homogenized in PPB buffer (100 mM Potassium 
Phosphate Buffer, pH 7.0 ± 0.1, with 0.1% Triton X-100 (Sigma), 2 mM EDTA, 2 mM 
leupeptin, 0.1 mM pepstatin A, 1 mM PMSF, and 0.5 mM sodium orthovanadate). 
Protein extracts were added to a standard reaction formula for either LDHA (pyruvate to 
lactate) or LDHB (lactate to pyruvate). The LDHA reaction formula included 30 mM 
sodium pyruvate (Sigma), 0.192 mM NADH (Sigma), and approximately 3 g of protein 
extract in 500 mM PPB, pH 7.4 ± 0.1 for a total volume of 50 L in a single well of a 
Nunc™ Black Polystyrene 96-well plate (Thermo Fisher Scientific). The LDHB reaction 
formula included 90 mM sodium lactate (Sigma), 1.287 mM NAD
+
 (Sigma), 218.4 M 
Hydrazine (Sigma), and approximately 3 g of protein extract in a buffer containing 0.5 
M Glycine and 2.5 mM EDTA, pH 9.5 ± 0.1 for a total volume of 50 L in a single well 
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of a Nunc™ Black Polystyrene 96-well plate (Thermo Fisher Scientific). The rate of 
NADH consumption or production (LDHA and LDHB reactions, respectively) was 
determined by measuring NADH fluorescence at excitation/emission of 340/460 nm 
using a Infinite M1000 microplate reader (TECAN) at 20 second intervals for 5 minutes. 
Concentration of NADH was determined at each time point by comparing each 
fluorescence value to a NADH fluorescence standard curve. One Unit of enzyme is 
defined as the amount of enzyme that catalyzes conversion of 1μmol of substrate per 
minute. A line-of-best-fit was modeled from a linear regression analysis and enzyme 
activity was expressed in Units per mg of protein, calculated using the slope 
(ΔNADH(μM)/min) of the reaction and the volume of the reaction (50 L) according to 
the following equation: 
                                                  
2.13 Hyperpolarized 
13
C-pyruvate magnetic resonance 
spectroscopy 
Images were acquired using a GE MR750 3.0T MRI (GE, Fairfield, CT, USA). A 
custom-built dual-tuned 
13
C-
1
H solenoid radiofrequency coil was used as and 
1
H and 
13
C 
images were inherently registered. A hyperpolarized [1-
13
C]-pyruvate buffered solution 
was prepared using a dynamic nuclear polarizer, Hypersense (Oxford Instruments, 
Abingdon, UK). The solution had a final concentration of 150 mM pyruvate with pH 7.4 
at 37 °C and with ~10% polarization at 3 T with T1 of ~60 seconds. The imaging session 
consisted of fast imaging employing steady-state acquisition (FIESTA) imaging and 
hyperpolarized 
13
C-MRS imaging. FIESTA images were acquired with the following 
imaging parameters: 30 x 30 mm field of view (FOV), 0.2 mm isotropic in-plane 
resolution, 0.4 mm slice thickness, repetition time (TR) = 10.3 ms, echo time (TE) = 5.2 
ms, bandwidth = 12.58 Hz, and phase cycling = 8. For hyperpolarized 
13
C-MRS imaging, 
a ~0.3 ml bolus of the hyperpolarized [1-
13
C]-pyruvate buffered solution was injected via 
a tail vein catheter. 15 seconds after the injection, 2D
 13
C-spectra were acquired using 
free induction decay chemical shift imaging (FID-CSI) with the following parameters: 30 
x 30 mm FOV, 2.5 mm isotropic in-plane resolution, slice thickness = 10~15 mm, TR = 
80 ms, spectral width = 5000 Hz and number of points = 256. DCA was freshly prepared 
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at a concentration of 40 mg/mL in sterile saline and neutralized to pH 7.4 ± 0.1 using 
NaOH. Mice were given 30 minutes to recover following hyperpolarized 
13
C-pyruvate 
injection before injection of DCA at 200 mg/kg via tail vein catheter. Mice were then 
given another 30 minutes to recover and another bolus of hyperpolarized 
13
C-pyruvate 
was injected and mice were scanned again as previously described. 
2.14 Statistical analysis 
Two-way ANOVA and Tukey’s post hoc comparisons were used for the following 
analyses: the difference between the genotypes over the course of aging for lactate levels 
deduced by 
1
H-MRS analysis, the difference between genotypes over the course of aging 
for band density derived from western blot analysis, as well as the levels of soluble and 
insoluble A(1-40) and A(1-42) from cortical extracts of APP/PS1 mice. A Bonferroni 
correction for multiple comparisons was used to adjust the significance value for western 
blot analysis. A two-way ANOVA with repeated measures was used to analyze the 
difference between genotypes for the latency to find the platform over the course of 
training days in the MWM. A Welch’s T-test was used to evaluate the difference between 
genotypes for individual measures of the MWM: total distance traveled, percent time 
spent in the correct quadrant, and latency to find the flag platform. A multiple linear 
regression model and ANCOVA was used to analyze the difference between genotypes 
for correlation of memory performance in the MWM and the relative band density by 
western blot analysis, in addition to the correlation of soluble and insoluble A levels 
with the relative band density by western blot analysis. A one-way ANOVA with 
repeated measures was used to analyze the difference between genotypes for each 
training phase of injected chemicals Isosafrol and DCA. Two-way ANOVA and Tukey’s 
post hoc comparisons were used to analyze the difference between the genotypes and 
chemical treatments on memory performance with the MWM. A Welch’s t-test with a 
Bonferroni correction for multiple comparisons was used to analyze the difference 
between saline- and DCA-injected control mice on band densitometry from western blot 
analysis. A Welch’s paired t-test was used to evaluate the difference between lactate-to-
pyruvate ratios for 
13
C-pyruvate MRS measurements of before and after DCA injection. 
A Welch’s t-test with a Bonferroni correction for multiple comparisons was used to 
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evaluate the difference between control mice injected saline and DCA for measures of 
memory performance in the MWM. A multiple linear regression model was used to 
analyze the difference between saline- and DCA-injected mice for the correlation of 
memory performance in the MWM and relative band density by western blot. Statistical 
evaluation was performed with Microsoft Excel 2007, RStudio v0.99.891, and GraphPad 
Prism v6.01. 
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Chapter 3  
3 Results 
3.1 Examination of lactate levels in the frontal cortex and 
hippocampus of APP/PS1 mice over the course of age 
To examine changes to brain lactate levels over the course of normal aging, in vivo 
1
H-
magnetic resonance spectroscopy (
1
H-MRS) was performed on the frontal cortex and 
hippocampus of control and APP/PS1 mice (Figure 5A). Lactate was identified as a peak 
at 1.33 ppm (Figure 5B) and quantified as a ratio to the metabolite, N-acetylaspartate 
(NAA). Lactate was measured at 3, 6, 9, and 12 months of age in the frontal cortex 
(Figure 6A). A two-way ANOVA (age × genotype) was performed, which revealed a 
significant effect of age (F(3,47) = 4.200, p = 0.010), and genotype (F(3,47) = 4.575, p = 
0.037). A Tukey’s post hoc comparison test determined that cortical lactate levels 
progressively declined starting at 9 months of age (p = 0.008) to 12 months of age (p = 
0.002).  In contrast, lactate levels did not significantly change for APP/PS1 mice 
throughout the course of aging.  In order to ensure that the standard reference metabolite 
did not change over the course of age, NAA was measured as a ratio to creatine at 3, 6, 9, 
and 12 months of age in the frontal cortex (Figure 6B). A two-way ANOVA (age × 
genotype) was performed, which revealed no significant effect for age (F(3,48) = 2.561, 
p = 0.066) or genotype (F(3,48) = 0.082, p = 0.776), which indicated that NAA levels did 
not change and was suitable as a reference metabolite for measuring lactate over the 
course of aging. In addition to the frontal cortex, lactate levels in the hippocampus of 
control and APP/PS1 mice  was assessed by 
1
H-MRS and expressed as a ratio to NAA at 
6 and 12 months of age (Figure 7A). A two-way ANOVA (age × genotype) was 
performed and revealed no significant effect of genotype on lactate levels in the 
hippocampus for age (F(1,54) = 3.863, p = 0.055) or genotype (F(1,54) = 0.349, p = 
0.557). The same analysis for levels of NAA/creatine (Figure 7B) revealed no significant 
effect of treatment for age (F(1,54) = 3.323, p = 0.074) or genotype (F(1,54) = 0.005, p = 
0.941), which indicated that NAA was a good reference metabolite for measuring lactate 
over the course of aging.  
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Figure 5: Representation of lactate levels in the frontal cortex and 
hippocampus of APP/PS1 mice measured by 
1
H-magnetic 
resonance spectroscopy.  
(A) Volume of interest in frontal cerebral cortex (left) and 
hippocampus (right) in the coronal plane. (B) Representative spectrum 
showing the raw data (red line) obtained from the frontal cortex of a 
6-month-old APP/PS1 mouse, the fitted result (green line), and the 
residual line (blue line), which is the difference between the fit and the 
spectrum. Cho, choline; Cr, creatine; Lac, lactate (highlighted by 
vertical red lines between 1.2 and 1.4 ppm); NAA, N-acetylaspartate.   
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Figure 6. Lactate levels remain unaltered in APP/PS1 mice from 3 
to 12 months of age, but decline in aged control mice.  
(A) 
1
H-MRS spectra were quantified and average lactate levels in the 
frontal cortex from 3 to 12 months of age were expressed as a ratio to 
total NAA for control mice and APP/PS1 mice. (B) Quantification of 
average NAA levels in the frontal cortex expressed as a ratio to total 
creatine for control mice and APP/PS1 mice. Data are shown as mean 
+ SEM, **p < 0.01, n = 5 and 12, respectively, for control and 
APP/PS1 mice at ages 3 - 9 months; n = 4 and 3, respectively, for 
control and APP/PS1 mice at age 12 months.  
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Figure 7. Lactate levels remain constant in the hippocampus over 
the course of age in both control and APP/PS1 mice.  
(A) 
1
H-MRS spectra were quantified and average lactate levels in the 
hippocampus at 6 and 12 months of age were expressed as a ratio to 
total NAA for control mice and APP/PS1 mice. (B) Quantification of 
average NAA levels in the frontal cortex expressed as a ratio to total 
creatine for control mice and APP/PS1 mice. Data are shown as mean 
+ SEM, n = 16 and 11, respectively, for control and APP/PS1 mice.  
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To rule out the possibility that the anesthetic isoflurane might influence brain metabolism 
during MRS analysis, in vivo microdialysis was performed in awake, freely moving mice 
to assess lactate levels in the hippocampal ISF (Figure 8). A one-way ANOVA followed 
by a Tukey’s post-hoc test revealed a significant age-dependent rise in lactate levels in 
APP/PS1 mice from 3 to 18 months of age (F(2,84) = 20.53, p < 0.001). Furthermore, 
hippocampal ISF lactate levels were significantly elevated in APP/PS1 mice at 12 months 
of age compared with control mice as determined by a two-way ANOVA (age × 
genotype) followed by a Bonferroni’s post-hoc test (F(1,75) = 5.870, p < 0.05). These 
observations reveal an age-dependent elevation in lactate levels within the cortex and 
hippocampal ISF of APP/PS1 mice compared with control mice.  
 
Figure 8. Interstitial lactate levels in the hippocampus are elevated 
in older APP/PS1 mice.  
Hippocampal ISF lactate levels in APP/PS1 mice are significantly 
elevated at 12 and 18 months of age compared with 3-month-old mice 
(left). A significant difference in hippocampal ISF lactate levels 
between control and APP/PS1 mice was detected at 12 months of age 
(right). *p < 0.05, **p < 0.01, ***p < 0.001. Data are shown as mean 
+ SEM. 
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3.2 Age-dependent changes in expression of lactate 
metabolism and transporting proteins in the frontal 
cortex and hippocampus of APP/PS1 mice 
To explore the mechanism by which lactate levels can change in the brain with age, I 
next examined the expression of proteins responsible for lactate metabolism and transport 
(Figure 9). Protein extracts from the frontal cortex of control and APP/PS1 mice 
euthanized at 6 and 12 months of age were resolved by SDS-PAGE and then 
immunoblotted using the antibodies indicated (Figure 10). The band density was 
quantified using -actin as a loading control and measurements were expressed as a ratio 
of density relative to control mice at 6 months of age (Figure 11). A two-way ANOVA 
(age × genotype) with a Bonferroni correction for multiple comparisons ( = 0.00625) 
revealed a significant age-dependent decline for proteins involved in lactate metabolism, 
including the following: PDK1 (F(1,12) = 39.677, p <0.001), LDHA (F(1,12) = 24.008, p 
< 0.001), and PKM1 (F(1,12) = 22.118, p < 0.001). An age-dependent decline was 
observed in several markers of aerobic glycolysis markers, including PDH-p/PDH 
(F(1,12) = 9.006, p = 0.011), LDHB (F(1,12) = 4.720, p = 0.050), and PKM2 (F(1,12) = 
7.168, p = 0.020), yet these did not reach the threshold set by the Bonferroni correction 
( = 0.00625). In contrast, expression of the lactate transporters was elevated with age: 
MCT2 (F(1,12) = 5.590, p = 0.036) and MCT4 (F(1,12) = 38.685, p < 0.001). A 
significant effect of genotype was found for PDK1 (F(1,12) = 9.718, p = 0.009), LDHB 
(F(1,12) = 7.960, p = 0.015), PKM1 (F(1,12) = 5.083, p = 0.044), and MCT4 (F(1,12) = 
6.237, p = 0.028). In addition, a significant interaction between age and genotype was 
found for PDK1 (F(1,12) = 13.417, p = 0.003) and PKM1 (F(1,12) = 5.181, p = 0.042).  
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Figure 9. Proposed metabolic pathway of lactate metabolism and 
transport in the brain.  
Glucose is broken down via glycolysis into phosphoenol pyruvate 
(PEP). PEP is then converted to pyruvate via pyruvate kinase M2 
(PKM2) or pyruvate kinase M1 (PKM1). Pyruvate can be metabolized 
to acetyl-CoA and used as a substrate for oxidative phosphorylation in 
the mitochondria, or converted to lactate as a by-product of aerobic 
glycolysis. Pyruvate dehydrogenase kinase 1 (PDK1) phosphorylates 
and inhibits the pyruvate dehydrogenase complex (PDH), which is 
responsible for converting pyruvate to acetyl-CoA. Lactate 
dehydrogenase A (LDHA) converts pyruvate to lactate primarily in 
astrocytes, while lactate dehydrogenase B (LDHB) catalyzes the 
reverse reaction of lactate to pyruvate mainly within neurons. 
Monocarboxylate transporter 4 (MCT4) and monocarboxylate 
transporter 2 (MCT2) are involved in shuttling lactate between 
astrocytes and neurons, respectively. 
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Figure 10. Age-dependent decline in expression of aerobic 
glycolysis proteins in the frontal cortex.  
Western blot analysis of mouse frontal cortex extracts from 6-month-
old and 12-month-old control mice and APP/PS1 mice using indicated 
antibodies as markers of aerobic glycolysis and lactate metabolism. 
The upper -Actin panel was used as a loading control for all 
indicated proteins above this panel whereas the lower -Actin panel 
was used as loading control for MCT2 and MCT4 protein levels. n = 4 
for each set of control mice and APP/PS1 mice at 6 and 12 months of 
age.  
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Figure 11. Age-dependent decline in expression of aerobic 
glycolysis proteins in the frontal cortex: Band densitometry 
analysis. 
Quantification of band densitometry for western blots of extracts from 
the frontal cortex of 6-month-old and 12-month-old control mice and 
APP/PS1 mice probed with the indicated antibodies. Relative band 
density was calculated relative to -actin. Data are shown as mean ± 
SEM, *p < 0.05, **p < 0.01, ***p < 0.001, n = 4 for each set of 
control mice and APP/PS1 mice at 6 and 12 months old.  
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Western blot analysis was also performed using extracts from the hippocampus of control 
and APP/PS1 mice euthanized at 6 and 12 months of age (Figure 12). Band densitometry 
measurements of proteins involved in lactate metabolism and transport were measured 
relative to -actin and a two-way ANOVA (age × genotype) with a Bonferroni correction 
for multiple comparisons ( = 0.00625) (Figure 13). This analysis revealed a significant 
age-dependent decline in markers of lactate metabolism, including the following: PDH-
p/PDH (F(1,19) = 23.106, p < 0.001), LDHA (F(1,19) = 28.244, p < 0.001), and PKM1 
(F(1,19) = 20.912, p < 0.001). Interestingly, in contrast to the measurements in the frontal 
cortex, there was an age-dependent increase in expression of certain lactate metabolism 
enzymes in the hippocampus including LDHB (F(1,19) = 19.496, p < 0.001) and PKM2 
(F(1,19) = 13.746, p = 0.002). In contrast to expression patterns in the cortex, a decrease 
in the lactate transport protein MCT4 (F(1,19) = 17.068, p < 0.001) was found in the 
hippocampus of both control and APP/PS1 mice with age. These data indicated that there 
is an age-dependent change in proteins involved in lactate metabolism and transport in 
the hippocampus that is distinct from that of the frontal cortex.  
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Figure 12. Differential expression of aerobic glycolysis proteins in 
the hippocampus with age. 
Western blot analysis of mouse hippocampal extracts from 6-month-
old and 12-month-old control mice and APP/PS1 mice probed with 
the indicated antibodies. n = 6 for each set of control mice and 
APP/PS1 mice at 6 and 12 months old.  
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Figure 13. Differential expression of aerobic glycolysis proteins in 
the hippocampus with age: Band densitometry analysis. 
Quantification of band densitometry for western blots of extracts from 
the hippocampus of 6-month-old and 12-month-old control mice and 
APP/PS1 mice probed with the indicated antibodies. Relative band 
density was calculated relative to -actin. Data are shown as mean ± 
SEM, *p < 0.05, **p < 0.01, ***p < 0.001, n = 6 for each set of 
control mice and APP/PS1 mice at 6 and 12 months old.  
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3.3 Correlation analysis of aerobic glycolysis enzyme 
expression in the frontal cortex and amyloid- dynamics 
Considering that a tight spatial correlation exists between A deposition and areas of 
high aerobic glycolysis in both the resting normal brain, it has been suggested that 
aerobic glycolysis may contribute to A processing262. In order to determine if aerobic 
glycolysis influences the production of A or if the deposition of A influences the 
expression of aerobic glycolysis enzymes, soluble and insoluble fractions of A were 
extracted from the frontal cortex of APP/PS1 mice at 12 months of age. The levels of 
unique A species, A(1-40) and A(1-42), were quantified by ELISA selective for A 
peptides with C-termini ending at residue 40 or 42, respectively. The average amount of 
A in each brain extract was calculated as a ratio to total protein and a two-way ANOVA 
was performed (fraction × A species). This analysis revealed a significant interaction 
between the type of fraction and A species suggesting that the burden of amyloid in the 
frontal cortex exists predominantly as insoluble A(1-42) (F(1,20) = 22.00, p < 0.001) 
(Figure 14). A multiple linear regression was then performed for relative band density of 
aerobic glycolysis enzymes and amount of A(1-40) or A(1-42) in either soluble or 
insoluble fractions (Figure 15). This analysis revealed no correlation between levels of 
soluble A(1-40) and A(1-42) with expression of aerobic glycolysis proteins: LDHA/LDHB 
(R
2
 = 0.418, p = 0.125), PDK1 (R
2
 = 0.269, p = 0.513), PDH-p/PDH (R
2
 = 0.352, p = 
0.220), and PKM2/PKM1 (R
2
 = 0.512, p = 0.055). The same analysis was performed for 
relative band density with insoluble A species and revealed no significant correlation 
with expression of aerobic glycolysis enzymes: LDHA/LDHB (R
2
 = 0.779, p = 0.075), 
PDK1 (R
2
 = 0.765, p = 0.564), PDH-p/PDH (R
2
 = 0.755, p = 0.896), or PKM/PKM1 (R
2
 
= 0.808, p = 0.419). These data suggested that expression of aerobic glycolysis enzymes 
likely has no influence on the tendency of A peptides to form insoluble species.  
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Figure 14. Soluble and insoluble A(1-40) and A(1-42) in the frontal 
cortex of APP/PS1 mice at 12 months old.  
Levels of A(1-40) and A(1-42) were quantified with ELISA using 
extracts from the frontal cortex of APP/PS1 mice at 12 months old in 
both soluble and insoluble fractions. Amount of A was expressed as 
a ratio to the total amount of protein as measured by Lowry assay. 
Data are shown as individual animals with mean as horizontal line, 
***p < 0.001, n = 6 mice.  
 
 
 
69 
 
 
 
 
70 
 
 
 
 
 
Figure 15. Deposition of A in APP/PS1 mice does not correlate 
with expression of aerobic glycolysis enzymes. 
Levels of A(1-40) and A(1-42) in both soluble (left) and insoluble 
(right) cortical extracts from APP/PS1 mice at 12 months old were 
correlated with expression of aerobic glycolysis enzymes: the ratio of 
LDHA/LDHAB, PDK1, the ratio of phosphorylated-PDH/PDH, and 
the ratio of PKM2/PKM1. n = 6 mice. No significant associations 
were detected. 
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3.4 Determining the cell-specific localization of aerobic 
glycolysis enzyme expression in control and APP/PS1 
mice 
To identify which cell types are expressing the enzymes responsible for aerobic 
glycolysis, frozen brain sections from control and APP/PS1 mice at 12 months of age 
were immunostained using antibodies specific for PDK1 and LDHA and co-stained with 
glial fibrillary acidic protein (GFAP) antibodies for reactive astrocytes and Class III -
Tubulin (TUJ1) for neurons. The sections were also stained with Thioflavin S (ThioS), 
which stains amyloid plaques. Within the frontal cortex of control mice, PDK1 and 
LDHA were exclusively expressed in the soma of TUJ1+ neurons (Figure 16). Within the 
frontal cortex of APP/PS1 mice, the expression of PDK1 and LDHA were observed 
primarily in the soma of TUJ1+ neurons and also in GFAP+ reactive astrocytes 
surrounding amyloid plaques. The same staining pattern was observed within the dentate 
gyrus of the hippocampus: PDK1 and LDHA expression was limited to the soma of 
TUJ1+ neurons in control mice and expression also observed in GFAP+ reactive 
astrocytes surrounding amyloid plaques in APP/PS1 mice (Figure 17). These 
observations indicate that PDK1 and LDHA are expressed primarily in the cell bodies of 
neurons, suggesting that this cell type is also capable of producing lactate through aerobic 
glycolysis. 
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Figure 16. PDK1 and LDHA are expressed in neurons of the 
frontal cortex of control and APP/PS1 mice and astrocytes co-
localized to A plaques of APP/PS1 mice. 
Fluorescence micrographs of the frontal cortex in control mice (top) 
and APP/PS1 mice (bottom) at 12 months old. Thioflavin S was used 
to visualize A plaque deposits (blue), while immunofluorescence 
was used to colocalize expression of PDK1 (red) and LDHA (red) 
with markers for astrocytes (GFAP +, green) and neurons (TUJ1 +, 
green). Merged images indicate that PDK1 and LDHA are primarily 
expressed in the soma of neurons in control mice and also in reactive 
astrocytes surrounding A plaques of APP/PS1 mice (bottom).  White 
arrows indicate co-localized expression of PDK1 and LDHA in 
cortical GFAP + cells in APP/PS1 mice. Scale bar, 100 m.  
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Figure 17. PDK1 and LDHA are expressed in both neurons and 
astrocytes co-localized to A plaques in the dentate gyrus of the 
hippocampus.  
Fluorescence micrographs of the dentate gyrus of the hippocampus in 
control mice (top) and APP/PS1 mice (bottom) at 12 months old. 
Thioflavin S was used to visualize A plaque deposits (blue), while 
immunofluorescence was used to colocalize expression of PDK1 (red) 
and LDHA (red) with markers for astrocytes (GFAP +, green) and 
neurons (TUJ1 +, green). Merged images indicate that PDK1 and 
LDHA are primarily expressed in the soma of neurons in control mice 
and also in reactive astrocytes surrounding A plaques of APP/PS1 
mice (bottom).  White arrows indicate co-localized expression of 
PDK1 and LDHA in cortical GFAP + cells in APP/PS1 mice. Scale 
bar, 100 m.  
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3.5 Determining the age of onset for visual-spatial memory 
deficit in APP/PS1 mice 
The MWM was used as a test of visual-spatial learning and memory at 12 months of age. 
Control mice and APP/PS1 mice were evaluated on their ability to learn the location of a 
hidden platform in the North-West quadrant of the water tank over the course of 4 
training days with 4 trials per day (Figure 18A). The latency time to find the platform 
was measured as an average of the 4 trials for each mouse and a two-way ANOVA with 
repeated measures (training day × genotype) was performed. This analysis revealed a 
significant effect of training day on the ability of mice to find the platform (F(3,72) = 
20.08, p < 0.001), but there was no significant effect with genotype (F(3,72) = 2.709, p = 
0.1128), or the interaction between training day and genotype (F(3,72) = 0.114, p = 
0.952). This analysis revealed that there is no difference between control mice and 
APP/PS1 mice in their ability to learn the location of the hidden platform during training. 
On the fifth day of testing, the hidden platform was removed and a probe trial was 
performed in which mice were allowed to swim for 60 seconds. The swim path of each 
mouse was used to compile a heat map representation of swimming behavior of each 
group of control and APP/PS1 mice during the probe trial (Figure 18B). The total 
distance covered during the probe trial was measured in order to determine if genotype 
had an effect on the physical ability of mice to swim in the tank of water (Figure 18C). A 
Welch’s t-test revealed no significant effect on total distance covered (t(21) = 1.516, p = 
1.445). The ability of mice to remember the location of the platform was assessed as the 
percent time spent in the correct quadrant (Figure 18D). A Welch’s t-test revealed a 
significant effect between genotypes (t(21) = 2.688, p = 0.007), which indicated that 
APP/PS1 mice have worse memory performance than control mice at 12 months of age. 
After the probe trial, a flag trial was performed to assess the ability of mice to use a 
visual cue to find the platform. Mice were allowed to swim in the tank for 90 seconds and 
the latency to find the flag-marked platform was recorded (Figure 18E). A Welch’s t-test 
revealed no significant effect between genotypes (t(22) = 1.301, p = 0.207), which 
indicated that both control mice and APP/PS1 mice were able to use the flag as a visual 
cue to determine the location of the hidden platform.  
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Figure 18. APP/PS1 mice have impaired visual-spatial memory at 
12 months of age.  
Memory performance in control mice and APP/PS1 mice at 12 months 
of age was assessed using the Morris water maze. (A) Mice were 
trained for 4 consecutive days to find the location of a hidden platform 
in the NW quadrant and the latency to escape was recorded. On day 5 
a probe trial was performed in which the platform was removed and 
mice were allowed to swim for 60 seconds (B-E). (B) The swim path 
for each group of mice was recorded and compiled into heat map 
representations. Measurements were taken for the total distance 
traveled (C) and the percentage of time spent in the correct quadrant 
(D). Immediately after the probe trial, a flag trial was performed to 
assess the ability of mice to use visual cues to find the platform. The 
platform was placed back in to the tank in the opposite quadrant and 
the latency to find the flag was recorded (E). Data shown are mean ± 
SEM, **p < 0.01, n = 12 and 11 for control and APP/PS1 mice, 
respectively.  
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3.6 Correlation analysis of aerobic glycolysis enzyme 
expression and memory performance in APP/PS1 mice 
at 12 months of age 
To determine whether aerobic glycolysis in the frontal cortex affects memory, the 
expression of aerobic glycolysis enzymes in the frontal cortex was compared with 
individual performances in the MWM at 12 months of age (Figure 19). A one-way 
ANCOVA was conducted on the linear regression of relative band density and percent 
time spent in the correct quadrant, controlling for genotype. This analysis revealed that 
genotype was a significant covariate for the enzymes involved in lactate production: 
LDHA (F(1,9) = 12.467, p = 0.008), PDH-p/PDH (F(1,9) = 5.588, p = 0.046), and 
PKM2/PKM1 (F(1,9) = 7.119, p = 0.028). This suggests that higher expression of these 
proteins correlates with better memory performance in control mice and worse 
performance in APP/PS1 mice. Genotype was not a significant covariate for the linear 
regression of LDHB expression on memory performance (F(1,9) = 2.161, p = 0.180). 
These data suggest that metabolism toward lactate production in the frontal cortex may 
be beneficial for memory processes in control mice and may in fact be detrimental to 
APP/PS1 mice. 
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Figure 19. Inverse relationship between expression of aerobic 
glycolysis enzymes in the frontal cortex and memory performance 
in APP/PS1 mice. 
Memory performance in the Morris water maze, as measured by 
percent time spent in the correct quadrant during the probe trial, was 
correlated with the expression of aerobic glycolysis enzymes in the 
frontal cortex of both control mice and APP/PS1 mice at 12 months of 
age. Higher expression of enzymes involved in lactate production, 
including LDHA, the ratio of PKM2/PKM1, and the ratio of 
phosphorylated-PDH/PDH, correlated with better memory 
performance in control mice, but not for APP/PS1 mice. Higher 
expression of LDHB, the enzyme that catalyzes the reverse reaction of 
LDHA, correlated with decreased memory performance for control 
mice, but an increase in memory performance for APP/PS1 mice. *p < 
0.05, **p < 0.01, n = 6 for each group of control and APP/PS1 mice. 
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A similar analysis examining the relationship between expression of aerobic glycolysis 
enzymes and memory was performed on extracts from the hippocampus (Figure 20). A 
one-way ANCOVA was conducted on the linear regression of relative band density and 
percent time spent in the correct quadrant, controlling for genotype. This analysis 
revealed that genotype was not a significant covariate for any of the markers of lactate 
metabolism: LDHA (R
2
 = 0.374, p = 0.073), LDHB (R
2
 = 0.148, p = 0.738), PDH-p/PDH 
(R
2
 = 0.141, p = 0.416), and PKM2/PKM1 (R
2
 = 0.168, p = 0.737). Altogether, these data 
indicate that aerobic glycolysis in the frontal cortex, and the concomitant production of 
lactate, may play a key role in memory processes. In contrast, the role of lactate 
metabolism in the hippocampus is less clearly defined. 
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Figure 20. Correlation analysis between expression of aerobic 
glycolysis enzymes in the hippocampus and memory performance 
in APP/PS1 mice. 
Memory performance in the Morris water maze, as measured by 
percent time spent in the correct quadrant during the probe trial, was 
correlated with the expression of aerobic glycolysis enzymes in the 
hippocampus of both control mice and APP/PS1 mice at 12 months 
old. n = 6 for each group of control mice and APP/PS1 mice. No 
significant interactions were detected. 
 
 
82 
 
3.7 Examining the effect of chronic oral administration of 
dichloroacetate on memory at 12 months of age 
Dichloroacetate (DCA) is a chemical inhibitor of PDK and is used in the treatment of 
congenital lactic acidosis
492
. DCA-mediated inhibition of PDK results in increased PDH 
activity and more glycolytic flux through the mitochondria with a concomitant decrease 
in lactate production
239
. Animal and clinical experiments indicate that a single oral dose 
of DCA has excellent bioavailability and can induce a lactate-lowering effect within 30 
minutes of administration
492
. In order to determine if DCA caused an effect on the 
memory performance, mice were exposed to 200 mg/kg of DCA in the drinking water 
from the time of weaning to 12 months of age when they were memory tested with the 
MWM. During the training phase of the MWM, mice were tasked with finding the 
location of a hidden platform in one of the quadrants of the tank. Mice were given 4 trials 
a day over 4 consecutive training days and the average time required to find the platform 
for each day was recorded (Figure 21A). A two-factor repeated measures ANOVA 
(genotype x treatment) was performed and revealed no significant interaction between 
genotype, treatment, and training day (F(3,123) = 0.106, p = 0.370). This indicated that 
the DCA in the drinking water did not have a preferential effect on one genotype over 
another in their ability to learn the location of the platform over the course of four 
training days. There was no effect from the interaction between treatment and training 
day (F(3,123) = 0.038, p = 0.999), indicating that DCA had no effect on mice of either 
genotype to learn the location of the platform. There was also no effect between genotype 
and training day (F(3,123) = 1.046, p = 0.375), indicating that control mice did not learn 
the location of the platform any faster than APP/PS1 mice. This analysis did reveal a 
significant effect from training day (F(3,123) = 35.743, p < 0.001), demonstrating that all 
mice from both genotypes and treatments found the platform faster over the course of 
four training days. In addition, there was a significant effect from genotype (F(1,41) = 
8.258, p = 0.006), suggesting that APP/PS1 mice took longer to find the platform on 
average for each training day regardless of DCA treatment. This indicated that the 
APP/PS1 mice have an impaired ability to learn the location of the platform at 12 months 
of age.  
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During the probe trial, the platform was removed from the tank and the mice were given 
60 seconds to swim and attempt to find the platform. The swimming path of the animals 
was recorded along with the time spent in the correct quadrant and the total distance 
covered during the swim. In order to visualize the memory performance of each group of 
mice, a heat map analysis was constructed that compiles the swimming path of each 
mouse into a collective representation of areas covered by the swimming group (Figure 
21B). The percentage of time spent in the correct quadrant was recorded during the probe 
trial as a measure of memory performance (Figure 21C). A two-way ANOVA (genotype 
× treatment) revealed a significant effect of genotype on memory performance (F(1,37) = 
10.63, p = 0.002), while there was no effect from DCA treatment (F(1,37) = 0.103, p = 
0.751) or interaction between genotype and treatment (F(1,37) = 0.028, p = 0.867). This 
indicated that chronic DCA treatment had no effect on memory performance for either 
genotype. The total distance covered during the probe trial was measured to evaluate the 
physical ability of mice to swim in the MWM (Figure 21D) and a two-way ANOVA 
(genotype × treatment) was performed. This analysis revealed no significant difference 
between genotypes (F(1,37) = 1.330, p = 0.256) or DCA treatment (F(1,37) = 0.085, p = 
0.772). These results suggest that the chronic treatment of DCA in the drinking water at 
200 mg/kg had no effect on the memory performance of either control or APP/PS1 mice 
at 12 months of age. Further, the only variable contributing to a difference in memory at 
this age was genotype of the animals. 
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Figure 21. Chronic exposure to dichloroacetate does not affect 
memory performance at 12 months of age.  
Memory performance of 12-month-old control mice and APP/PS1 
mice provided either normal water or DCA-water (200 mg/kg) was 
assessed by the Morris water maze. (A) Mice were trained for 4 
consecutive days (4 trials per day) to find the location of a hidden 
platform in the NW quadrant and the latency to escape was recorded. 
On day 5 a probe trial was performed in which the platform was 
removed and mice were allowed to swim for 60 seconds (B-D). (B) 
The swim path for each group of mice was recorded and compiled into 
heat map representations. Measurements were taken for the percentage 
of time spent in the correct quadrant (C) and the total distance traveled 
(D). The dashed horizontal line at 25% represents the amount of time 
spent in the correct quadrant by random chance. Data shown are mean 
± SEM, **p < 0.01, n = 12 and 11 for control and APP/PS1 mice 
provided normal water, respectively, and n = 10 and 9 for control and 
APP/PS1 mice provided DCA water, respectively. 
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3.8 Determining the effect of chronic oral dichloroacetate 
administration on PDH phosphorylation in the brain 
Although short-term oral administration of DCA has been shown to diminish cortical 
lactate levels
493
, the effect of chronic oral DCA administration on PDH phosphorylation 
and metabolism in the brain has never been examined.  The expression of aerobic 
glycolysis enzymes was examined at 12 months of age by western blot analysis in the 
frontal cortex of control mice provided either normal water or DCA-water (Figure 22). 
Band densitometry analysis was then performed (Figure 23) and a Welch’s t-test 
(treatment) revealed no significant effect on the ratio of phosphorylated-PDH to total 
PDH (t(12) = 0.204, p = 0.842), or the protein expression of PDK1 (t(12) = 1.042), p = 
0.327), LDHA (t(12) = 1.480, p = 0.167), LDHB (t(12) = 1.020, p = 0.3348, PKM2 (t(12) 
= 2.081, p = 0.060), or PKM1 (t(12) = 0.211, p = 0.837). These observations collectively 
suggest that chronic exposure to 200 mg/kg of DCA in the drinking water had no effect 
on the phosphorylation level of PDH or the expression of lactate metabolism enzymes at 
12 months of age.  
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Figure 22. Chronic exposure to dichloroacetate in the drinking 
water does not affect phosphorylation levels of PDH or expression 
of aerobic glycolysis enzymes in the frontal cortex of control mice.  
Western blot analysis of extracts from the frontal cortex of 12 month 
old control mice drinking either normal water or DCA water (200 
mg/kg) using indicated antibodies as markers of aerobic glycolysis 
and lactate metabolism. n = 6 and 8, respectively, for control mice 
with normal water and DCA water.  
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Figure 23. Chronic exposure to dichloroacetate in the drinking 
water does not affect phosphorylation levels of PDH or expression 
of aerobic glycolysis enzymes in the frontal cortex of control mice: 
Band densitometry analysis.  
Quantification of band densitometry for western blots of extracts from 
the frontal cortex of 12 month old control mice drinking either normal 
water or DCA water (200 mg/kg) using indicated antibodies as 
markers of aerobic glycolysis and lactate metabolism. Relative band 
density was calculated relative to -actin. Data are shown as mean ± 
SEM, n = 6 and 8, respectively, for control mice with normal water 
and DCA water.  
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3.9 Determining the effect of acute dichloroacetate injection 
on PDH phosphorylation in the brain 
Due to the inability of chronic oral administration of DCA to inhibit PDH 
phosphorylation, alternative strategies were considered to deliver chemical inhibitors. I 
decided to perform an acute injection of both Isosafrol and DCA. Isosafrol is a specific 
inhibitor of LDHA that has been shown to cross the blood-brain barrier and prevent 
chemically induced seizures in mice
491
. To determine if acute exposure to DCA had an 
effect on brain metabolism, the expression of aerobic glycolysis enzymes was examined 
at 17 - 18 months of age by western blot analysis in the frontal cortex of control mice 
injected with either saline or DCA (200 mg/kg) 30 minutes before euthanization (Figure 
24A). Band densitometry analysis was then performed and expressed as standardized 
ratio to saline-injected mice relative to -actin (Figure 24B). A Welch’s t-test revealed a 
significant effect on the ratio of phosphorylated-PDH to total PDH at Serine-232 (t(10) = 
9.083, p < 0.001) and Serine-293 (t(10) = 16.261, p < 0.001) in DCA-injected mice 
compared to saline-injected mice. This analysis also revealed a significant effect of 
treatment on PDK1 levels (t(10) = 2.837), p = 0.018). These data indicated that 
intraperitoneal injection of DCA at 200mg/kg inhibited phosphorylation of PDH in the 
frontal cortex. In addition, extracts from the hippocampus of mice injected 
intraperitoneally with either vehicle or Isosafrol were tested for LDHA or LDHB activity 
with a fluorescence-based enzyme activity assay (Figure 24C). A decrease in LDHA 
activity was observed in the hippocampus of mice injected with Isosafrol (14.31 ± 1.340 
Units/mg) as compared to mice injected with vehicle (21.23 ± 4.712 Units/mg). A 
Welch’s t-test revealed that this difference was not significant (p = 0.09). Injection of 
Isosafrol caused no difference in LDHB activity (p = 0.405). These findings demonstrate 
that both DCA and Isosafrol affect their protein targets in the brains of mice within 30 
minutes of injection.  
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Figure 24. Acute exposure to dichloroacetate decreases 
phosphorylation of PDH and Isosafrol may alter enzyme activity in 
the frontal cortex.  
(A) Western blot analysis of frontal cortex extracts from 18-month-old 
control mice euthanized 30 minutes after intraperitoneal injection with 
either saline or DCA (200 mg/kg). Levels of phosphorylated-PDH at 
Serine-232 or Serine-293, total PDH, and PDK1 were measured using 
indicated antibodies. (B) Quantification of band densitometry for western 
blots of extracts. Relative band density was calculated relative to -actin.  
n = 6 for each set of saline- and DCA-injected mice. (C) Isosafrol 
decreases LDHA, but not LDHB activity in the frontal cortex. Mice 
injected intraperitoneally with either vehicle or Isosafrol (300 mg/kg). 
After 30 minutes mice were sacrificed, perfused with PBS and brains were 
snap frozen. Hippocampal extracts were analyzed for LDHA and LDHB 
activity. n = 1 mouse with 6 technical repeats. Data are shown as mean ± 
SEM, *p < 0.05, ***p < 0.001. 
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3.10 Examining the effect of acute Isosafrol and 
dichloroacetate injection on memory performance  
A single cohort of control mice and APP/PS1 mice were assessed using the MWM over 
the course of 12 to 18 months of age
 
in four consecutive training and probe trial 
experiments. The location of the platform was moved after each exposure so the mice had 
to re-learn the location at each training session. All mice were injected with the treatment 
on the day of the probe trial, 30 minutes before entering the pool. The treatments for each 
probe trial were as follows: (1) the vehicle of Isosafrol (1% carboxymethylcellulose) with 
platform location South-East, (2) Isosafrol (300 mg/kg) with platform location North-
West, (3) DCA (200 mg/kg) with platform location North-East, and (4) the vehicle of 
DCA (saline) with platform location South-West. During the training phase, the mice 
were given 4 trials a day over 4 consecutive days to find the location of the hidden 
platform and the average latency time for each day was recorded (Figure 25). A one-way 
ANOVA with repeated measures (genotype x training day) revealed a significant delay in 
the latency time for APP/PS1 mice to find the platform for the first three training sessions 
compared to control mice: Vehicle (F(1,23) = 12.920, p = 0.002), Isosafrol (F(1,22) = 
21.100, p < 0.001), and DCA (F(1,21) = 5.631, p = 0.0273). However, there was no 
significant difference in latency times between control and APP/PS1 mice in the fourth 
training session: Saline (F(1,16) = 2.185, p = 0.159). This analysis indicated that the 
APP/PS1 mice were slower at learning to find the platform than the control mice during 
the first three training periods, yet by the fourth training session they performed equally 
to control mice. These data suggest that APP/PS1 mice at an age of up to 18 months are 
capable of learning the location of the platform just as well as control mice following 
repeated training.  
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Figure 25. Overview of training program in the Morris water 
maze for mice treated with Isosafrol and dichloroacetate.  
The effect of metabolic inhibitors on memory performance in control 
mice and APP/PS1 mice starting at 12 months of age was repeatedly 
tested using the Morris water maze. Mice were given four training 
trials a day to find the location of a hidden platform in one quadrant of 
the water tank (position indicated on bottom left of each training 
phase). On the fifth day, the platform was removed from the tank and 
a probe trial was performed 30 minutes after intraperitoneal injection 
of the indicated treatment (indicated by syringe). Mice were given a 
two week recovery period between training phases and the location of 
the platform changed for each treatment. Data shown are mean ± 
SEM, asterisks indicate a significant difference between genotype for 
a particular training phase as determined by a two-way ANOVA with 
repeated measures, *p < 0.05, **p < 0.01, ***p < 0.001, n = 17 and 8, 
respectively, for control mice and APP/PS1 mice for vehicle phase, n 
= 16 and 8, respectively, for control mice and APP/PS1 mice for 
Isosafrol phase, n = 15 and 8, respectively, for control mice and 
APP/PS1 mice for DCA phase, and n = 13 and 5, respectively, for 
control mice and APP/PS1 mice for saline phase. 
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The memory performance of each mouse on the probe trial was then compared over the 
course of treatments to determine if there was an observable effect from acute exposure 
to Isosafrol or DCA. The ability of mice to remember the location of the platform was 
measured as the percent time spent in the correct quadrant (Figure 26A). A two-way 
ANOVA analysis (genotype × treatment) of the time spent in the correct quadrant 
revealed a significant effect associated with genotype (F(1,81) = 4.280, p = 0.042), and 
treatment (F(3,81) = 5.651, p = 0.001), as well as the interaction between genotype and 
treatment (F(3,81) = 3.453, p = 0.021). In order to compare the memory of control mice 
over the course of different treatments, a Tukey’s post-hoc test was performed and 
revealed no significant difference between vehicle and Isosafrol treatment (p = 0.236), 
but there was a significant difference between vehicle and DCA treatment (p < 0.001), as 
well as the difference between DCA and saline treatment (p = 0.004). This analysis 
revealed no significant difference in memory for control mice between vehicle and saline 
treatments (p = 0.999), which indicated that these mice are just as capable of 
remembering the location of the platform at an older age than when they started the first 
training session. Interestingly, the APP/PS1 mice exhibited better memory (43.9% ± 
5.4%) than the control mice (37.8% ± 2.0%) with the DCA treatment, although this 
difference was not significant (p = 0.698). This analysis also revealed that memory 
performance in APP/PS1 mice were unaffected by acute exposure to metabolic inhibitors 
of aerobic glycolysis. The total distance covered during the probe trial was measured in 
order to determine if genotype or treatment had an effect on the physical ability of mice 
to swim in the tank of water (Figure 26B). A two-way ANOVA (genotype × treatment) 
revealed no significant effect of genotype (F(1,81) = 0.004, p = 0.952) or treatment 
(F(3,81) = 1.606, p = 0.195), or the interaction between genotype and treatment (F(3,81) 
= 2.213, p = 0.093) on swimming distance. Thus, neither the genotype nor chemical 
treatment had any effect on locomotor activity in mice. Altogether, these data collected 
from the MWM suggested that acute exposure to chemical inhibitors of aerobic 
glycolysis had a significant effect on the memory performance of control mice, yet had 
no effect on APP/PS1 mice. Further, acute exposure to DCA appeared to exert a more 
pronounced effect on memory processes than Isosafrol in control mice.  
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Figure 26. Acute exposure to dichloroacetate impairs memory 
performance in control mice.  
The Morris water maze was used to evaluate memory performance, as 
measured during a 60 second probe trial by the percent time spent in the 
quadrant that contained the hidden platform during training (A). Mice 
were exposed to the probe trial 30 minutes after intraperitoneal injection 
of the indicated treatment. Horizontal dotted line at 25% represents the 
percent of time spent in the correct quadrant by random chance. Control 
mice injected with DCA (200 mg/kg) performed significantly worse 
than when injected with vehicle or saline. (B) Total distance covered 
during the probe trial was used as a measure of locomotor ability. Data 
shown are mean ± SEM, asterisks indicate a significant difference 
between treatments as determined by a two-way ANOVA followed by 
Tukey’s post-hoc test, **p < 0.01, ***p < 0.001, n = 17 and 8, 
respectively, for control mice and APP/PS1 mice for vehicle phase, n = 
16 and 8, respectively, for control mice and APP/PS1 mice for Isosafrol 
phase, n = 15 and 8, respectively, for control mice and APP/PS1 mice 
for DCA phase, and n = 13 and 5, respectively, for control mice and 
APP/PS1 mice for saline phase. 
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3.11 Replicating the effect of acute dichloroacetate injection 
on memory performance in control mice 
In the initial study, we attempted to determine the effect of the aerobic glycolysis 
inhibitors Isosafrol and DCA on memory performance using a single group of mice with 
repeated memory testing under different treatment conditions. This experimental design 
introduces the confounding factor of repeated testing, which could influence the outcome 
of successive memory tests. Previous studies have shown that repeated memory testing 
influence the successive behavior outcome on the MWM
494
. Thus, it was important to test 
the effect of aerobic glycolysis inhibitors on mice that had no previous exposure to any 
agent. Considering that DCA had a more pronounced effect on memory performance in 
the MWM than Isosafrol (Figure 26), DCA was selected as a single experimental 
treatment with saline as a negative control.  
A new group of 20 control mice aged 9-months was randomly divided into saline and 
DCA treatment groups. The mice were given 2 weeks to acclimatize to their environment 
before beginning memory testing as described above with the platform located in the 
south-west quadrant. The latency to find the location of the platform during the training 
phase was recorded and a two-way ANOVA with repeated measures (training day × 
treatment) was performed (Figure 27A). This analysis revealed no significant effect on 
memory by DCA treatment (F(1,17) = 0.525, p = 0.478), or the interaction between 
treatment and training day (F(3,51) = 0.880, p = 0.458), which suggested that there was 
no difference in the ability of the two treatment groups to learn the location of the 
platform during training. On the fifth day of training, the platform was removed and the 
mice were injected intraperitoneally with either saline or DCA (200 mg/kg) 30 minutes 
before entering the pool for a probe trial. The swimming path of each mouse was 
recorded and a heat map representation of swimming behaviour was constructed for the 
two treatment groups (Figure 27B). The total distance covered during the probe trial was 
recorded (Figure 27C), and a Welch’s t-test revealed no significant effect of DCA 
treatment on total distance covered (t(18) = 0.805, p = 0.4331). Several different 
measures of memory performance were collected during the probe trial and a Welch’s t-
test with a Bonferroni correction for multiple comparisons ( < 0.01) was performed to 
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determine if there was a difference between the two treatment groups. There was no 
significant effect on the following measures of memory performance: (Figure 27D) the 
percent of time spent in the correct quadrant (t(18) = 0.516, p = 0.307), (Figure 27E) the 
number of entries to the platform location (t(18) = 0.766, p = 0.227), and (Figure 27F) the 
latency to the first entry to the platform location (t(18) = 1.322, p = 0.102). The latency to 
the first entry to the platform location during the probe trial was then compared to the 
average latency of each mouse to find the platform during the last day of training (Figure 
27G). This analysis was performed to determine if there was an effect of DCA exposure 
on the ability of mice to continue learning the location of the platform. On average, mice 
injected with saline before the probe trial crossed the boundary of the platform 4.88 ± 
1.09 seconds faster than the average of their previous attempts on the last day of training. 
In contrast, mice injected with DCA before the probe trial crossed the boundary of the 
platform on average 0.16 ± 1.96 seconds slower than the average of their previous 
attempts on the last day of training. A Welch’s t-test was performed on the difference in 
latency to the platform between the probe trial and the final day of training. This analysis 
revealed a potential effect (t(18) = 2.241, p = 0.021), yet it did not reach the threshold 
determined by the Bonferroni correction for multiple comparisons (a = 0.01). Although 
this result should be interpreted with caution, it suggested that DCA may have had an 
effect on the ability of mice to continue learning the location of the hidden platform. 
After the probe trial, the platform was placed back into the tank in the opposite quadrant 
and a red flag was attached to the platform as a visual cue of its location. Mice were 
allowed to swim in the tank for 90 seconds and the latency to find the flag-marked 
platform was recorded (Figure 27H). A Welch’s t-test revealed no significant effect (t(18) 
= 0.158, p = 0.438), which indicated that the ability of mice to use the flag as a visual cue 
to determine the location of the hidden platform was not compromised by DCA 
treatment. Altogether, these data suggested that acute exposure to DCA did not have an 
observable effect on the memory performance of mice, yet may impair the ability of mice 
to continue learning the location of the platform.  
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Figure 27. Acute exposure to dichloroacetate does not alter spatial 
memory performance in naïve mice. 
Naïve control mice were intraperitoneal injected with saline or DCA 
(200 mg/kg) at 9 months of age followed by memory assessment using 
the Morris water maze. (A) Mice were trained for 4 consecutive days (4 
trials per day) to find the location of a hidden platform in the SW 
quadrant and the latency to escape was recorded. On day 5 a probe trial 
was performed in which the platform was removed and mice were 
allowed to swim for 60 seconds (B-H). (B) The swim path for each 
group of mice was recorded and compiled into heat map 
representations. Measurements were taken for the total distance traveled 
(C), the percentage of time spent in the correct quadrant (D), the 
number of times crossing the boundary of the platform (E), the latency 
to the first platform entry (F), and the difference in latency between the 
average of training day 4 and the first platform entry during the probe 
trial (G). Immediately after the probe trial, a flag trial was performed to 
assess the ability of mice to use visual cues to find the platform. The 
platform was placed back in to the tank in the opposite quadrant and the 
latency to find the flag was recorded (H). Data shown are mean ± SEM, 
*p < 0.05, n = 9 and 10 for saline and DCA treatments, respectively.  
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3.12 Assessing the efficacy of acute dichloroacetate injection 
to reduce the conversion of pyruvate to lactate in the 
brain 
In order to determine if DCA injection had a metabolic effect on the brain, mice were 
scanned with a 3T-MRI after injection with hyperpolarized 
13
C-pyruvate (Figure 28A). 
Hyperpolarized 
13
C-pyruvate MRS measures the kinetic conversion of pyruvate to lactate 
in vivo. 
13
C-substrates can be highly magnetized (hyperpolarized) by dynamic nuclear 
polarization (DNP) in vitro and then used as injectable agents to probe in vivo 
metabolism
495
. This hyperpolarization technique provides signal-to-noise enhancements 
on the order of 10,000-fold over non-hyperpolarized 
13
C-imaging methods
495
.  In 
addition, the metabolic rate of conversion of pyruvate to lactate in the brain can be 
measured over the course of ~1 minute following injection of hyperpolarized 
13
C-
pyruvate. Mice were injected with 
13
C-pyruvate and its conversion to lactate was 
measured 30 minutes before and 30 minutes after injection of DCA (200 mg/kg) using an 
intravenous tail-vein catheter and the ratio of lactate-to-pyruvate peaks was quantified as 
an indication of pyruvate breakdown to lactate in the mouse brain (Figure 28B). This 
analysis revealed that the ratio of lactate-to-pyruvate peaks was reduced from 0.104 ± 
0.013 before DCA exposure to 0.056 ± 0.196 after DCA exposure (Figure 28C). 
However, due to variability in the conversion rate, a paired Welch’s t-test revealed that 
there was no significant difference between before and after DCA injections (t(4) = 
2.010, p = 0.069). These data indicate that DCA may reduce the conversion of pyruvate-
to-lactate in the brain, although there was variability in the degree to which DCA 
interfered with this conversion and additional mice need to be tested.   
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Figure 28. Hyperpolarized 
13
C-pyruvate magnetic resonance 
spectroscopy revealed a potential decrease in conversion of 
pyruvate to lactate in DCA-injected mice. 
Control mice at 9 months old were injected with a 0.3 mL bolus of 
hyperpolarized [1-
13
C]-pyruvate via tail vein catheter and the 
conversion of pyruvate-to-lactate was measured using free induction 
chemical shift imaging (FID-CSI). (A) 
1
H-MRI image of the brain in 
the coronal field overlaid with voxels of 13C-pyruvate spectra (yellow). 
(B) Conversion of pyruvate-to-lactate was measured as a ratio of the 
observed lactate peak to pyruvate peak. A pyruvate hydrate peak was 
also recorded. 30 minutes after the first 
13
C-pyruvate injection was 
measured (before), DCA (200 mg/kg) was injected using the tail vein 
catheter followed by a 30 minute recovery time, after which another 
injection of 
13
C-pyruvate was performed (after). The difference in the 
ratio of lactate-to-pyruvate peaks from before DCA injection (blue line) 
and after (red dashed line) was used to evaluate the effect of DCA on 
pyruvate conversion to lactate in the brain. (C) The ratio of lactate-to-
pyruvate peaks was measured following hyperpolarized 
13
C-pyruvate 
injection before and after DCA (200 mg/kg) exposure in control mice at 
9 months old. Data shown are mean ± SEM, p = 0.068, as calculated by 
paired Welch’s t-test, n = 5 mice. 
 
 
 
 
 
101 
 
3.13 Replicating the effect of acute dichloroacetate injection 
on PDH phosphorylation in the brain 
In order to evaluate the physiological effect of DCA injection on the brain of affected 
mice, mice were euthanized 30 minutes after injection of saline or DCA. Brain extracts 
from the frontal cortex were analyzed by western blotting using antibodies targeting key 
proteins involved in lactate metabolism and transport (Figure 29). The band density was 
quantified using -Actin as a loading control and a Welch’s t-test was performed with a 
Bonferroni correction for multiple comparisons ( = 0.00625) to determine the difference 
between saline- and DCA-injected mice (Figure 30). This analysis revealed a significant 
effect for the phosphorylation level of PDH (t(14) = 8.198, p < 0.001), which indicated 
that phosphorylation levels were reduced in DCA-injected mice. A significant effect was 
also revealed for the expression of PDK1 (t(14) = 3.362, p = 0.005), indicating an 
increase in expression in DCA-injected mice. There was no effect on the expression of 
the following enzymes: LDHA (t(14) = 1.647, p = 0.122), LDHB (t(14) = 0.966, p = 
0.350), PKM2 (t(14) = 1.680, p = 0.115), and PKM1 (t(14) = 0.321, p = 0.753).  This 
analysis also revealed a significant effect for the expression of the astrocyte-specific 
lactate transporting protein: MCT4 (t(14) = 3.468, p = 0.004). Mice injected with DCA 
had lower expression of MCT4 than saline-injected mice. There was no effect for 
expression of the neuron-specific MCT2 (t(14) = 0.636, p = 0.535). These observations 
indicated that the injection of DCA caused a significant decline in phosphorylation levels 
of PDH in the frontal cortex, and may also influence expression of PDK1 and the lactate 
transporter protein, MCT4.  
 
 
 
 
102 
 
 
 
Figure 29. Acute exposure to dichloroacetate reduces 
phosphorylation levels of PDH in the frontal cortex.  
Western blot analysis was performed on extracts from the frontal cortex 
of control mice intraperitoneal injected with either saline or DCA (200 
mg/kg) 30 minutes prior to euthanization. Indicated antibodies were 
used to detect proteins involved in aerobic glycolysis and lactate 
metabolism. n = 10 and 9, respectively, for saline- and DCA-injected 
mice.  
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Figure 30. Acute exposure to dichloroacetate reduces 
phosphorylation levels of PDH in the frontal cortex: Band 
densitometry analysis. 
Quantification of band densitometry for western blots of extracts from 
the frontal cortex of control mice injected with saline or DCA (200 
mg/kg) 30 minutes prior to euthanization. Indicated antibodies were 
used as markers of aerobic glycolysis and lactate metabolism. Relative 
band density was calculated relative to -actin. A significant decline in 
phosphorylation levels of PDH was measured following DCA injection. 
Data are shown as mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001, n 
= 10 and 9, respectively, for saline- and DCA-injected mice.  
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Extracts from the hippocampus were also analyzed by western blotting with antibodies 
for lactate metabolism and transport (Figure 31). Band densitometry analysis was 
performed using -actin as a loading control and a Welch’s t-test with a Bonferroni 
correction for multiple comparisons ( = 0.00625) was used to evaluate the effect of 
DCA injection (Figure 32). This analysis revealed a significant effect for the 
phosphorylation levels of PDH (t(14) = 4.493, p < 0.001), which indicated that 
phosphorylation of PDH was reduced in DCA-injected mice. This analysis also revealed 
a potential effect for the expression of LDHA (t(14) = 2.249, p = 0.041) and the neuron-
specific lactate transporter MCT2 (t(14) = 2.276, p = 0.039), yet these did not reach the 
threshold determined by the Bonferroni correction for multiple comparisons.  There were 
no other significant effects for any of the following lactate metabolism or transporting 
proteins: PDK1 (t(14) = 0.910, p = 0.379), LDHB (t(14) = 1.790, p = 0.095), PKM2 
(t(14) = 2.002, p = 0.065), PKM1 (t(14) = 0.524, p = 0.609), or the astrocyte-specific 
lactate transporter MCT4 (t(14) = 1.373, p = 0.191). Altogether, these analyses indicated 
that injection of DCA caused a reduction in phosphorylation of PDH in the frontal cortex 
and hippocampus of affected mice.  
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Figure 31. Acute exposure to dichloroacetate reduces 
phosphorylation levels of PDH in the hippocampus.  
Western blot analysis was performed on extracts from the hippocampus 
of control mice intraperitoneal injected with either saline or DCA (200 
mg/kg) 30 minutes prior to euthanization. Indicated antibodies were 
used to detect proteins involved in aerobic glycolysis and lactate 
metabolism. n = 10 and 9, respectively, for saline- and DCA-injected 
mice.  
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Figure 32. Acute exposure to dichloroacetate reduces 
phosphorylation levels of PDH in the hippocampus: Band 
densitometry analysis. 
Quantification of band densitometry for western blots of extracts from 
the hippocampus of control mice injected with saline or DCA (200 
mg/kg) 30 minutes prior to euthanization. Indicated antibodies were 
used as markers of aerobic glycolysis and lactate metabolism. Relative 
band density was calculated relative to -actin. A significant decline in 
phosphorylation levels of PDH was measured following DCA injection. 
Data are shown as mean + SEM, *p < 0.05, ***p < 0.001, n = 10 and 9, 
respectively, for saline- and DCA-injected mice.  
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3.14 Replicating the correlation analysis of PDH 
phosphorylation and memory performance in control 
mice 
Considering that there was an inverse correlation between expression of aerobic 
glycolysis enzymes in the frontal cortex and memory performance of control mice and 
APP/PS1 mice (Figure 19), the expression of these same proteins was compared to 
memory performance of saline-injected and DCA-injected mice. Band densitometry 
measurements in the frontal cortex were correlated to the individual measures of percent 
time spent in the correct quadrant during the MWM probe trial and a multiple linear 
regression model (relative band density x treatment) was performed (Figure 33). This 
analysis revealed a significant positive correlation for the level of phosphorylation of 
PDH in saline-injected mice (R
2
 = 0.7443, p = 0.006), which indicated that mice with 
higher phosphorylation levels performed better in the memory task. There was no 
correlation for phosphorylated-PDH in DCA-injected mice (R
2
 = 0.049, p = 0.600). A 
correlation was also detected in saline-injected mice for the expression of PKM1 (R
2
 = 
0.528, p = 0.041), indicating that mice with higher PKM1 performed better in memory 
testing. This analysis also revealed a significant correlation in DCA-injected mice for 
expression of the astrocyte-specific lactate transporter MCT4 (R
2
 = 0.746, p = 0.012), yet 
there was no correlation for MCT4 expression in saline-injected mice (R
2
 = 0.004, p = 
0.883). A one-way ANCOVA was conducted on the linear regression of relative band 
density and percent time spent in the correct quadrant, controlling for treatment. This 
analysis revealed that DCA treatment was not a significant covariate for any of the 
measured proteins. The memory performance of mice injected with saline or DCA was 
also correlated with the expression of lactate metabolism and transport enzymes in the 
hippocampus. The same analysis was performed on relative band densitometry and 
percent time spent in the correct quadrant for saline- and DCA-injected mice (Figure 34). 
A multiple linear regression model (relative band density x treatment) was then 
performed and revealed only one significant correlation for expression of PKM1 (R
2
 = 
0.625, p = 0.020) in saline-injected mice. This analysis suggested that mice with higher 
expression of PKM1 in the hippocampus performed worse on the memory task. 
Interestingly, this is opposite to the trend observed in the frontal cortex.  
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Figure 33. Memory performance correlates with phosphorylation of 
PDH in saline-injected mice and MCT4 expression in 
dichloroacetate-injected mice within the frontal cortex.  
Band densitometry measurements using indicated antibodies in the 
frontal cortex were compared with memory performance of control 
mice injected with saline (open diamond) and DCA (closed diamond) in 
the Morris water maze probe trial as a measure of percent time spent in 
the correct quadrant. Lines-of-best-fit are overlaid for saline-injected 
mice (solid) and DCA-injected mice (dashed). A significant positive 
correlation was observed for phosphorylated-PDH in saline-injected 
mice and also for MCT4 in DCA-injected mice. Horizontal dotted line 
at 25% represents the probability of spending the same amount of time 
in the correct quadrant by chance. n = 8 for each group of saline- and 
DCA-injected mice. 
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Figure 34. Correlations of memory performance with band 
densitometry in the hippocampus.  
Band densitometry measurements using indicated antibodies in the 
hippocampus were compared with memory performance of control 
mice injected with saline (open diamond) and DCA (closed diamond) in 
the Morris water maze probe trial as a measure of percent time spent in 
the correct quadrant. Lines-of-best-fit are overlaid for saline-injected 
mice (solid) and DCA-injected mice (dashed). Horizontal dotted line at 
25% represents the probability of spending the same amount of time in 
the correct quadrant by chance. n = 8 for each group of saline- and 
DCA-injected mice. 
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In order to further validate the correlation between phosphorylation of PDH in the frontal 
cortex and memory performance in saline-injected mice, the relative band density was 
correlated to several other measures of memory performance in the MWM (Figure 35). A 
multiple linear regression (relative band density x treatment) was performed on the 
number of platform entries with phosphorylation of PDH and revealed a significant 
positive correlation for saline-injected mice (R
2
 = 0.546, p = 0.036). This correlation was 
not observed for DCA-injected mice (R
2
 = 0.003, p = 0.900). This indicated that saline-
injected mice with higher phosphorylation of PDH crossed the platform boundary more 
often. A one-way ANCOVA was conducted on the linear regression of relative band 
density and number of platform entries, controlling for treatment. This analysis revealed 
that DCA treatment was not a significant covariate. The latency to the first entry of the 
platform boundary was then compared to phosphorylation of PDH using an exponential 
decay equation. This analysis revealed a strong correlation (R
2
 = 0.967), which suggested 
that saline-injected mice with higher phosphorylation of PDH were able to find the 
platform boundary faster. This correlation was not observed in DCA-injected mice (R
2
 = 
0.227). Finally, the difference in latency to the first platform entry between the probe trial 
and the final training day was correlated to phosphorylation of PDH using a multiple 
linear regression (relative band density x treatment). This analysis revealed no correlation 
for saline-injected mice (R
2
 = 0.324, p = 0.182) and no correlation for DCA-injected mice 
(R
2
 = 0.057, p = 0.570). Altogether, these data indicate that phosphorylation level of PDH 
in the frontal cortex was positively correlated to several measures of memory 
performance in the MWM.  
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Figure 35. Phosphorylation of PDH correlates with memory 
performance in control mice. 
Band densitometry measurements of phosphorylated PDH in the frontal 
cortex of control mice injected with either saline (open diamond) or 
DCA (closed diamond) were compared with memory performance in 
the Morris water maze probe trial for measures of (A) percent time 
spent in the correct quadrant, (B) number of platform entries, (C) 
latency to the first platform entry, and (D) the difference in time 
between average latency to find the platform on training day 4 and the 
latency to the first entry of the platform on the probe trial. Lines-of-
best-fit are overlaid for saline-injected mice (solid) and DCA-injected 
mice (dashed). Levels of phosphorylated PDH in control mice correlate 
with all measures of memory performance. n = 9 and 10 for saline and 
DCA treatments, respectively.  
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Chapter 4  
4 Discussion 
This work produced several novel observations, which gave rise to some conclusions that 
need to be addressed.  This chapter is split into two main categories of discussion: 
examining the temporal and spatial expression of aerobic glycolysis enzymes and lactate 
levels, and examining the relationship between cerebral aerobic glycolysis and memory 
performance. Each conclusion is addressed independently by interpreting the results and 
determining how they fit into the context of the greater research field.  
4.1 Examining the temporal and spatial expression of 
aerobic glycolysis enzymes and lactate levels 
4.1.1 Cerebral lactate levels decline with age 
Lactate production, consumption, and transport between astrocytes and neurons has been 
examined extensively
425
, yet little emphasis has been placed on examining changes in this 
metabolism with age. In vivo 
1
H-MRS is a powerful tool to detect metabolic signatures of 
different brain regions non-invasively over the course of normal aging. In this study, 
1
H-
MRS was used to measure lactate in the frontal cortex and hippocampus of control mice 
and APP/PS1 mice from 3 to 12 months of age. This analysis revealed a decline in lactate 
levels from 6 to 12 months of age in the frontal cortex of control mice (Figure 6), 
whereas the hippocampus revealed no significant decline in lactate levels between 6 and 
12 months of age (Figure 7). Consistent with this finding, a 
1
H-MRS longitudinal study 
of metabolites in healthy C57BL/6 mice between 3 and 24 months of age also revealed a 
progressive decline in lactate levels in the cortex but not hippocampus
496
. However, in 
contrast to our findings, a study using 
1
H-MRS reported that cortical lactate levels 
increased with age in a mitochondrial DNA mutator mouse model of advanced aging
330
. 
However, it is not clear if brain metabolism in mutant advanced-aging mice is an accurate 
reflection of brain metabolism that occurs during normal aging. Collectively, these 
observations suggest that a decline in glycolytic metabolism occurs with advanced age in 
the frontal cortex, whereas the hippocampus appears to be less affected.  
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Examination of lactate levels by 
1
H-MRS revealed a decline in the frontal cortex of aged 
control mice and no change in APP/PS1 mice. In addition, there was found to be no 
significant change with age or genotype in the hippocampus. Maintained lactate in the 
frontal cortex of aged APP/PS1 mice could be attributed to an increase in regional 
glucose uptake and glycolytic metabolism. An increase in glucose uptake in the cortex 
and hippocampus, as measured by 
18
F-FDG-PET, was reported in 12-month-old APP/PS1 
mice when compared to control animals
234
. The authors ruled out the contribution of 
cerebral blood flow by demonstrating that cerebral perfusion is reduced in APP/PS1 mice 
at this age. A similar study measured an increase in glucose utilization in the frontal 
cortex and hippocampus of APP/PS1 mice at 3.5 and 5 months of age, which correlated 
with improved performance in the MWM
497
. Increased glucose uptake has also been 
measured using 
18
F-FDG-PET in the cortex, hippocampus, and striatum of 7- and 9-
month old APP(Tg2576) mice
498
, in 12-month old PDAPPV717F mice
499,500
, in 16-month-old 
APP(Tg2576)/PS1M146L mice
501
and in 12-month-old 5xFAD mice
502
. However, a decline in 
glucose uptake has also been measured by 
18
F-FDG-PET in several animal models of 
AD, including 18-month-old 3xTG mice
503
. Hypometabolism is a common pathological 
feature of AD indicating a reduction in neuronal energy demand from loss of synaptic 
activity at later stages of the disease, yet inconsistencies in glucose uptake measurements 
using 
18
F-FDG-PET have been noted in AD animal models
504
. Different states of glucose 
uptake have been reported, even among the same transgenic strains, including APP(Tg2576) 
mice
498,505
 and 5xFAD mice
502,506
. However, in APP/PS1 mice, only increases in glucose 
uptake have been measured at 3.5, 5, and 12 months of age
234,497
.   
The majority of 
1
H-MRS studies of AD in rodent models do not report lactate 
measurements
507–509
. This is because the lactate peak is largely obscured by lipid signals 
with similar resonance frequencies and is difficult to measure
510,511
. In many cases, brain 
extracts from post-mortem tissue are analyzed instead of in vivo longitudinal 
measurements over the course of age. A 
1
H-MRS metabolomics study of extracted brain 
samples revealed an elevation in lactate levels in the hippocampus and frontal cortex of 
the TgCRND8 mice compared to controls at both 2-3 months of age and 12-13 months of 
age
512
. However, a recent high-throughput metabolomics study on 6-month-old APP/PS1 
mice using ultra performance liquid chromatography followed by gas chromatograph 
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mass spectrometry measured a decline in lactate, creatine, and NAA in the hippocampus 
and cortex compared to controls
513
. These observations highlight the need for consistency 
in measuring metabolites, including lactate, across animal models of AD to reliably 
evaluate the age-associated changes in brain metabolism. The concentration of 
metabolites detected by 
1
H-MRS can be quantified using an unsuppressed water signal 
from the same volume of interest as an internal reference
496
, yet in this study lactate was 
measured using NAA as a reference metabolite and has been previously reported
514
. 
Second only to the neurotransmitter glutamate, NAA is the most abundant metabolite in 
the brain and is mainly produced in neurons where it is shuttled to oligodendrotyes and is 
used for myelin production
515
. In order to determine if NAA levels change with age, 
NAA in the frontal cortex and hippocampus was quantified as a ratio to total creatine, 
which is frequently used as a reference metabolite in 
1
H-MRS studies
508,514
. We found 
that the ratio of NAA to creatine in both the frontal cortex and hippocampus did not 
change over the course of age in control mice or APP/PS1 mice (Figure 5 and Figure 6), 
which is consistent with the findings of other groups
496,507–509
. Therefore, NAA was a 
suitable metabolite to standardize lactate measurements over the course of aging.  
Although we did not detect a difference in hippocampal lactate levels using 
1
H-MRS 
analysis, we did observe an increase in hippocampal ISF lactate levels using 
microdialysis analysis in awake mice (Figure 8).  The discrepancies in measured lactate 
levels using the two methods may be due to the low level of sensitivity for the detection 
of lactate by 
1
H-MRS and the small size of the hippocampus.  In contrast, microdialysis 
has higher detection capabilities for lactate and was performed in awake mice.  The use 
of isoflurane anesthetic during 
1
H-MRS analysis may have influenced lactate levels in the 
hippocampus and obscured genotype-specific differences
516
.  These findings underscore 
the need to develop more sensitive and non-invasive techniques for measuring lactate 
levels in vivo. 
4.1.2 The expression of lactate metabolism and transport proteins 
declines with age in both control mice and APP/PS1 mice 
Maintained lactate levels in the APP/PS1 brain is indicative of higher levels of aerobic 
glycolysis and resembles the metabolic profile of the Warburg effect in cancer cells
243
. It 
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has been previously demonstrated that nerve cells selected for resistance to A toxicity 
up-regulate aerobic glycolysis as a protective mechanism
239
. Chemical or genetic 
disruption to key aerobic glycolysis enzymes PDK1 or LDHA resulted in re-sensitization 
of resistant lines, while over-expression of PDK1 or LDHA conferred resistance to A 
and other neurotoxins in naïve lines
240
. Elevated lactate in the frontal cortex and 
hippocampus of APP/PS1 mice at this age may indicate the up-regulation of glucose 
uptake or a metabolic shift from oxidative phosphorylation to aerobic glycolysis as a 
protective resistance to A toxicity. Nerve cell lines and primary cortical neurons that are 
resistant to Atoxicity had enhanced glucose consumption, increased activity of 
glycolytic enzymes including HK, glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), and PK, and increased flux through the PPP
260
. The A-induced changes to 
metabolism were found to be due to activation of the transcription factor HIF-1, which 
regulates cellular responses to low oxygen by up-regulating glycolytic metabolism, 
including enzymes PDK and LDHA. It was anticipated that western blot analysis of brain 
extracts would reveal an increase in aerobic glycolysis enzyme expression in APP/PS1 
mice compared to control mice at the same age. A two-way ANOVA identified an 
increase in expression of PDK1 at 6 months of age in the frontal cortex of APP/PS1 mice 
when compared to controls, indicating a possible up-regulation of aerobic glycolysis. 
However, these mice also had an increase in PKM1 (non-glycolytic isozyme) and no 
significant difference in expression of LDHA, PKM2, or the phosphorylation levels of 
PDH (Figure 11). These observations indicate a lack of collective up-regulation of 
enzymes involved in aerobic glycolysis in APP/PS1 mice. Interestingly, this analysis 
revealed a significant age-dependent decline in all proteins involved in glucose 
metabolism for both control and APP/PS1 mice from 6 to 12 months of age indicating a 
general decline in glucose metabolism with age. The cerebral CMRglc can be estimated 
using 
18
F-FDG PET imaging as a marker of glucose uptake and metabolism. Several 
studies have demonstrated that CMRglc declines significantly in older individuals in 
several brain regions  including the parietal, temporal, and frontal cortex, with the 
greatest reduction observed in the frontal cortex
517–520
. Furthermore, the metabolism of 
ketones, the brains’ major alternative fuel source, can be measured using 11C-AcAc PET 
as a marker of cerebral metabolic rate of acetoacetate (CMRa). In contrast to CMRglc, 
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the CMRa does not decline with age in the same brain regions
521
. It has been suggested 
that the decline in CMRglc may be due to brain atrophy and lower cortical thickness in 
cognitively normal individuals
519,522
, yet even after correction for partial volume effects, 
the same trends in CMRglc and CMRa were observed
523
. These studies suggest that a 
general decline in cerebral glucose uptake and metabolism occurs with age that may not 
be adequately compensated by the metabolism of ketones as an alternative fuel source, 
and is consistent with the age-dependent decline in expression of glycolytic enzymes 
observed in the frontal cortex of both control and APP/PS1 mice in this study.  
If we assume that glucose influx and metabolism is elevated in aged APP/PS1 mice, then 
an increase in lactate levels measured by 
1
H-MRS in the frontal cortex of 9-12-month-old 
APP/PS1 mice supports the hypothesis that aerobic glycolysis is up-regulated in neurons 
in order to promote A resistance. Yet, given a general decline in expression of 
glycolytic enzymes with age in both control and APP/PS1 mice, an alternate explanation 
may be that lactate efflux from the brain is diminished in APP/PS1 mice. Western blot 
analysis of brain extracts revealed an age-dependent increase in expression of the lactate 
transporters: MCT2 (neuronal-specific) and MCT4 (astrocyte-specific), in the frontal 
cortex of control mice, but not in APP/PS1 mice. At 12 months of age, the expression of 
MCT4 was found to be significantly elevated in the frontal cortex of control mice 
compared to APP/PS1 mice (Figure 11). This indicates that lactate transport may be 
compromised in APP/PS1 mice. During neuronal activation, a high energy demand is 
placed on astrocytes, which need to rapidly clear glutamate from the synapse and 
necessitating aerobic glycolysis for rapid energy production. As a result, the majority of 
lactate released from astrocytes is beyond the metabolic need of activated neurons, and 
thus is expelled from the brain
524
. There is substantial evidence that suggests astrocytes in 
the AD brain become “reactive”  or “activated” in response to inflammatory cytokines 
produced by microglia, including Interleukin-1 (IL-1) and IL-6
525,526
. Reactive astrocytes 
change their phenotype by interweaving themselves within amyloid plaques and up-
regulating expression of several marker proteins including GFAP and the S100 calcium-
binding protein B (S100)527,528. Yet it was recently discovered in APP/PS1 mice that 
reactive astrocytes do not migrate to plaques; instead they respond to plaque-induced 
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injury by changing phenotype and function
529
. Consequently, reactive astrocytes may 
provide less support to neurons because they are functionally different and can no longer 
fulfill their normal roles
530,531
. The data presented here suggest that a decline in glycolytic 
metabolism occurs in the cortex during normal aging while a concurrent increase in MCT 
expression arises as a possible compensatory response to maintain neuronal activity. In 
contrast, while a decline in glycolytic metabolism occurs in the APP/PS1 brain, no 
increase in MCT expression was detected. Thus, in the absence of enhanced lactate 
transport, lactate may accumulate either within reactive astrocytes or in the extracellular 
space.  
4.1.3 The interaction between the frontal cortex and the 
hippocampus 
In this study, both the frontal cortex and the hippocampus were examined in parallel as 
both these brain regions play key roles in memory. It is understood that the hippocampus 
and the frontal cortex both participate in memory consolidation and retrieval. Many of the 
pioneering studies investigating the involvement of specific brain regions in memory 
come from lesion studies in humans. The most famous of these cases being the patient 
H.M., who had most of his medial temporal lobe (which includes the hippocampus) 
bilaterally removed in an attempt to cure his epilepsy. Following surgery, H.M. 
developed severe anterograde amnesia, meaning he could not develop any new memories 
or consolidate newly acquired memories
532
. This evidence strongly implicated the 
hippocampus as the central mediator of episodic memory formation and has encouraged 
decades of research detailing the interaction of the hippocampus with other brain regions 
to support memory consolidation and retrieval
533
. In a similar study of brain lesions using 
paired-associate learning tasks, in which two lists of cue words are paired with different 
response words, patients with damage to the frontal cortex have difficulty with the 
second-list learning
534
. This suggests that the frontal cortex is responsible for control of 
memory associations as part of a memory-filtering mechanism. Several studies using 
animal models have shown that damage to the frontal cortex impairs the ability of the 
brain to alter behaviour in response to stimuli with different emotional significance
535
, 
learn the association of different perceptual stimuli with a food reward
536
, or to switch 
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between memory associations of odor or place stimuli
537
. These studies demonstrate that 
the frontal cortex is involved in memory consolidation and retrieval by associating 
incoming stimuli with a context of familiar experiences within related memories. The 
association between hippocampus and frontal cortex is best understood using the railroad 
metaphor in which the hippocampus is responsible for placing new railroad tracks 
(memory formation), while the frontal cortex is responsible for flexibly switching 
between tracks that have already been laid (memory association)
538,539
.   
The frontal cortex and hippocampus also have dramatically different metabolic profiles. 
The regional distribution of aerobic glycolysis can be measured using multimodal PET by 
comparing the cerebral metabolic rate for oxygen (CMRO2) using [
15
O-H2O] and 
CMRglc using [
18
F-FDG]. Aerobic glycolysis is estimated as the oxygen-glucose index 
(OGI), which compares the molar ratio of oxygen-to-glucose. An OGI of 6 indicates that 
all glucose is converted to carbon dioxide and water, and an OGI of less than 6 indicates 
that non-oxidative glucose metabolism (aerobic glycolysis) is occurring. In a recent study 
measuring the OGI from different brain regions of normal young adults at rest, aerobic 
glycolysis was found to be elevated in the DMN and in areas of the frontal and parietal 
cortex, while the cerebellum and the hippocampus had reduced aerobic glycolysis relative 
to the brain average
351
. In a follow up study, the authors demonstrated that the brain 
regions with high aerobic glycolysis in young healthy adults strongly correlated with the 
regions of high A deposition, as measured by PET using [11C-PiB] retention540. Yet, the 
age-associated metabolic changes in the frontal cortex and hippocampus of the AD brain 
have yet to be investigated. In this study, 
1
H-MRS analysis of the hippocampus revealed 
that lactate levels decline with age for both control mice and APP/PS1 mice, although not 
significantly, and there was no difference between control mice and APP/PS1 mice. In 
contrast, microdialysis sampling revealed elevated extracellular lactate in the 
hippocampus of aged APP/PS1 mice compared to controls. These data suggest that either 
aerobic glycolysis declines with age in the hippocampus, or lactate export increases, and 
is counter to the hypothesis that aerobic glycolysis is promoted in neurons in response to 
A deposition.  
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Western blot analysis of brain extracts from the hippocampus revealed a significant 
change in expression of aerobic glycolysis enzymes from 6 to 12 months in both control 
and APP/PS1 mice. A two-way ANOVA revealed a significant age-dependent decline in 
phosphorylated PDH levels, LHDA and PKM1 expression, along with an increase in 
expression of LDHB and PKM2 (Figure 13). The decline in phosphorylated PDH levels 
suggests an increase in PDH activity, while a decline in LDHA and an increase in LDHB 
suggest an increase in lactate oxidation with age. This analysis also revealed a significant 
interaction between age and genotype for PDK1 and LDHB, indicating that PDK1 
increases in control mice and decreases in APP/PS1 mice with age, while LDHB 
expression increases in control mice and does not change in APP/PS1 mice with age. 
These changes indicate a shift in metabolism toward oxidative phosphorylation in both 
control and APP/PS1 mice. The age-dependent decline in PKM2 and increase in PKM1 is 
unexpected since expression of PKM2 is closely associated with aerobic glycolysis in 
cancer cells
301,336,541,542
. Expression of PKM2 is induced by insulin signaling and mTOR 
activation
336
, as well as epidermal growth factor receptor (EGFR) activation
543
. Elevated 
PKM2 expression is also found in adult stem cells while PKM1 is expressed in 
differentiated cells of the brain
544,545
. Western blot expression analysis of the lactate 
transporters MCT2 (neuron-specific) and MCT4 (astrocyte-specific) in the hippocampus 
revealed an age-dependent decline in MCT4 for both control and APP/PS1 mice, but no 
difference in age or genotype for MCT2. These findings suggest that lactate efflux may 
decline within hippocampal astrocytes with a concomitant metabolic shift toward 
oxidative phosphorylation with age. Further investigation is warranted to discern how 
expression of aerobic glycolysis enzymes is regulated over the course of age and in 
different regions of the AD brain.  
The 
1
H-MRS analysis of cerebral lactate levels was complemented by microdialysis 
measurements of hippocampal ISF of control and APP/PS1 mice performed by Macauley 
and colleagues. This analysis revealed an age-dependent increase in ISF lactate for 
APP/PS1 mice from 3 to 18 months of age, as well as a significant increase at 12 months 
of age compared to control mice (Figure 8). These results appear counter to the unaltered 
hippocampal lactate levels in APP/PS1 mice as measured by 
1
H-MRS (Figure 7), as well 
as the age-dependent decline in expression of aerobic glycolysis enzymes and lactate 
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transporters in the hippocampus as measured by western blot analysis (Figure 13). One 
important distinction between these experiments is the physiological condition of the 
animal. During in vivo microdialysis sampling of ISF lactate, mice are awake and freely 
moving, while 
1
H-MRS measurements of lactate was performed under isoflurane 
anesthesia. Isoflurane has been shown to influence brain metabolism
516
. In addition, in 
vivo 
1
H-MRS has a low level of sensitivity for the detection of lactate, a limitation that is 
further compounded by the small size of the hippocampus.  
It is well established that aerobic glycolysis is upregulated during neuronal activation 
with a concomitant increase in ISF lactate concentration
346,349,361,363,377,546
. The age-
dependent increase in hippocampal ISF lactate concentrations in APP/PS1 mice may be 
indicative of an increased capacity to perform aerobic glycolysis during neuronal 
activation, which is supportive of my hypothesis that neurons upregulate aerobic 
glycolysis in response to A deposition. Moreover, MCT2 expression levels did not 
decline with age, suggesting that neuronal-generated lactate may be exported at a higher 
level in APP/PS1 mice relative to control aged mice.  These findings underscore the need 
to develop more sensitive and non-invasive techniques for measuring lactate levels in 
vivo.   
4.1.4 Aerobic glycolysis does not influence amyloid- processing  
The interplay between A production and glycolytic metabolism may occur through 
neuronal activity. Regional ISF measurements using in vivo microdialysis in APP(Tg2576) 
transgenic mice at 3 months of age demonstrated that neuronal activity increases ISF A 
and lactate concentrations
547
. The acute injection of glucose increases hippocampal ISF 
lactate concentration, A levels, and neuronal activity in both 3-month-old and 18-month 
old APP/PS1
93,483,548
. Interestingly, 
1
H-MRS measurements of lactate levels in the frontal 
cortex of 24-month-old PS2APP mice correlated significantly with higher plaque 
levels
514
. Neuronal activation may also promote A production through altered APP 
processing. In a study that used primary neuronal cultures harvested from APP(Tg2576) 
embryos, neuronal activation was found to promote A production while neuronal 
inhibition decreased A production by mediating the interaction between APP and 
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PS1
549
. In a similar study, activation of the NMDA receptor increased the production and 
secretion of A by shifting APP processing from the -secretase to the -secretase550. 
Perhaps the most compelling evidence linking neuronal activation to aerobic glycolysis 
and A production comes from PET imaging.  The  regional distribution of aerobic 
glycolysis in the resting human brain is predominantly in the DMN, a region that 
correlates spatially with deposition of A in the AD brain540. The authors suggest this 
may be due to a persistent level of neuronal activity in the DMN when individuals are not 
engaged in specific goal-directed behaviours
352,551,552
. The DMN is also active during 
light sleep
553,554
 and persists in deep sleep yet connectivity between frontal and posterior 
regions is lost during this time
555
.  ISF lactate and A levels exhibit diurnal fluctuation 
that are co-regulated and consistent with neuronal activity during sleep/wake cycles in 
both normal mice and APP/PS1 mice; A production increases during wakefulness and 
decreases with sleep
547,556–558
. Furthermore, A plaque formation can interrupt the normal 
sleep-wake cycle of 9-month-old APP/PS1 mice resulting in increased wakefulness and 
decreased sleep in a feed-forward loop that promotes A production557. This is consistent 
with diurnal fluctuations in CSF A levels and disrupted sleep-wake cycles observed in 
humans
556,559–561
. These observations indicate a possible feed-forward mechanism 
between regional neuronal activity and increases in glucose uptake, aerobic glycolysis, 
and A production, but it is currently unknown if aerobic glycolysis promotes A 
production or whether it is merely a consequence of neuronal activity. 
In order to measure A dynamics in the APP/PS1 mouse brain, an ELISA was performed 
on extracts from the frontal cortex of 12 month-old mice. The relative concentrations of 
A(1-40) and A(1-42) were measured as a ratio to total protein in either soluble or insoluble 
fractions from the frontal cortex of APP/PS1 mice. This analysis revealed that the 
majority of A in the brains of these mice was insoluble A(1-42)  (Figure 14). This finding 
is in agreement with the genetic elements of APP/PS1 mice: the Swedish mutation 
(K670N:M671L) in APP increases production and secretion of both A(1-40) and A(1-
42)
562–566
, while expression of PSEN1 lacking exon 9 (ΔE9) shifts the cleavage of APP to 
favor A(1-42) over A(1-40)
96
. The levels of A in APP/PS1 mice have been examined 
extensively and the majority of A burden in the brain is consistently the A(1-42) species 
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in insoluble (plaque) fractions
96,481,567–570
. Interestingly, the levels of soluble A(1-40) and 
A(1-42) in the cortex and hippocampus both correlate negatively with measures of spatial 
learning and memory in the MWM, but not insoluble A(1-40) and A(1-42)
570
. In order to 
test the hypothesis that aerobic glycolysis influences A production, the levels of soluble 
and insoluble A(1-40) and A(1-42) were correlated with the expression of aerobic 
glycolysis enzymes in the frontal cortex (Figure 15). There were significant relationships 
detected for levels of soluble A(1-40) and A(1-42) with PDK1, LDHA/LDHB, PDH-
p/PDH, or PKM2/PKM1. In addition, there were no significant interactions between 
levels of insoluble A(1-40) and A(1-42) with expression of any of the aerobic glycolysis 
enzymes investigated. This analysis indicates that aerobic glycolysis in the frontal cortex 
does not influence the production of A or the cleavage of APP to favor A(1-40) or A(1-
42). Further studies using neuronal cell culture models evaluating the effect of altered 
aerobic glycolysis enzyme expression on A dynamics would help elucidate the interplay 
between these two processes. 
4.1.5 Aerobic glycolysis enzymes are expressed primarily in 
neurons and reactive astrocytes surrounding plaques 
The cell-specific spatial expression of enzymes responsible for aerobic glycolysis and 
lactate production in the mouse brain has not previously been investigated. Several lines 
of evidence support distinct metabolic phenotypes between neurons (mainly oxidative) 
and astrocytes (mainly glycolytic)
378
. Measurements of cerebral lactate by 
1
H-MRS or 
western blot analysis of protein extracts do not distinguish between these two 
predominant cell types. To identify which cell types are expressing the enzymes 
responsible for aerobic glycolysis, frozen brain sections from control and APP/PS1 mice 
at 12 months of age were immunostained using antibodies specific for PDK1 and LDHA 
and co-stained with antibodies for astrocytes (GFAP) and neurons (TUJ1). Within the 
frontal cortex and hippocampus of control mice, PDK1 and LDHA expression was 
localized primarily to the soma of TUJ1+ neurons (Figure 16 and Figure 17). This 
observation demonstrates that neurons are capable of using aerobic glycolysis in both 
control mice and APP/PS1 mice. In support of this observation, LDHA has been found to 
be expressed in the cytosol of rat primary cortical neurons and astrocytes, while LDHB 
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expression was prevalent in synaptosomes
329
. In contrast, previous studies have found 
neurons exclusively immunoreactive with LDHB antibodies, while astrocytes were 
immunoreactive with both LDHA and LDHB antibodies in the human hippocampus and 
occipital cortex
328,409
. In a similar study of primary astrocyte and neuron cultures from 
chick embryos, astrocytes were found to predominantly express LDHA and neurons were 
found to predominantly express LDHB
571
. Interestingly, in this study PDK1 and LDHA 
were also expressed in GFAP+ reactive astrocytes surrounding amyloid plaques in the 
frontal cortex and hippocampus of APP/PS1 mice. It was surprising to find an absence of 
PDK1 or LDHA expression in astrocytes of control mice. The GFAP antibody used for 
this experiment may not have been sensitive enough to visualize astrocytes in control 
mice and future experiments should make use of an antibody that reliably stains native 
astrocytes. However, if PDK1 and LDHA were expressed in astrocytes of the control 
mouse brain then fluorescence signal would have labeled these cells red in the merged 
confocal image, and this was not detected. The expression of PDK1 and LDHA in 
reactive astrocytes, but not in native astrocytes, may indicate that these cells up-regulate 
aerobic glycolysis as a consequence of disease pathogenesis. A similar staining pattern 
has been characterized in TgCRND8 mice at 12 months of age showing co-
immunostaining of reactive astrocytes with PFKFB3 expression, a main regulator of 
glycolysis
572
. Up-regulation of aerobic glycolysis in reactive astrocytes may be 
responsible for the increase in lactate observed in the frontal cortex of APP/PS1 at 9 and 
12 months of age. Further investigation is warranted to test if reactive astrocytes display 
metabolic reprogramming toward aerobic glycolysis. Collectively these observations 
indicate that PDK1 and LDHA are expressed primarily in the cell bodies of neurons, yet 
both cell types may be capable of producing lactate through aerobic glycolysis.  
4.2 Examining the relationship between cerebral aerobic 
glycolysis and memory performance 
4.2.1 Expression of aerobic glycolysis enzymes in the frontal 
cortex correlates with memory performance 
Previous work has demonstrated that both the hippocampus and the frontal cortex are 
involved in spatial memory retrieval using the MWM
573–576
. More recently, it was 
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demonstrated that lesions to the frontal cortex impaired memory in a partial-cue 
environment, showing that an interaction between the frontal cortex and hippocampus 
was required for pattern completion during memory retrieval
577
. However, it has yet to be 
determined if aerobic glycolysis in the frontal cortex or hippocampus plays a role in 
spatial memory recall. In order to test the hypothesis that aerobic glycolysis contributes to 
memory processes, a correlation analysis was performed comparing expression of aerobic 
glycolysis proteins in extracts from the frontal cortex and hippocampus at 12 months of 
age (Figure 19 and Figure 20). A multiple linear regression model was then fit on the 
percentage of time spent in the correct quadrant during the probe trial. This analysis 
revealed a significant interaction with memory for enzymes involved in lactate 
production including LDHA, the ratio of phosphorylated PDH to total PDH, and the ratio 
of PKM2 to PKM1, suggesting that higher expression, or phosphorylation, of these 
proteins correlates with better memory performance in control mice and worse 
performance in APP/PS1 mice. These observations support the hypothesis that aerobic 
glycolysis contributes to memory processes in control mice, but not in APP/PS1 mice. It 
stands to reason that if neuronal activity is linked to a focal elevation of aerobic 
glycolysis and lactate efflux
578
, then a higher expression of aerobic glycolysis would 
enhance neuronal activation.  
It is currently unknown why higher aerobic glycolysis may be detrimental to memory in 
the AD brain. In the context of AD in humans, elevated lactate levels correlate negatively 
with memory performance. Increased lactate within the precuneus/posterior cingulate of 
individuals with MCI is associated with poorer memory performance
579
. AD patients also 
show a significant increase in CSF lactate levels compared with age-matched non-
demented individuals or patients with vascular dementia
580,581
. In addition, intravenous 
lactate infusion does not improve semantic memory in AD patients
582
. These findings 
suggest that perturbed lactate metabolism may be involved in the pathophysiological 
processes in AD. One possible explanation may be that enhanced aerobic glycolysis and 
neuronal activation promote A deposition leading to interference with synaptic 
transmission and memory processes
570
. However, the ELISA analysis of soluble and 
insoluble levels of A(1-40) and A(1-42) demonstrated no such relationship in the frontal 
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cortex (Figure 15). The same multiple linear regression analysis in the hippocampus 
revealed no significant interaction between relative band intensity and genotype on 
percent time spent in the correct quadrant for any of the markers of aerobic glycolysis 
(Figure 20). This finding suggests that aerobic glycolysis may play a role in memory 
processes in the frontal cortex but not the hippocampus.  
4.2.2 Chronic oral administration of dichloroacetate does not affect 
memory at 12 months of age 
The behaviour of APP/PS1 mice is well characterized but the age of cognitive decline 
varies between laboratories and husbandry conditions. In the MWM, impairment in 
spatial memory has been reported as early as 3.5 months of age
583
 and 6 months of age
584
, 
yet 8-14 months of age is the most commonly reported age for onset of spatial memory 
impairment in APP/PS1 mice when using the MWM
97,569,570,585,586
. In order to test the two 
central hypotheses, that neurons upregulate aerobic glycolysis to promote A resistance, 
and aerobic glycolysis contributes to memory processes, a chemical inhibitor of aerobic 
glycolysis, DCA, was orally administered to control and APP/PS1 mice at a dose of 200 
mg/kg per day via drinking water, beginning at the age of weaning. It was anticipated that 
APP/PS1 mice exposed to DCA would lose a protective resistance mechanism and 
succumb to neurodegeneration at an earlier age than APP/PS1 mice exposed to normal 
drinking water. Spatial learning and memory was assessed using the MWM at 12 months 
of age (Figure 18). The ability of mice to learn the location of the platform was measured 
as the change in latency time required to find the platform over the course of 4 training 
days. APP/PS1 mice showed a delay in finding the platform on each training day 
compared to control mice. This is in agreement with similar studies demonstrating a 
spatial learning impairment at this age
97,584
, yet disagrees with one report showing no 
difference between genotypes
585
. Interestingly, a study using the visual platform water 
maze demonstrated that APP/PS1 mice have a significant increase in thigmotaxis, or 
tendency to cling to or follow the wall instead of actively search for the platform, and 
also demonstrated more excessive floating in the pool than control mice
587
. This indicates 
that stress may be a confounding factor for spatial memory performance for these mice. 
In order to account for this possibility, mice that displayed excessive thigmotaxis or 
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floating in either genotype were eliminated from analysis in both the training phase and 
probe trials.  
On day 5 a probe trial was performed in which the platform was removed and mice were 
tested on their ability to remember the location of the platform, as measured by the 
percent time spent in the correct quadrant. A two-way ANOVA revealed that APP/PS1 
mice have a significant decrease in the percent time spent in the correct quadrant, 
regardless of DCA exposure. There was no effect from treatment or the interaction 
between genotype and treatment, suggesting that DCA had no effect on the ability of 
mice of either genotype to remember the location of the platform. This indicated that 
either chronic exposure to DCA had no physiological effect on the brain, or that aerobic 
glycolysis did not participate in A resistance and memory performance. As a measure of 
physical ability to perform the task, the total distance covered during the probe trial was 
measured and a two-factor ANOVA was performed. This analysis revealed no significant 
effect from genotype or treatment, or the interaction between genotype and treatment, 
indicating that all mice swam a comparable distance. This suggests that impairment in 
memory performance of APP/PS1 mice is reflective of impaired spatial memory and not 
altered physical ability. It also demonstrates that chronic oral exposure to DCA does not 
have a negative consequence to physical ability.  
4.2.3 Chronic oral administration of dichloroacetate does not have 
a physiological effect on the brain at 12 months of age 
The effect of DCA exposure has been well documented in humans due to its ability to 
reduce lactate levels in patients with congenital forms of MELAS (mitochondrial 
myopathy, encephalopathy, lactic acidosis, and stroke-like episodes)
588
 and preclinical 
evidence that it might be beneficial in cancer 
589
. Acute administration of DCA at 35-50 
mg/kg increases PDH activity by 3-6 fold and reduces lactate levels by more than 60% in 
muscle tissue
590,591
. It has been estimated that the maximal reduction in circulating lactate 
levels is achieved at an acute dose of DCA at 100 mg/kg, yet a dose-dependent reduction 
in lactate continues beyond 200 mg/kg
493
. In order to confirm the physiological effect of 
DCA, brain extracts were harvested at 12 months of age from the frontal cortex of control 
mice exposed to chronic DCA and compared to mice that were provided normal drinking 
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water. DCA is a specific inhibitor of PDK, the kinase that phosphorylates and inhibits the 
PDH complex
489,592
. It was expected that mice exposed to DCA would have a decline in 
PDH phosphorylation levels when compared to mice that were provided normal drinking 
water. However, this analysis revealed that there was no difference in PDH 
phosphorylation between these two groups (Figure 23). In addition, there was no 
difference in expression levels of any other marker of aerobic glycolysis between the two 
treatment groups. This indicates that chronic exposure to DCA at an oral dose of 
200mg/kg daily since the age of weaning does not have a physiological effect on the 
mouse at 12 months of age.  
Despite several studies demonstrating the effectiveness of acute DCA exposure activating 
PDH and lowering lactate levels, the physiological effect of chronic DCA exposure is 
less clear. In one study of four MELAS patients, chronic oral exposure to DCA at a daily 
dose of 25 mg/kg appeared to maintain lower serum lactate levels, yet there was no 
change in CSF lactate levels over a course of 5 years
593
. In a larger study of 30 MELAS 
patients given a chronic daily DCA dose of 25 mg/kg, there was no significant difference 
between DCA and placebo groups in 
1
H-MRS estimation of cerebral lactate, CSF lactate, 
or venous lactate, over the course of 24 months
594
. In addition, all 15 of the patients 
randomly assigned to DCA had to prematurely discontinue the study due to side effects 
from peripheral nerve toxicity. DCA is cleared more efficiently from plasma after an 
initial acute dose than after 6 months of 25 mg/kg daily exposure
595
. Moreover, older 
subjects aged 14 – 33.9 years were less efficient at clearing DCA from plasma than 
younger subjects aged 2.2 – 7.1 years after 6 months of 25 mg/kg daily exposure595. This 
finding has also been recapitulated in rats, demonstrating an age-associated effect on 
DCA plasma clearance after chronic exposure for 6 months at 25 mg/kg daily
596
. These 
studies demonstrate a lack of knowledge on the physiological effect between acute and 
chronic DCA exposure. In this study, one control mouse and 3 APP/PS1 mice were 
euthanized after approximately 5 months of 200 mg/kg daily oral DCA exposure due to 
tissue damage to the ends of their tails and hind feet. All other mice appeared to tolerate 
DCA well up to 12 months of age. During the probe trial of the MWM, there was no 
significant effect of DCA treatment on the total distance covered, suggesting that there 
was no physical impairment due to DCA exposure on the ability of these mice to swim. 
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In summary, these observations indicate that chronic oral administration of DCA at 200 
mg/kg daily for 12 months has no discernible effect on lactate levels or phosphorylation 
levels of PDH in the frontal cortex. This suggests that chronic oral DCA administration 
may be unsuitable for the long-term modulation of aerobic glycolysis in the brain.  
4.2.4 Acute inhibition of aerobic glycolysis impairs memory 
In order to further test the hypothesis that aerobic glycolysis contributes to memory 
processes, the chemicals DCA and Isosafrol were used to inhibit the activity of PDK and 
LDHA, respectively. Instead of a chronic exposure to these chemicals, an acute 
intraperitoneal injection was used to deliver the treatment 30 minutes before entering the 
MWM on the probe trial. The ability of these agents to target their intended protein in the 
CNS after a single intraperitoneal injection was confirmed by western blot and enzyme 
activity analysis (Figure 24). A single cohort of control mice and APP/PS1 mice starting 
at 12 months of age was selected for this experiment and all mice were injected with the 
same treatment at each of the probe trials (Figure 25). Mice were trained to learn the 
location of the platform over the course of 4 training days and the latency to find the 
platform was recorded for each training phase.  This analysis revealed a significant 
difference in latency time to find the platform between genotypes for the vehicle phase, 
Isosafrol phase, and the DCA phase, but not the final saline phase of training. This 
suggests that APP/PS1 mice may show an improvement in memory over the course of 
repeated memory testing. However, the pre-exposure to the test agents might also have 
had a differential effect on memory in the APP/PS1 mice. Future studies using naïve 
APP/PS1 mice would help resolve this issue.  
The difference between genotypes for latency to find the platform in the first three phases 
may be accounted by the tendency of APP/PS1 to display thigmotaxis and excessive 
floating as a stress response
587
. This behaviour was observed in some of the APP/PS1 
mice over the course of the experiment and these mice were removed from analysis if the 
behaviour persisted across consecutive training days (Table A2). However, these mice 
were allowed to swim in subsequent training phases and were included in analysis if they 
did not display excessive stress behaviour. Interestingly, there was no difference in 
latency to find the platform during training between control mice and APP/PS1 mice for 
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the final training phase indicating that these mice are capable of spatial learning at 18 
months of age given repeated testing. This analysis also showed no overt toxicity from 
acute injection of Isosafrol or DCA given that all mice were able to recover 2 weeks after 
chemical administration and perform just as well during the next training phase.  
At each individual phase of the experiment, the chemical treatment of vehicle, Isosafrol, 
DCA, or saline, was given to the mice 30 minutes before entering the probe trial. This 
time point was chosen due to previous reports showing a physiological effect on the brain 
at this time for both Isosafrol at 300 mg/kg
491
 and DCA at 200 mg/kg
493
. During each 
probe trial, the percent time spent in the correct quadrant was recorded as a measure of 
memory and the total distance covered was recorded as a measure of physical ability to 
swim in the water tank (Figure 26). A two-way ANOVA revealed a significant effect of 
genotype and treatment, as well as an interaction between genotype and treatment. When 
compared to the initial injection of the vehicle (1% Carboxymethylcellulose), Isosafrol 
had no effect on the ability of control mice or APP/PS1 mice to remember the location of 
the platform. In contrast, DCA administration had a significant effect on control mice, yet 
had no effect on APP/PS1 mice, when compared to either the first injection with vehicle 
or the last injection with saline. The same analysis was performed on the total distance 
travelled during the probe trial and this revealed no significant effect from genotype or 
treatment, suggesting that all mice were equally capable of physically performing the 
memory task. These observations suggest that DCA may influence memory for control 
mice and support the hypothesis that aerobic glycolysis contributes to memory processes. 
These results also complement the earlier correlation analysis, which demonstrated an 
inverse relationship between expression of aerobic glycolysis enzymes in the frontal 
cortex and memory performance in control mice and APP/PS1 mice. There appeared to 
be no effect from chemical administration in APP/PS1 mice, indicating that aerobic 
glycolysis may not contribute to memory recall in these mice. 
4.2.5 Acute injection of dichloroacetate has a physiological effect 
on the brain 
Considering that chronic exposure through drinking water did not exhibit a physiological 
response in the brains of affected mice at 12 months of age, it was important to determine 
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if acute injection of DCA had a measurable effect. Western blot analysis was performed 
on extracts from the frontal cortex of control mice euthanized after injection of either 
saline or DCA at 200 mg/kg (Figure 24A). This analysis revealed that mice injected with 
DCA had a significantly lower ratio of phosphorylated PDH to total PDH. This suggests 
that acute DCA exposure resulted in a physiological response in the brains of affected 
animals and is in agreement with other reports showing DCA causes a decline of 
phosphorylated PDH levels in mouse liver extracts
597
, and isolated mitochondria from the 
mouse brain
598
. Intraperitoneal injection of DCA has also been shown to increase PDH 
activity in the brain
599,600
, yet to the best of my knowledge this is the first report of DCA 
intraperitoneal injection demonstrating a reduction in phosphorylation levels of PDH in 
the brain. The relative band density of PDK1 was also measured to determine if there was 
any difference in the levels of the target of DCA. A significant decrease in PDK1 
expression was detected in animals injected with DCA compared to saline. It is unclear if 
a 30 minute exposure to DCA is long enough to induce changes in transcription and 
translation, but long-term exposure to DCA has been shown to reduce PDK4 expression 
through the Forkhead box protein O1 (FOXO1) transcription factor
601
. In addition to the 
direct chemical inhibition of PDK, DCA exposure may also promote a decline in PDK1 
expression further potentiating the decrease in PDH phosphorylation and promoting 
oxidative phosphorylation.  Altogether, these results demonstrate that an acute injection 
of DCA causes an observable reduction in phosphorylation levels of PDH in the frontal 
cortex of affected mice.  
4.2.6 The inhibition of memory performance from acute injection of 
dichloroacetate is not reproducible 
One of the main goals of scientific experimentation is to ensure that the outcomes are 
reproducible. In animal behaviour experiments, there may be several confounding 
variables that influence the outcome of a particular test. One possible confounding factor 
is repeated testing, in which a previous experience influences the outcome of subsequent 
tasks. Animals that have been exposed to a behavioural test often perform differently than 
naïve animals
494
, although the relative influence of repeated testing depends on the 
specific test being administered
602
, the strain of the animal
603
, and time interval between 
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behavioural tests
604
. One study using C57BL/6J and 129S2/Sv strains in the MWM 
reported that mice who had previously experienced the test did not perform any 
differently than naïve mice during training or during the probe trial
605
. Another study 
using C57BL/6J and NMRI strains showed that training at 2 months of age did not 
improve performance in the MWM at 10 months of age compared to naïve mice, and also 
did not affect from their performance when they were tested again at 18 months of age
606
. 
A similar study using C57BL/6J and NMRI strains showed that training at 2 months of 
age improved performance at 6 and 10 months of age in NMRI mice when compared to 
naïve mice, but this effect was not observed in C57BL/6J mice who showed no difference 
to naïve mice
603
. However, in the case of this study the time interval between training 
was approximately 2 weeks, and it is unclear if previous experiences changed the 
outcome of subsequent trials with a different chemical treatment. Another confounding 
variable that may have influenced the outcome of these tests is age. Control mice and 
APP/PS1 mice started the first training phase at approximately 12 months of age and 
finished the last probe trial at approximately 16 months of age. It is unclear if aging 
negatively affected mice at later experimental phases. In an attempt to address these 
confounding variables and determine if repeated trials or age had an influence on 
subsequent outcomes, a saline injection phase was performed as the final treatment 
(Figure 26). This analysis revealed no difference between either control mice or APP/PS1 
mice injected with saline at the very end of the study or vehicle at the very beginning of 
the study. Although these results need to be taken with caution, they suggest that these 
confounding variables did not impair the ability of these mice to perform during the final 
probe trial.  
In order to further test the hypothesis that aerobic glycolysis contributes to memory 
processes, a new experiment was conducted where each of the previous confounding 
variables was removed. DCA was selected as the treatment instead of Isosafrol because 
control mice showed a greater impairment in memory from DCA injection than Isosafrol 
treatment in the previous study. The latency time required to find the platform was 
recorded over the course of four training days and a one-way repeated measure ANOVA 
revealed no difference between mice assigned to saline or DCA treatments (Figure 27). 
This indicated that there was no inherent difference in the ability of mice from either 
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treatment group to learn the location of the hidden platform. Several measures of 
performance were recorded during the probe trial including the total distance traveled, the 
percent time spent in the correct quadrant, the number of platform entries, the latency to 
the first platform entry, and the difference in latency to the platform between the probe 
trial and the average of the final training day (Figure 27). Mice injected with DCA 
travelled the same total distance as mice injected with saline, suggesting that DCA had no 
effect on the ability of mice to swim in the tank. Mice injected with DCA spent the same 
percent of time in the correct quadrant as mice injected with saline, and crossed the 
boundary of the platform the same number of times. These measures suggest that there 
was no significant difference in memory performance between saline and DCA-injected 
mice at 9 months of age. The latency to the first platform entry was also recorded and 
there was no difference between DCA-injected mice and saline-injected mice. In contrast, 
the difference between the latency to find the platform boundary during the probe trial 
and the average latency to find the platform on training day 4 revealed that saline mice 
found the platform boundary faster than their previous average time (-4.88 ± 1.09 
seconds), while the DCA mice did not find the platform any faster than their previous 
average time (0.16 ± 1.96 seconds). There was a considerable difference between these 
two groups (p = 0.042), yet it did not reach the significance threshold set by the 
Bonferroni correction for multiple comparisons ( < 0.01). This finding should be 
interpreted with caution, but suggests that DCA may cause a delay in memory recall and 
could have had an effect on the ability of mice to continue to learn the location of 
platform. Future experiments should examine the effect of DCA injection before each 
training day in order to determine if DCA impairs learning ability in these mice. 
Moreover, the previous study was performed with mice at 12 months of age. The effect 
of DCA on mice at different ages should also be considered. 
Following the probe trial, a flag trial was performed where the platform was placed back 
into the tank in the opposite quadrant and a red flag was attached as a visual cue. The 
latency to find the platform during this trial found no difference between DCA-injected 
mice and saline-injected mice, suggesting that DCA did not interfere with the ability of 
mice to use visual cues to find the platform. Altogether, these data indicate that acute 
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exposure to DCA does not impair memory performance in naïve mice, which is counter 
to the previous study showing a significant decline in memory performance of DCA-
injected mice. However, there was indication that learning might be compromised by 
DCA exposure. Further studies using different ages of mice and repeated injection 
strategies will be required to formally determine the effect of DCA-mediated inhibition of 
aerobic glycolysis on learning and memory. 
4.2.7 Acute injection of dichloroacetate may reduce conversion of 
pyruvate to lactate in the brain 
Recent advances in MRI technology have enabled the monitoring of brain metabolism 
non-invasively with the use of hyperpolarized 
13
C-labelled metabolites coupled with 
MRS. Injection of hyperpolarized 
13
C-pyruvate generates pyruvate and lactate peaks that 
are linearly proportional to their concentration, and thus can be used to quantify the 
conversion of pyruvate-to-lactate in the brain
607
. Considering that acute exposure to DCA 
had no effect on memory performance of naïve mice, DCA was tested for a physiological 
response on the brain using hyperpolarized 
13
C-pyruvate MRS. The target of DCA is 
PDK, which phosphorylates and inhibits the PDH complex resulting in higher activity 
and a drop in brain lactate levels
600
. In order to measure the conversion of pyruvate to 
lactate in the brain, 9-month-old naïve mice (n = 5) were injected via tail vein with 
13
C-
pyruvate and the resulting peaks of pyruvate and lactate were measured 30 minutes 
before and 30 minutes after tail vein injection of  DCA (200 mg/kg). The whole brain 
was imaged by 
1
H-MRI and individual 
13
C-pyruvate spectra were overlaid to a coronal 
field of view (Figure 28). The average of all spectra for each individual mouse was 
calculated for both before and after DCA injection and the average of all mice in the 
experiment was then compiled. This analysis revealed a decline in the ratio of lactate-to-
pyruvate from before (0.10 ± 0.01) to after (0.06 ± 0.02) DCA injection (Figure 28). A 
paired Welch’s t-test revealed that this difference was not statistically significant (p = 
0.07), however, only five mice were analyzed and there was considerable variability in 
lactate levels detected using this scanning technique. Further 
13
C-pyruvate MRS 
experiments should be completed to improve the sample size and increase the power of 
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the analysis in order to conclusively determine that DCA causes a decline in brain lactate 
production.   
4.2.8 Acute injection of dichloroacetate causes a decline in 
phosphorylated PDH levels in the brain 
To determine if DCA injection in these mice caused a change in phosphorylation levels 
of PDH, mice were euthanized 30 minutes after intraperitoneal injection with either 
saline or DCA (200 mg/kg) and brain extracts from the frontal cortex and hippocampus 
were examined by western blotting (Figure 30 and Figure 32). This analysis revealed that 
DCA caused a significant reduction in levels of phosphorylated PDH to total PDH in both 
the frontal cortex and the hippocampus, indicating that DCA caused a physiological 
response in the affected animals. This analysis also revealed a significant increase in 
PDK1 expression and a significant decrease in MCT4 expression in the frontal cortex of 
DCA-injected mice.  There was no significant difference between saline- and DCA-
injected mice for any of the proteins investigated in the hippocampus. A decrease in 
expression of LDHA and MCT2 was noted but these differences did not pass the 
significance threshold as determined by the Bonferroni correction for multiple 
comparisons. Altogether, these results confirm the previous observations that DCA 
injection causes a decline in levels of phosphorylated PDH in the frontal cortex and 
hippocampus of affected mice.   
4.2.9 The correlation between the expression of aerobic glycolysis 
enzymes in the frontal cortex and memory performance is 
reproducible 
In order to further examine the relationship between aerobic glycolysis and memory, the 
percent time spent in the correct quadrant during the probe trial of the MWM was 
correlated to the band density from western blots of aerobic glycolysis and lactate 
transporter proteins in the frontal cortex and hippocampus of saline- and DCA-injected 
mice (Figure 33 and Figure 34). A multiple linear regression revealed that the ratio of 
phosphorylated PDH to total PDH in the frontal cortex positively correlated with memory 
performance for saline-injected mice. This suggests that mice with higher 
phosphorylation of PDH in the frontal cortex performed better on the memory task than 
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mice with lower phosphorylation of PDH. It is intriguing that DCA-injected mice had a 
significant reduction in levels of phosphorylated-PDH and yet this did not confer 
impairment in memory performance. This suggests that compensatory responses may 
have been activated to maintain energetic demand during memory testing despite the drop 
in PDH phosphorylation. A significant positive correlation was also observed between 
memory performance and the expression of the astrocyte-specific lactate transporter, 
MCT4, in the frontal cortex of DCA-injected mice. This indicates that mice with higher 
MCT4 expression performed better on the memory test than mice with lower expression. 
Previous reports have demonstrated that inhibition of MCT4 leads to amnesia, which can 
be rescued by lactate but not equicaloric glucose, yet the inhibition of MCT2 leads to 
amnesia that cannot be rescued by lactate or glucose
462
. Assuming that DCA caused a 
decline in lactate levels by inhibiting PDK and thus reducing phosphorylation of PDH, an 
increase in lactate transport may have arisen to maintain neuronal activity. The positive 
correlation between memory performance and levels of phosphorylated-PDH in the 
frontal cortex is consistent with previous observations in control mice (Figure 19). 
However, these mice also displayed a positive correlation for lactate-producing enzymes 
LDHA and PKM2/PKM1, suggesting a relationship between lactate production and 
improved memory. This collective trend is absent from saline-injected mice in this 
analysis, which showed no correlation for LDHA, LDHB, PKM2, or PKM1. In 
agreement with previous observations, there were no significant correlations between 
memory and expression of aerobic glycolysis proteins or lactate transporters in the 
hippocampus. These results indicate that aerobic glycolysis in the frontal cortex may play 
a more fundamental role than it does in the hippocampus.  
It is also possible that aerobic glycolysis does not contribute to memory processes. Mice 
injected with DCA did not exhibit impaired memory despite a decline in levels of 
phosphorylated-PDH in both the frontal cortex and hippocampus. In addition, memory 
performance did not correlate with expression of any marker of aerobic glycolysis other 
than phosphorylation of PDH. However, earlier results from the correlation analysis of 
control and APP/PS1 mice demonstrated a clear positive correlation between memory 
and expression of lactate producing enzymes whereas the opposite effect was observed 
for the lactate consuming enzyme (Figure 19). Furthermore, a significant decline in 
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memory performance was measured from DCA-injected control mice when compared to 
vehicle-injected and saline-injected control mice (Figure 26). These observations 
highlight the need to reproduce experiments and test the hypothesis under different 
conditions. In order to further examine the relationship between memory and aerobic 
glycolysis, each measure of memory performance from the MWM was correlated to 
levels of phosphorylated PDH in the frontal cortex of saline- and DCA-injected mice 
(Figure 35). As previously demonstrated, a multiple linear regression revealed a 
significant correlation between levels of phosphorylated PDH and percent time spent in 
the correct quadrant.  
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Chapter 5  
5 Conclusions 
There are two main conclusions that can be drawn from this work: (1) the deposition of 
A in the AD brain perturbs lactate metabolism as indicated by the maintained lactate 
levels with age in the frontal cortex of APP/PS1 mice, which interferes with memory 
processes normally beneficial to the healthy aging brain, and (2) aerobic glycolysis plays 
a role in spatial memory as demonstrated by the correlation analysis between protein 
expression and memory performance, yet is not explicitly required for proper memory 
function. There are several strengths and limitations to this study that are addressed in 
this chapter, as well as future directions for further addressing these emergent hypotheses.  
5.1 Thesis summary 
Alzheimer’s disease is a neurodegenerative disorder characterized by the accumulation of 
intracellular amyloid plaques and extracellular neurofibrillary tangles. The amyloid 
plaques are comprised of aggregated A peptides that cause mitochondrial dysfunction 
and neuronal death. Nerve cells can become resistant to A-toxicity by up-regulating 
aerobic glycolysis, a metabolic phenotype that predominantly uses glycolysis for energy 
production despite the availability of oxygen. Yet, it is currently unknown if neurons are 
capable of escaping A-mediated toxicity by up-regulating aerobic glycolysis in vivo, and 
whether aerobic glycolysis contributes to memory. The studies outlined in this 
dissertation tested the hypotheses that neurons upregulate aerobic glycolysis to promote 
A resistance, and that aerobic glycolysis contributes to memory processes. In vivo 1H-
MRS revealed an age-dependent decline in lactate levels within the frontal cortex of 
control mice, whereas lactate levels remained unaltered in APP/PS1 mice from 3 to 12 
months of age. In the hippocampus, lactate levels declined with age for both genotypes, 
but sampling of ISF found elevated levels of lactate in APP/PS1 mice. An age-dependent 
decline in levels of aerobic glycolysis enzymes in both control mice and APP/PS1 mice 
was detected along with a concomitant increase in lactate transporter expression in 
control mice. Immunofluorescence microscopy revealed the expression of aerobic 
142 
 
glycolysis enzymes PDK1 and LDHA primarily in neurons within the frontal cortex and 
hippocampus, and also in activated astrocytes in APP/PS1 mice. These findings suggest 
that aerobic glycolysis plays an important role in memory in control mice but may be 
detrimental in AD mice.  
In order to test the hypothesis that aerobic glycolysis contributes to memory processes, a 
single cohort of mice were injected with an acute dose of Isosafrol, an inhibitor of 
LDHA, and also DCA, an inhibitor of PDK, in consecutive independent trials 
immediately before entering the MWM. Control mice exposed to DCA performed worse 
in the memory task compared to vehicle or saline injections, while APP/PS1 mice were 
unaffected. A second experiment was performed to confirm these observations using two 
independent groups of randomly assigned naïve control mice. In this case, mice injected 
with DCA were found to have similar memory performance to mice injected with saline.  
In vivo hyperpolarized 
13
C-pyruvate MRS was used to validate the effectiveness of DCA 
by demonstrating a reduction in conversion of pyruvate to lactate in the brain. Western 
blots from extracts of the frontal cortex and hippocampus of DCA-injected mice revealed 
a significant decline in phosphorylation of PDH. In support of previous findings, 
phosphorylation of PDH correlated with better memory performance in saline-injected 
mice. These observations support the hypothesis that aerobic glycolysis contributes to 
memory, yet is likely not the only contributing factor. Together, this evidence indicates 
that production of lactate, via aerobic glycolysis, is beneficial for memory function 
during normal aging. A deposition may perturb lactate processing and contribute to 
cognitive decline in AD.  
5.2 Strengths and limitations of the study 
5.2.1 Disparity between human patients and the APP/PS1 mouse 
model of Alzheimer’s disease  
Transgenic mouse models of AD offer a unique opportunity to examine pathogenic 
mechanisms and test novel therapeutics. However, given the high failure rate of clinical 
trials, several questions have arisen about the validity of using laboratory animals to 
model a complex age-related neurodegenerative disease in humans
608,609
. All transgenic 
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mouse models of AD carry autosomal dominant mutations identified from early-onset 
variants of the disease in humans, yet this accounts for less than 1% of all AD cases, 
while the vast majority of AD cases are sporadic in nature and arise as a consequence of 
age and genetic or lifestyle risk factors
610
. This means that these animals are good models 
of a small subset of AD patients, but do not accurately represent the pathophysiological 
changes associated with sporadic AD in the general public. In addition, most transgenic 
mouse models only recapitulate amyloid accumulation, yet fail to develop other 
pathological hallmarks including neurofibrillary tangles and neuronal loss
611
. Transgenic 
mice that do carry mutations driving both amyloid plaques and neurofibrillary tangles 
develop neurodegeneration and early cognitive deficits in a supra-physiological 
manner
612
. These models are efficient for experimental purposes because of the rapid 
onset of pathology and early cognitive decline, yet the progression of pathophysiology in 
humans with sporadic AD occurs over the course of decades and this cannot be 
accurately recapitulated in experimental models. 
All of my experiments were performed using the APP/PS1 mouse model of AD. These 
mice carry the Swedish mutation (K670N:M671L) in the APP gene that results in 
increased production and secretion of the A peptide562–566, while expression of PSEN1 
lacking exon 9 (ΔE9) shifts the cleavage of APP to favor A(1-42) over A(1-40)
96
. I chose 
this model for several reasons: (1) the resistance mechanism in immortalized nerve 
cultures was identified in A toxicity independent of tau pathology260; (2) these mice 
develop cognitive impairment between 8 and 14 months of age
481
, which is suitable for 
the purposes of finishing experiments within a doctoral timeline; and (3) these mice do 
not develop neurodegeneration at the age of cognitive impairment
613
, suggesting that a 
resistance mechanism to A may exist in order to facilitate neuron survival despite the 
widespread accumulation of plaque at this age. Yet, if these mice do not experience 
neurodegeneration, then why do they develop cognitive impairment? It was recently 
discovered that APP/PS1 mice have impaired synaptic rewiring of cholinergic 
interneurons in the hippocampus that is required for fear-conditioned learning
614
. In 
addition, hippocampal pyramidal cells of APP/PS1 mice have early deficits in long-term 
potentiation (LTP) that are independent of altered dendritic spine morphology
615
. These 
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studies highlight a key disparity between these mice and human AD patients, where 
cognitive decline is highly correlated with neurofibrillary tangles and neuron loss
616–619
. 
The results of this dissertation suggest that memory deficit in APP/PS1 mice may also lie 
in altered lactate metabolism, although further experiments are needed to confirm this 
hypothesis. 
5.2.2 Protein expression may not reflect enzyme activity 
Western blot analysis of protein expression levels and phosphorylation of PDH may not 
accurately reflect enzyme activity or the direction of metabolic pathways. A recent 
1
H-
MRS study demonstrated that brain lactate levels increase with age and this is 
characterized by a shift in the ratio of LDH isozyme expression of high LDHA and low 
LDHB
330
. This change in the ratio of LDHA to LDHB has also been described in 
different tissues of the rat, including brain, in response to hypoxia
620
. However, 
considering that the equilibrium constant is the same for all isozymes, because it is the 
same reaction being catalyzed, it can be assumed that the LDH reaction is a near-
equilibrium reaction and steady state conditions apply. This means that the isozyme 
pattern cannot have an influence on the equilibrium lactate concentration
331
. If non-steady 
state conditions apply, such as a rapid glycolytic flux or lactate export from the cell, then 
the isozyme pattern may influence lactate concentration. In support of the expression 
analysis of LDH isozyme pattern, Ross and colleagues also performed LDH activity 
assays and demonstrated a significant increase in LDH activity in the direction of the 
reaction from pyruvate to lactate
330
. In this dissertation, the ratio of LDHA to LDHB was 
measured using western blot analysis from brain extracts, yet the activity of this reaction 
was not measured and it was assumed that a shift in the ratio of LDHA/LDHB would 
translate to a change in the direction of the pyruvate to lactate reaction.  
By the same measure, it was assumed that a change in the level of PDH phosphorylation 
was an indication of the activity of the enzyme, yet this is not always the case. Purified 
PDH from bovine kidney mitochondria could be inactivated in a dose-dependent manner 
by incubating the reaction mixture in ATP independent of PDH kinases or 
phosphatases
592
. The regulation of PDH by phosphorylation is also site-specific. In an 
elegant study by Korotchikina and Patel, the three phosphorylation sites of mammalian 
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PDH were mutated from Serine to Alanine either individually or in combination. The 
activity of these PDH mutants demonstrated little decline in activity for mutations in 2 of 
the 3 phosphorylation sites, yet a 50-70% decline in activity of the mutant at Serine-
293
621
. One study using human mitochondria from muscle found that the phosphorylation 
of PDH at two independent sites, Serine-293 and Serine-300, were negatively correlated 
with PDH activity using an exponential model (R
2
 = 0.43 and 0.46, respectively), yet this 
accounts for only 43% and 46% of the variation in PDH activity suggesting alternate 
regulatory mechanisms may be present
622
. Furthermore, elevated phosphorylation of 
PDH did not compromise the regulation of PDH activity during exercise. Dynamic 
changes to the concentrations of substrates (pyruvate, NAD
+
, CoA) or products (acetyl-
CoA, CO2, NADH) may also influence the activity of PDH independent of the PDH 
kinases or phosphatates
623
. Considering that the acute exposure to DCA reduced 
phosphorylation levels of PDH at both sites Serine-232 and Serine-293 in the brains of 
affected mice (Figure 24), it was assumed that PDH activity was increased. However, this 
was not measured and it is possible that the change in phosphorylation level was not 
reflective of activity. If phosphorylation does not accurately reflect PDH activity, it is 
possible that DCA failed to inhibit memory performance because PDH activity was 
maintained following DCA exposure. Future experiments should measure activity of 
PDH from these samples to confirm that DCA exposure affects the activity of the enzyme 
in vivo.  
Western blot analysis of protein expression and phosphorylation of PDH were correlated 
to memory performance in the MWM. Interestingly, the expression of lactate-producing 
enzymes in the frontal cortex correlated with better memory whereas expression of 
LDHB correlated with worse memory in control mice. In addition, saline-injected mice 
showed a positive correlation between phosphorylation of PDH in the frontal cortex and 
memory. Correlations of gene expression in the brain and behavioural changes have 
previously been described
624–627
, indicating a relevant relationship between expression of 
certain proteins in the brain and behavioural phenotype. It was assumed that the protein 
levels from brain extracts of euthanized mice were reflective of actual protein expression 
during the memory test. However, it is currently unknown how stable these expression 
patterns are during stressful conditions of memory testing or over the course of time. 
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Several different factors are known to influence gene expression of glycolytic enzymes, 
including physical exercise
628
, hypoxia
629
, glucose availability
630
, circadian rhythm
631
, 
and neuronal activation
632
. Protein phosphorylation is an especially labile regulatory 
mechanism that changes rapidly in response to cellular environment
633
. In terms of 
metabolic signaling, phosphorylation is especially sensitive to changes in nutrient 
availability and energetic status of the cell considering that ATP is the donor of 
phosphate groups
634
. Phosphorylation of PDH can occur as quickly as 2 minutes in 
response to glucose stimulation in pancreatic -cells635. In response to hypoxia, PDH 
phosphorylation occurs within 30 minutes, while transcriptional upregulation of HIF-1 
target genes occurs after 4-6 hours
636
. Given that protein expression and phosphorylation 
is constantly changing in response to a dynamic cellular environment, future experiments 
should aim to euthanize mice immediately following memory testing to ensure accurate 
correlations are made. 
5.2.3 Off-target effects and increased variability with chemical 
modulation from Isosafrol and dichloroacetate  
In order to modulate the activity of key aerobic glycolysis enzymes, the chemicals DCA 
and Isosafrol were used to inhibit the aerobic glycolysis enzymes PDK and LDHA, 
respectively. Chemical modulation is a simple, effective, and inexpensive way to test the 
effect of target molecules on a biological system. Chemical modulation is used 
extensively in vitro in part due to the simplicity of the cell culture system, yet there are 
certain challenges associated with in vivo biological systems. The single largest limitation 
discovered in this work was the loss of effect in chronic exposure to DCA. Thus the 
ability to test the hypothesis that aerobic glycolysis is upregulated in neurons to promote 
A resistance, could not be properly investigated. Other main limitations of chemical 
modulation in laboratory animals are potential off-target effects and variable 
bioavailability and clearance of these agents.  
Despite several studies demonstrating the high affinity of DCA for PDK
599
 and Isosafrol 
for LDHA
491
, these chemicals have several additional off-target effects. DCA is 
transported across the plasma membrane by the MCT family of transporters that are also 
responsible for shuttling lactate, pyruvate, and ketone bodies
637
. This means that DCA 
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could interfere with transport of metabolites within the brain and across the blood-brain 
barrier by directly competing with these substrates. The primary site of DCA metabolism 
is the liver, where it is dehalogenated to glyoxylate in a reaction that requires glutathione 
and eventually converted to glycine, oxalate, and CO2
637,638
. Yet, a minority of DCA may 
also undergo reductive dechlorination to monochloracetate, which is highly neurotoxic
596
. 
Peripheral neuropathy is a common side effect of DCA in humans
595
 and laboratory 
animals
639
. This likely occurs via reduction in expression of myelin-related proteins in 
Schwann cells
640
. Over the course of this dissertation, several mice had to be euthanized 
after months of chronic exposure to DCA due to tissue damage to the ends of their tails 
and hindfeet. While all other mice appeared to tolerate DCA during the course of 
exposure, and there was no observable effect of DCA on the ability of mice to swim in 
the MWM, it was assumed that nerve toxicity did not have an effect on cerebral lactate 
metabolism. Isosafrol has a shorter history than DCA and so less is known about its 
pharmacology or pharmacotoxicology. Oral administration of isosafrol in rats resulted in 
89% of the dose excreted in urine after 72 hours suggesting it has less bioavailability than 
DCA
641
. Isosafrol is an analog of stiripentol, which indirectly inhibits cytochrome P450 
enzymes
642
 and may affect detoxification reactions in the liver or synthesis of hormones, 
cholesterol, or vitamin D
643
.  
Chemical modulation also introduces a source of individual variability between animals 
of the same treatment. The mode of delivery of chronic DCA exposure was oral 
administration in the drinking water. The dosage of DCA was calculated based on an 
average weight of all animals in the same cage and an assumed daily consumption of 5 
mL per animal. Given that animals in the same cage had different weights and likely 
consumed different amounts of water, the specific dose of each animal would have been 
slightly different. Precise dosages of DCA and Isosafrol were achieved by intraperitoneal 
injection. The dose of each injection was calculated by weight of each individual animal, 
which was more accurate than oral administration, yet there were likely subtle differences 
in the site of injection of each animal that introduced variability in biological 
measurements. In addition, mice that were injected with DCA or Isosafrol were memory 
tested or euthanized 30 minutes after delivery, yet the half-life of the drug is dependent 
on its detoxification in the liver or clearance in the kidney and would be slightly different 
148 
 
for each animal. For these reasons, the introduction of chemicals to a biological system as 
a means to study the effect of inhibiting an enzyme introduces addition sources of 
variability between individuals within a treatment group.  
5.3 Future directions 
Due to technical limitations of chemical-induced inhibition of enzymes, future work 
should be aimed at using more reliable and robust methods of modifying the expression 
or activity of these enzymes in order to reduce off-target effects and limit additional 
sources of variation. Genetic manipulation allows precise temporal and spatial control 
over expression of gene targets. This gives researchers the tools for examining the 
biological consequence of altered expression within a given age of an animal’s lifespan 
and within specific tissues of interest.  
Future projects will be aimed at over-expressing or knocking-out LDHA in either neurons 
or astrocytes and testing the behavioural outcome at an appropriate age. In addition, 
crossing these mice to a mouse model of AD would greatly help towards identifying the 
role of LDHA expression, and associated lactate production, on AD progression. Some of 
this work has already been accomplished. In consultation with Christopher Pin and the 
London Regional Transgenic and Gene Targeting Facility (LRTGT), I created a new 
transgenic mouse line over-expressing mouse LDHA with a C-terminal HA tag. Founder 
mice for this transgenic line are currently in our colony. The Ldha gene was cloned into 
the pTRE-Tight (Clontech) tetracycline-inducible expression vector, which contains a 
minimal CMV promoter (PminCMVΔ) immediately downstream of a tetracycline response 
element (TREmod) consisting of seven direct repeats of a 36 bp sequence containing the 
19 bp tetracycline operator sequence (tet-O). In order to test the efficiency of expression 
in response to tetracycline, the mLDHA-HA-pTight construct was transfected into HeLa 
cells that stably express the reverse tetracycline transactivator (rtTA). The HeLa-rtTA 
cells were kindly provided by Dr. Nina Jones of Guelph University. A dose-dependent 
increase in mLDHA-HA protein level was found with a 24 hour exposure to tetracycline 
as determined by western blot analysis of cell lysates using anti-HA antibodies (Figure 
A1B). The mLDHA-HA-pTight construct was then digested with the Xho1 restriction 
enzyme to isolate the fragment containing the Ptight promoter and the mLDHA-HA gene 
149 
 
with a polyadenylation tail. This fragment was used for pronuclear injection into 
fertilized embryos for the creation of a novel transgenic mouse at the LRTGT facility. 
Tail samples from weaned pups were tested for the presence of the mLDHA-HA 
transgene using primers within the Ptight promoter and the first exon of the LDHA gene. 
This analysis identified two female mice positive for the mLDHA-HA transgene. These 
founders were bred to male C57BL/6J mice and the litters were tested for the presence of 
the transgene using ear punch tissue from weaning. One of the founder females produced 
a single female pup that was positive for mLDHA-HA, indicating that the transgene was 
within the germline and could be passed through breeding (Figure A1C).  
This mLDHA-HA transgenic mouse line will be crossed to mice containing the reverse 
tetracycline transactivator (rtTA) under control of the neuron-specific CaMKII  
promoter in order to drive expression of mLDHA-HA specifically in neurons in response 
to oral administration of doxycycline
644
. In order to drive expression in astrocytes, tet-O-
mLDHA-HA transgenic mice will be crossed to mice containing the rtTA element under 
control of the astrocyte-specific Gfap promoter
645,646
. In a preliminary experiment to 
confirm the tight inducible expression of the mLDHA-HA construct, 1-month-old mice 
that express either the mLDHA-HA alone or rtTA alone, or mice expressing both 
mLDHA-HA and rtTA will be switched to a doxycycline chow for a time course of 2 
weeks and then euthanized. Western blot analysis using HA-specific monoclonal 
antibodies will be used to confirm the expression of the mLDHA-HA construct in double 
transgenic mice alone. A sub-cohort of double transgenic mice will be treated with 
doxycycline for 2 weeks and removed from doxycycline for 2 weeks to demonstrate that 
removal of doxycycline after induction can suppress expression of the transgene. Once 
the regulation of transgene expression has been confirmed, double-transgenic mice will 
be allowed to age to 12 months and exposed to doxycycline chow for 2 weeks that will 
activate mLDHA-HA expression in either neurons or astrocytes.   
In order to knock-out LDHA expression in either neurons or astrocytes, an alternate 
approach will be taken. Transgenic mice containing loxP sites flanking exon 2 in the 
Ldha alleles (LDHA
fl/fl
) will be crossed to mice containing Cre-recombinase under 
control of the tet-O promoter (tet-O-Cre)
647
. The LDHA
fl/fl
 mouse line is commercially 
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available and has successfully been used to conditionally knockout the Ldha gene only in 
bone marrow stem cells
648
. These double-transgenic mice will be crossed to mice 
containing the tetracycline-transactivator (tTA) cassette under control of the CaMKII 
promoter to drive expression in neurons
649
 or the Gfap promoter to drive expression in 
astrocytes
650
. The tTA element will repress expression of Cre in the presence of 
doxycycline and activate Cre when doxycycline is removed. Considering that complete 
knockout of LDHA is embryonic lethal
651
, pregnant mothers will be put on doxycycline 
chow to prevent the expression of Cre during gestation and neonatal development in 
triple-transgenic mice. In a preliminary experiment to confirm the absence of LDHA 
expression, 1-month-old triple-transgenic mice will be switched from a doxycycline 
chow to a normal chow for a time course of 2 weeks and then euthanized. Western blot 
analysis of brain extracts using LDHA-specific antibodies will be used to determine the 
expression of LDHA protein relative to double-transgenic mice that lack the tet-O-Cre 
cassette. A sub-cohort of triple transgenic mice will be switched to normal food for 2 
weeks and then back to doxycycline for 2 weeks to demonstrate that removal of 
doxycycline induces a permanent excision of the floxed Ldha gene. Once the regulation 
of the transgenic elements have been established, triple-transgenic mice will be 
maintained on doxycycline until 12 months of age and switched to normal chow to 
remove LDHA expression in either neurons or astrocytes. 
These genetic mouse lines allow for convenient temporal and spatial control over 
expression of LDHA response to doxycycline chow. Transgenic mice that are either not 
exposed to doxycycline chow (for over-expression line) or exposed to doxycycline chow 
(for knock-out line) can be conveniently used as littermate controls. The behaviour of 
LDHA over-expression mice or LDHA knock-out mice will be evaluated using several 
different memory tests, including the MWM, the Barnes maze
652
, and the novel object 
recognition test
653
. In order to assess stress and anxiety of these animals, the open-field 
test
654
, the elevated plus maze
655
, and the light-dark exploration test
656
 will be used. All of 
these behavioural tests are available to our laboratory. The amount of lactate will be 
measured in vivo using 
1
H-MRS examining different brain regions including the frontal 
cortex, the hippocampus, and the cerebellum. Mice will be euthanized and brain tissue 
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harvested for western blot analysis of the frontal cortex, the hippocampus, and the 
cerebellum, in order to confirm the expression of the mLDHA-HA construct using HA-
specific antibodies or the deletion of LDHA using LDHA-specific antibodies. The tissue-
specific expression or knock-out of LDHA in neurons or astrocytes will be evaluated 
using cryo-immunofluorescence microscopy with TUJ1 antibodies to target neurons and 
GFAP antibodies to target astrocytes with co-immunostaining using HA-specific 
antibodies and LDHA-specific antibodies. It is predicted that mice over-expressing 
mLDHA-HA in neurons or astrocytes will display higher levels of cerebral lactate and 
have enhanced memory performance. In contrast, mice that lack LDHA expression will 
display decreased levels of cerebral lactate and will have memory deficits. These results 
will offer robust evidence to accept or reject the hypothesis that aerobic glycolysis 
contributes to memory processes. Any differences between the genetic manipulations of 
LDHA in neurons or astrocytes will indicate a functionally distinct role of aerobic 
glycolysis in these two different cell types.  
In order to test the hypothesis that aerobic glycolysis promotes A resistance in AD, 
double-transgenic LDHA over-expression mice and triple-transgenic LDHA knock-out 
mice will each be crossed to the 5xTg mouse line. These mice contain 5 different 
mutations targeting the A pathway: APPKM670/671NL (Swedish), APPI716V (Florida), 
APPV7171 (London), PSEN1M146L, and PSENL286V. This mouse model of AD has several 
benefits over the APP/PS1 mouse line; including deficits in spatial learning that occur at 
4-5 months of age and apparent neurodegeneration at 9-12 months of age
657
. Considering 
that these mice exhibit dramatic rises in A(1-42) levels beginning at 1.5 months of age, 
the induction of LDHA over-expression or knock-out will be initialized immediately after 
weaning. These mice will be monitored over the course of age and behavioural testing 
will be administered at 4 months of age. The progression of amyloid pathology will be 
examined over the course of aging by euthanizing mice at regular intervals of age. Brain 
cryo-sections will be stained with Thioflavin S to visualize amyloid plaques via 
immunofluorescence, while cerebral levels of A(1-40) and A(1-42) will be measured using 
ELISAs. Synaptic dysfunction and neurodegeneration will be evaluated by western blot 
analysis measuring levels of syntaxin and post-synaptic density protein 95 (PSD-95), 
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both synaptic markers, and p25 as a marker for the neurodegeneration pathway
657
. It is 
anticipated that over-expression of LDHA in neurons or astrocytes will maintain neuron 
survival in 5xTg mice at 9 months of age, while the opposite trend is expected with 
LDHA knock-out mice. These experiments will provide sufficient evidence to accept or 
reject the hypothesis that aerobic glycolysis promotes Aresistance in AD. 
 
5.4 Concluding remarks 
A number of significant and novel findings were realized in this study. First, lactate 
levels in the frontal cortex decline with age, yet are maintained in APP/SP1 mice. A 
significant correlation exists between expression of lactate producing enzymes and 
memory performance in control mice, but not in APP/PS1 mice. These findings suggest 
that lactate production plays a beneficial role in memory in the healthy aging brain but 
might contribute to memory decline in the AD brain. Second, expression of PDK1 and 
LDHA, two central regulators of aerobic glycolysis was found primarily in the soma of 
neurons, but also in reactive astrocytes surrounding amyloid plaques. These observations 
indicate that neurons can also generate lactate, and that reactive astrocytes may play a 
role in the elevated lactate levels detected in the AD brain. Finally, chemical inhibition of 
aerobic glycolysis appeared to inhibit learning in mice whereas it had little to no effect on 
spatial memory. Thus, aerobic glycolysis may play a more prominent role in different 
regions of the brain affecting other cognitive processes and behaviours independent of 
memory.  Each of these observations need to be examined further in order to provide a 
more complete mechanistic overview of cerebral lactate metabolism in the healthy brain 
and its role in memory. This work will also lead to a better understanding of how aerobic 
glycolysis and cerebral A interact in the AD brain and could lead to the development of 
novel metabolic strategies to treat this devastating disease. 
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Appendix A: Supplementary Figures and Tables 
 
Figure A1. Creation of novel transgenic mouse line containing 
mLDHA-HA-pTight expression cassette.  
(A) Western blot analysis of cell lysates probed using HA- and 
GAPDH-antibodies showing tetracycline-inducible expression of 
mLDHA-HA in HeLa-rtTA cells. (B) PCR-based genotyping of ear 
punch from litter of female founder mouse #849 with positive pup #6 
demonstrating germline transmission of the mLDHA-HA-pTight 
transgene.  
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Table A2. List of mice removed from analysis due to stress effects in a particular 
training phase.  
Mice could be removed from analysis if they display behaviour that clearly demonstrates 
no attempt to actively search for the platform during the training phase. The number of 
control mice and APP/PS1 mice out of the total for each training phase is displayed. 
 
 
 Number of mice removed from analysis due to stress 
Training Phase Control APP/PS1 
Vehicle 0 / 17 3 / 11 
Isosafrol 0 / 16 1 / 9 
DCA 0 / 15 1 / 9 
Saline 0 / 13 1 / 7 
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